UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 10-K
| þ | ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | |
For the fiscal year ended December 30, 2012
or
| o | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | |||
| For the transition period from to . | ||||
Commission file number:000-30361 001-35406
Illumina, Inc.
(Exact name of Registrantregistrant as Specifiedspecified in Its Charter)charter)
| Delaware | 33-0804655 | |||
(State or other incorporation or | ||||
( Identification No.) | ||||
San Diego, California | 92122 | |||
| (Address of principal executive offices) | (Zip Code) | |||
Registrant’s telephone number, including area code:
(858) 202-4500
Securities registered pursuant to Section 12(b) of the Act:
| Title of | Name of | |
| which registered | ||
| Common Stock, $0.01 par value (including associated Preferred Stock Purchase Rights) | The NASDAQ Global Select Market | |
Securities registered pursuant to Section 12(g) of the Act: None
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes þ No o
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes o No þ
Indicate by check mark whether the Registrantregistrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrantregistrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes þ No o
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 ofRegulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes þ No o
Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 ofRegulation S-K is not contained herein, and will not be contained, to the best of Registrant’sregistrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of thisForm 10-K or any amendment to thisForm 10-K. o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule12b-2 of the Exchange Act. (Check one):
Large accelerated filer þ | Accelerated filer o | Non-accelerated filer o | Smaller reporting company o |
| (Do not check if a smaller reporting company) | |||
Indicate by check mark whether the registrant is a shell company (as defined inRule 12b-2 of the Exchange Act). Yes o No þ
As of February 4, 2011,January 31, 2013, there were 127,626,004124,040,754 shares (excluding 24,868,92946,449,505 shares held in treasury) of the Registrant’s Common Stock outstanding. The aggregate market value of the Common Stock held by non-affiliates of the Registrant as of July 4, 20102, 2012 (the last business day of the Registrant’sregistrant’s most recently completed second fiscal quarter), based on the closing price for the Common Stock on The NASDAQ Global Select Market on that date,June 29, 2012 (the last trading day before July 2, 2012), was $3,554,527,753.$3.8 billion. This amount excludes an aggregate of 41,715,009approximately 29.3 million shares of Common Stock held by officers and directors and each person known by the Registrantregistrant to own 10% or more of the outstanding Common Stock. Exclusion of shares held by any person should not be construed to indicate that such person possesses the power, directly or indirectly, to direct or cause the direction of the management or policies of the Registrant,registrant, or that the Registrantregistrant is controlled by or under common control with such person.
DOCUMENTS INCORPORATED BY REFERENCE
Portions of the Registrant’sregistrant’s definitive proxy statement for the 2013annual meeting of stockholders expected to be held on May 10, 2011 are incorporated by reference into Items 10 through 14 of Part III of this Report.
ILLUMINA, INC.
FORM 10-K
FOR THE FISCAL YEAR ENDED JANUARY 2, 2011
December 30, 2012
December 30, 2012
TABLE OF CONTENTS
1
1
Special Note Regarding Forward-Looking Statements
This annual report onForm 10-K contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements discuss our current expectations concerning future results or events, including our future financial performance. We make these forward-looking statements in reliance on the safe harbor protections provided under the Private Securities Litigation Reform Act of 1995. These statements include, among others:
statements concerning our expectations as to our future financial performance, results of operations, or other operational results or metrics;
statements concerning the benefits that we expect will result from our business activities and certain transactions we have completed, such as product introductions, increased revenue, decreased expenses, and avoided expenses and expenditures; and statements of our expectations, beliefs, future plans and strategies, anticipated developments (including new products and services), and other matters that are not historical facts. |
These statements may be made expressly in this document or may be incorporated by reference to other documents we have filed or will file with the Securities and Exchange Commission, or SEC. You can identify many of these statements by looking for words such as “anticipates,” “believes,” “can,” “continue,” “could,” “estimates,” “expects,” “intends,” “may,” “plans,” “potential,” “predicts,” “should,” or “will” or the negative of these terms or other comparable terminology and similar references to future periods. These forward-looking statements are subject to numerous assumptions, risks, and uncertainties that may cause actual results or events to be materially different from any future results or events expressed or implied by us in those statements. Many of the factors that will determine or effectaffect these results or events are beyond our ability to control or project. Specific factors that could cause actual results or events to differ from those in the forward-looking statements include:
our ability to maintain our revenue levels and profitability during periods of research funding reduction or uncertainty and adverse economic and business conditions, including as a result of slowing economic growth in the United States or worldwide;
our ability to further develop and commercialize our sequencing, array, PCR, consumables, and diagnostics technologies and to deploy new products, services, and applications, and expand the markets, for our technology platforms;
our ability to manufacture robust instrumentation and consumables;
our ability to successfully identify and integrate acquired technologies, products, or businesses;
our expectations and beliefs regarding future prospects and growth of the business and the markets in which we operate;
the assumptions underlying our critical accounting policies and estimates, including our estimates regarding stock volatility and other assumptions used to estimate the fair value of share-based compensation; the future cash flows used to estimate the cease-use loss upon our exit of certain facilities; and expected future amortization of acquired intangible assets;
our belief that the investments we hold are not other-than-temporarily impaired;
our assessments and estimates that determine our effective tax rate;
our assessments and beliefs regarding the future outcome of pending legal proceedings and the liability, if any, that we may incur as a result of those proceedings; and
other factors detailed in our filings with the SEC, including the risks, uncertainties, and assumptions described in Item 1A “Risk Factors” below, or in information disclosed in public conference calls, the date and time of which are released beforehand.
2
Our forward-looking statements speak only as of the date of this annual report. We undertake no obligation, and do not intend, to publicly update or revise forward-looking statements, to review or confirm analysts’ expectations, or to provide interim reports or updates on the progress of any current financial quarter, whether as a result of new information, future events, or otherwise. All subsequent written and oral forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the cautionary statements contained in this annual report. Given these uncertainties, we caution investors not to unduly rely on our forward-looking statements.
Available Information
Our annual report onForm 10-K, quarterly reports onForm 10-Q, current reports onForm 8-K, and all amendments to those reports are available free of charge on our website,www.illumina.com. The information on our website is not incorporated by reference into this report. Such reports are made available as soon as reasonably practicable after filing with, or furnishing to, the SEC. The SEC also maintains an Internet site atwww.sec.govthat contains reports, proxy and information statements, and other information regarding issuers
2
that electronically file with the SEC. Copies of our annual report onForm 10-K will be made available, free of charge, upon written request.
Unless the context requires otherwise, references in this annual report onForm 10-K to “Illumina,” the “Company,” “we,” “us,” and “our” refer to Illumina, Inc. and its subsidiaries.
3
PART I
ITEM 1.Business |
Overview
We are a leading developer, manufacturer, and marketer of life science tools and integrated systems for the analysis of genetic variation and function. We were incorporated in California in April 1998 and reincorporated in Delaware in July 2000. Our principal executive offices are located at 9885 Towne Centre Drive,5200 Illumina Way, San Diego, California 92121.92122. Our telephone number is(858) 202-4500.
Using our proprietary technologies, we provide a comprehensive line of genetic analysis solutions, with products and services that serve a broad range of highly interconnected markets, including sequencing, genotyping, and gene expression, and molecular diagnostics.expression. Our customers include leading genomic research centers, academic institutions, government laboratories, and clinical research organizations, as well as pharmaceutical, biotechnology, agrigenomics, and consumer genomics companies.companies, and in vitro fertilization clinics.
Our broad portfolio of systems, consumables, and analysis tools are designed to simplify genetic analysis. This portfolio addresses a range of genomic complexity, price points, and throughputs, enabling researchers to select the best solution for their scientific challenge. In 2007, through our acquisition of Solexa, Inc., we acquired our proprietaryOur leading edge sequencing by synthesis (SBS) technology that is at the heart of our leading-edge sequencing instruments. These systemsinstruments can be used to efficiently perform a range of nucleic acid (DNA, RNA) analyses on large numbers of samples. For more focused studies, our array-based solutions provide ideal tools to perform genome-wide association studies (GWAS) involving single-nucleotide polymorphism (SNP) genotyping and copy number variation (CNV) analyses, as well as gene expression profiling, and other DNA, RNA, and protein studies.
In 2012 and early 2013, we took significant steps to support our goal of becoming the leader in genomic-based diagnostics by acquiring BlueGnome Ltd. (BlueGnome) in September 2012 and signing a definitive agreement to acquire Verinata Health, Inc. (Verinata) in January 2013. Our acquisition of BlueGnome, a leading provider of solutions for the screening of genetic abnormalities associated with developmental delay, cancer, and infertility, enhances our ability to establish integrated solutions in reproductive health and cancer. Upon completion of the Verinata acquisition, our focus on reproductive health will be further strengthened by having access to Verinata’s verifi® prenatal test, the broadest non-invasive prenatal test (NIPT) available today for high-risk pregnancies, and what we believe to be the most comprehensive intellectual property portfolio in the NIPT industry. To further enhance our genetic analysis workflows, in January 2011 we acquired Epicentre Technologies Corporation, a leading provider of nucleic acid sample preparation reagents and specialty enzymes for sequencing and microarray applications. In 2010, through our acquisition of Helixis, Inc. (Helixis), we expanded our portfolio to include real-time polymerase chain reaction (PCR), one of the most widely used technologies in life sciences. Our new Eco Real-Time PCR System provides researchers with an affordable, full-featured system to perform targeted validation studies.
Industry Background
Genetics Primer
The instruction set for all living cells is encoded in deoxyribonucleic acid, or DNA, with the complete set of DNA for any organism referred to as its genome. DNA contains small regions called genes, which comprise a string of nucleotide bases labeled A, C, G, and T, representing adenine, cytosine, guanine, and thymine, respectively. These nucleotide bases are present in a precise order known as the DNA sequence. When a gene is “expressed,” a partial copy of its DNA sequence —- called messenger RNA (mRNA) —- is used as a template
4
to direct the synthesis of a particular protein. Proteins, in turn, direct all cellular function. The illustration below is a simplified gene expression schematic.
4
Variations among organisms are due, in large part, to differences in their DNA sequences. Changes caused by insertions, deletions, inversions, or duplications of nucleotide bases may result in certain genes becoming over-expressed (excessive protein production), under-expressed (reduced protein production), or silenced altogether, sometimes triggering changes in cellular function. These changes can be the result of heredity, but most often they occur at random. The most common form of variation in humans is called a single-nucleotidesingle nucleotide polymorphism (SNP), which is a variation in a single position of a nucleotide base in a DNA sequence. Copy number variations (CNVs) occur when there are fewer or more copies of certain genes.genes, segments of a gene, or stretches of DNA.
In humans, genetic variation accounts for many of the physical differences we see (height,(e.g., height, hair, eye color, etc.). More importantly, these genetic variations can have medical consequences affecting disease susceptibility, including predisposition to complex genetic diseases such as cancer, diabetes, cardiovascular disease, and Alzheimer’s disease. They can also impact an individual’s response to certain drug treatments, causing them to respond well, not respond at all, or experience adverse side effects —- an area of study known as pharmacogenomics.
Scientists are studying these variations and their consequences in humans, as well as a broad range of animals, plants, and microorganisms. Researchers investigating human, viral, and bacterial genetic variation are helping us to better understand the mechanisms of disease, and thereby develop more effective therapeutics and diagnostics. Greater insight into genetic variation in plants (e.g., food and biofuel crops) and animals (e.g., livestock and domestic animals) is enabling scientists to improve crop yields and animal breeding programs.
The methods for studying genetic variation and biological function include sequencing, SNP genotyping, CNV analysis, gene expression profiling, and gene regulation and epigenetic analysis, each of which is addressed by our breadth of products and services.
Life Sciences Research Primer
Life science research encompasses the study of all living things, from humans, animals, and plants, to viruses and bacteria. It is being performed in government, university, pharmaceutical, biotechnology, and agrigenomics laboratories around the world, where scientists are seeking to expand our knowledge of the biological functions essential for life. Beginning at the genetic level, where our tools are used to elucidate the correlation between gene sequence and biological processes, life science research expands to include the study of the cells, tissues, organs, systems, and other components that make up living organisms. This research
5
supports development of new, more effective clinical diagnostics and medicines to improve human health, as well as advances in agriculture and animal husbandry to meet the world’s growing needs for food and energy.
Molecular Diagnostics Primer
Molecular diagnostic assays (or tests) are designed to identify the biological indicators linked with disease and drug metabolism,response, providing physicians with information to more effectively diagnose, treat, and monitor both acute and chronic disease conditions. They are an integral part of personalized healthcare, where the unique makeup of each individual willcan be taken into account in diagnosing disease and managing treatment through the use of more tailored therapies. Biological indicators that can be measured by these assays include protein or gene expression, methylation levels, copy number variations, and the presence or absence of a specific gene or group of genes.
5
There are molecular diagnosticdiagnostics assays on the market, including assays for infectious disease, cancer, and heart disease, as well as molecular-based drug metabolism and response assays to help physicians select the most effective therapy with the fewest side effects. Our innovative technologies and products are contributing to the development of a wide-rangewide range of potential genomic-based molecular diagnosticdiagnostics assays. Our own efforts in this area are currently focused on the identification of certain genetic markers with potential diagnostic and therapeutic utility.
Growing news coverage about the clinical relevance of newly discovered genetic markers has prompted consumers’consumer interest in having their personal genomes analyzed, sparking the development of the consumer genomics market. We believe there are distinct medical benefits, especially for people with family histories of certain diseases, of knowing yourpotential disease predisposition.predispositions. Several companies, including Illumina, now offer personal sequencing or genotyping services, working with physician groups and genetic counselors to interpret the results for consumers.
We believe the growth in consumer genomics and the use of moleculargenomic-based diagnostic assays will trigger a fundamental shift in the practice of medicine and the economics of the pharmaceutical industry and health care by facilitating an increased emphasis on preventative and predictive molecular medicine, ushering in the era of personalized medicine.
Our Principal Markets
From the company’s inception, we have believed that the analysis of genetic variation and function will play an increasingly important role in molecular biology, and that by empowering genetic analysis, our tools will advance disease research, drug development, and the creation of molecular diagnostic tests. In addition to developing sequencing- and array-based solutions for life science, applied, and consumer genomics markets, we are making inroads intofacilitating the emerging markettransition of molecular diagnostics.sequencing to the clinic, by supporting and carrying out clinical trials to gather data for regulatory submissions in the US and globally, and establishing infrastructure to offer products designed and manufactured in compliance with global quality standards for medical devices.
Life Sciences Research Market
Applied Markets
We provide products and services for various other markets, which we refer to as “applied markets.” The largest among these is the “Agbio”agricultural market, where government and corporate researchers use our sequencing-sequencing and array-based tools to accelerate and enhance agricultural research. For example, we currently offer
6
microarrays that contain SNPs for custom and focused genotyping of seeds and crops (such as maize)maize, tomatoes, apples, and potatoes), livestock (such as cattle, horses, pigs, goats, and sheep), and companion animals (such as dogs). Customers use themthese tools to perform selective breeding through high-value trait screening methods, thereby accelerating and enhancing the process overas compared to traditional methods such as cross-breeding. We have developed a high-growth recurring revenue business in both the livestock and agricultural segments, and emerging opportunities in the applied markets include forensics and pet genomics.
Molecular Diagnostics Market
Molecular diagnostics makes upis the fastest growing segment inof the clinical diagnostics market, with the primarymarket. At present, this growth drivers beingis largely driven by infectious disease testing, but molecular diagnostics is rapidly expanding into new areas such as reproductive health (including non-invasive prenatal testing) and cancer management - both are areas of focus for our diagnostics business. The increasing efficacy of molecular diagnostics is driven by the continued discovery of genetic markers with proven clinical utility, the increasing adoption of genetic-based diagnostic tests, and the expansion of reimbursement programs to include a greater number of approved molecular diagnostic tests. We believe our BeadXpresssequencing and array instrument platform, usingplatforms are foundational to continued growth in this market.
In September 2012 we acquired BlueGnome, a leading provider of solutions for screening genetic abnormalities associated with developmental delay, cancer, and infertility. The combination of BlueGnome’s solutions with our VeraCode technology, is ideally suitedmicroarray
6
and sequencing platforms will enable the development of next-generation tools for these markets. In January 2013, we signed a definitive agreement to provideacquire Verinata Health, Inc. Upon completion of the Verinata acquisition, our focus on reproductive health will be further strengthened by having access to Verinata’s verifi® prenatal test, the broadest non-invasive prenatal test (NIPT) available today for high-risk pregnancies, and what we believe to be the most comprehensive intellectual property portfolio in the NIPT industry.
In December 2012, we submitted a cost-effective, high-throughput, mid-510(k) application for a version of our MiSeq system (the MiSeqDx) to low-multiplex solution to the molecular diagnostic market. In April 2010, we obtained 510(K) approval for the BeadXpress platform from the U.S. Food and Drug Administration, (FDA). We have initiated developmentor FDA, for marketing as a cleared device for use with in vitro diagnostic (IVD) products. In connection with our FDA submission of the MiSeqDx system, we submitted two cystic fibrosis (CF) assays - a varietydiagnostic assay and a carrier screening assay - to the FDA that, if cleared, would be sold as IVD kits to be run on the MiSeqDx system. The MiSeqDx Cystic Fibrosis Diagnostic Assay is designed for simultaneous detection of clinical diagnostic testing panels for this platformall mutations and are continuing research intovariants within the potential development of cancer diagnostic panels, initially focusing on ovarian, gastric, and colorectal cancers. During the fourth quarter of 2009, we made an FDA pre-IDE (investigational device exemption) submission for a cytogeneticscystic fibrosis transmembrane conductance regulator (CFTR) gene. The test is intended to be used on our iScan instrument platform as an aid in the postnatal diagnosis of chromosomal abnormalities knownindividuals with suspected CF or congenital bilateral absence of vas deferens (CBAVD). Results of this test are intended to be associatedinterpreted by a certified clinical molecular geneticist or equivalent. The MiSeqDx Cystic Fibrosis Carrier Screening Assay is designed for simultaneous detection of clinically relevant variants within the CFTR gene, including those currently recommended for carrier screening purposes by the American College of Medical Genetics (ACMG) and the American College of Obstetricians and Gynecologists (ACOG). The test is intended to be used in general population screening to determine CF carrier status, as an aid in newborn screening for CF, and as an initial genetic test to aid in the diagnosis of individuals with developmental delaysuspected CF or CBAVD.
As the molecular diagnostics market continues to evolve and mental retardation. Following completionemerge, we believe the translational market will prove to be another growth opportunity for us. In September 2012, Illumina introduced TruSight content sets for use by laboratories with next-generation sequencing systems such as the MiSeq. Comprised of oligonucleotide probes targeting genes and gene regions thought to be relevant for specific genetic diseases or conditions, TruSeq content sets are designed for use by laboratories in the required clinical trial, we intend to seek FDA clearance for the iScan instrument platform and related consumables.development of their own unique targeted sequencing tests.
Consumer Genomics Markets
New sequencing and genotyping technologies, such as those developed by Illumina, are driving down the cost of performing comprehensive sequencing and genotyping analyses, which are increasingly valuable inrapidly paving the way to improving diagnosing diseaseof diseases and evaluatingevaluation of disease risk. Consumer genomics is a nascent market, but one we believe has the potential for high growth as the cost per analysis continues to drop. In June 2009, we launched our Individual Genome Sequencing Service, the first physician-intermediated personal genome sequencing service for consumers. Built around physician-patient consultation, the service requires a physician’s order to initiate the process, with genome sequencing performed using our CLIA-certified, CAP-accredited laboratory. We have established collaborations with partners to perform the secondary data analysis of a personal genome (such as calculation of disease risk, ancestry, and information on traits of interest). Some of our partners, as well as other companies in thedirect-to-consumer market, use our genotyping technology and products to perform personal genotyping services.
Our Principal Technologies
Our unique technology platforms enable the scale of experimentation necessary for genome-wide discovery, target selection, and validation studies (see Figure 1 below). More than 2,5008,000 customer-authored scientific publicationspapers have been published to date using these technologies, representing the efforts of a large and dynamic Illumina user community. Through rapid innovation, we believe we are changing the economics of genetic research, enabling projects oncethat were previously considered unapproachable to now be within reachunapproachable.
7
Figure 1: Illumina Platform Overview:
Sequencing Technology
DNA sequencing is the process of determining the order of nucleotide bases (A, C, G, or T) in a DNA sample. Our HiSeq 2500/2000, HiSeq 1500/1000, Genome Analyzer IIx, MiSeq, and HiScanSQ systems represent a family of systems that we believe are setting the standard for productivity, cost-effectiveness, and accuracy among next-generation sequencing technologies. They are used by customers to perform whole-genome, de novo, and targeted re-sequencing of genomes, and to analyze specific gene regions and genes. In January 2011, we announced the MiSeq Personal Sequencing System, which will expand our family of sequencing systems to include a low-cost personal sequencing system that will provide individual researchers a sequencing platform that can go from purified DNA to analyzed data in as few as eight hours or can generate in excess of 1 gigabase (Gb) per run in slightly over a day.
Whole-genome sequencing determines an organism’s complete DNA sequence. In de novo sequencing, the goal is to sequence a representative sample from a species never before sequenced. In targeted re-sequencing, a sequence of nucleotide bases is compared to a standard or reference sequence from a previously sequenced species to identify changes that reflect genetic variation. Understanding the similarities and differences in DNA sequence between and within species furthers our understanding of the function of the structures encoded in the DNA.
Our DNA sequencing technology is based on our proprietary reversible terminator-based sequencing chemistry, referred to as sequencing by synthesis (SBS) biochemistry. In SBS, single stranded DNA is extended from a priming site, one base at a time, using reversible terminator nucleotides. These are DNA bases that can be added to a growing second strand, but which initially cannot be further extended. This means that at each cycle of the chemistry, only one base can be added. Each base that is added includes a fluorescent label that is specific to the particular base (A, C, G, or T). Following incorporation, the emitted light can be imaged to determine its color and thus determine the base. Once this is done, an additional step removes both the fluorescence and the blocking group that had prevented further extension of the second
8
BeadArray Technology
Our BeadArray technology combines microscopic beads and a substrate in a proprietary manufacturing process to produce arrays that can perform many assays simultaneously, enabling large-scale analysis of genetic variation and biological function in a unique high-throughput, cost effective, and flexible manner. The arrays manufactured using BeadArray technology are imaged by our iScan, HiScan, and HiScanSQ systems for a broad range of DNA and RNA analysis applications including SNP discovery, SNP genotyping, CNV analysis, gene expression analysis, and methylation analysis.
Our proprietary BeadArray technology consists of microscopic silica beads, with each bead covered with hundreds of thousands of copies of oligonucleotides, or oligos, that act as the capture sequences in one of our assays. We deploy our BeadArray technology on BeadChips;BeadChips - silicon wafers the size of a microscope slide, with varying numbers of sample sites per slide. BeadChips are chemically etched to create tens of millions of wells for each sample site.
8
9
Using our BeadArray technology, we achieve high-throughput analysis with a high density of test sites per array, and are able to format arrays in various configurations. We seek to maximize cost effectiveness by reducing consumption of expensive consumables and valuable samples, and through the low manufacturing costs associated with our technologies. Our ability to vary the size, shape, and format of the well patterns and to create specific bead pools for different applications provides the flexibility to address multiple markets and market segments. These features enable our BeadArray technology to be applied to high-growth markets of SNP genotyping and CNV analysis and have allowed us to be a key player in the gene expression market.
Eco Real-Time PCR Technology
In April 2010, we purchased Helixis Inc. and its novel real-time PCR technology and in July 2010 introduced the Eco Real-Time PCR System to the market. Real-Time PCR (also known as quantitative PCR or qPCR) is used to amplify and simultaneously quantify a targeted DNA molecule, with applications in gene expression, viral quantification, array data validation, pathogen detection, and genotyping. The procedure follows the same steps as PCR, whereby thermal cycling (alternately heating and cooling the DNA sample from 20 to 40 times) causes the DNA to self-replicate, resulting in the doubling of DNA product with each cycle. Real-time PCR uses various fluorescent detection chemistries to enable the monitoring of the PCR reaction as it progresses. Data are collected at each cycle rather than at the end of the reaction, providing higher precision, increased sensitivity, increased dynamic range, and higher resolution.
The Eco System combines a proprietary thermal system, four-color multiplex capabilities, and a fine-tuned optical system to deliver accurate qPCR results. Its unique design provides superior thermal uniformity, supporting high-quality PCR performance for demanding applications such as high resolution melt (HRM) curve analysis used for SNP genotyping, DNA fingerprinting, species identification, HLA compatibility typing, allelic prevalence, and DNA methylation analysis. Measuring just over one cubic foot in size, we believe the Eco System’s overall performance rivals larger, more expensive systems and provides us with a highly differentiated entry into this market.systems.
Our Products
Using our proprietary technologies, our products give our customers the ability to analyze the genome at any level of complexity, from whole-genome sequencing to low-multiplex assays, and enable us to serve a number of markets, including research, agriculture, forensics, pharmaceuticals, and genomic-based molecular diagnostics.
The majority of our product sales consist of instruments and consumables (which include reagents, flow cells, and BeadChips) based on our proprietary technologies (see Figure 2 below).technologies. For the fiscal years ended December 30, 2012, January 1, 2012, and January 2, 2011 January 3, 2010, and December 28, 2008,, instrument sales comprised 36%27%, 34%35%, and 32%36%, respectively, of total revenues, and consumable sales represented 56%64%, 59%56%, and 58%56%, respectively, of total revenues.
Based on our proprietary SBS technology, our next-generation sequencing platforms are designed to meet the workflow, output, and accuracy demands of a full range of sequencing applications. Designed for high-throughput (upsequencing, the HiSeq 2500 is a fast, easy-to-use instrument that can generate either up to 600 Gb per run andof data in high-output mode or up to 80120 Gb in rapid run mode. In the high-output mode, the HiSeq 2500 processes either up to five human genomes (120 Gb per day) sequencing, the HiSeq 2000 is fast, easy-to-use, and cost-effective, generating the sequence of twogenome) in ten days or a single human genomes per rungenome at 30×30x coverage for less than $5,000 (USD) in consumable cost per genome.approximately one day. Offering the same cost per data output and user experience,flexibility, the HiSeq 10001500 accommodates lower throughput needs, with an easy upgrade path to the HiSeq 2000. The Genome Analyzer IIx offers the simplest and fastest workflow for medium to high-throughput applications, generating up to 95 Gb per run. Introduced2500. Launched in January 2011, with first customer shipments expected mid-2011, our MiSeq Personal Sequencing System delivers the fastest time to an answer (as little as eight2-3 hours) and offers a breadth of sequencing applications in a compact and economical instrument to meet the needs of individual researchers.
Sequencing/Array Combination Platforms
The HiScanSQ combines our SBS sequencing technology and iScanHiScan microarray analysis instrumentation into one system, with a modular design that can evolve with changing research needs. This flexible system allows researchers to use our sequencing and array technologies interactively to bring increased power to their experiments.
Array Platforms
The HiScan and iScan System is ourSystems are dedicated array scannerscanners that supportssupport the rapid, sensitive, and accurate imaging of our array-based genetic analysis products. It incorporatesThey incorporate high-performance lasers, optics, and detection systems, deliveringsub-micron resolution and unmatched throughput rates. The HiScan and iScan supportssupport our Infinium, GoldenGate, DASL, gene expression, and methylation assays. Our BeadXpress Reader is designed
9
Consumables
We have developed a variety of sample preparation and sequencing kits to simplify workflows and accelerate analysis. Some provide all the necessary consumables needed for both small and high-throughput laboratories conducting molecular testing with multiplexed-based assays deployedanalyses, such as our Standard Sequencing Kit (SBS chemistry on our VeraCode bead technology. It supports a wide rangesequencing platforms) and Infinium Assay Kit (array-based genotyping on our array platforms). Others support more discrete analyses, such as our Paired-End Genomic DNA Sample Prep Kit for streamlining library preparation for the generation of applications, including DNA, RNA,200-500 kb insert paired-end reads for sequencing, gene expression, and protein-based assays,epigenetic analysis. Our TruSeq SBS Sequencing Kit enhances sequencing studies with our HiSeq, Genome Analyzer IIx, and is FDA clearedMiSeq systems, by enabling researchers to extend the read lengths, achieve higher Gb of mappable data, and deliver the highest yield of perfect reads to maximize the ability to accurately characterize the genome. Through our acquisition of Epicentre Technologies Corporation in 2011, we acquired the proprietary Nextera technology for in vitro diagnosticsnext-generation sequencing library preparation. This technology has enabled us to offer sequencing library preparation kits with specific VeraCode FDA-cleared tests.
11
Our InfiniumHD Whole-Genome BeadChips represent our most technologically advanced multi-sample DNA analysis microarrays, enabling the interrogation of up to 2.5approximately 5 million markers per sample, depending on the BeadChip. The most recent additions to the Omni family, the HumanOmni5-Quad, the HumanOmni2.5, and the HumanOmni1S BeadChips, provide comprehensive coverage of common and rare variants identified by the 1000 Genomes Project for performing rich GWAS projects. This product line also includes agriculturally relevant genome panels such as the BovineHD and MaizeSNP50 BeadChips.
For researchers who want to study focused genomic regions of interest, or are interested in organisms for which there are no standard products, we offer iSelect Custom Genotyping BeadChips. Easily developed to fit any experimental design, these SNP genotyping arrays can be used to investigate from 3,000 to 1,000,000 markers targeting any species.
Through our acquisition of BlueGnome in 2012, we are a leading provider of solutions for the screening of genetic abnormalities associated with developmental delay, cancer, and infertility. BlueGnome supplies to some of the world’s leading in vitro fertilization (IVF) centers a preimplantation genetic screening (PGS) test for counting the chromosomes in a single human cell. Studies have shown that PGS improves IVF success, increasing pregnancy rates for women and reducing miscarriages and multiple births.
Our GoldenGate Universal-32 Sample BeadChip providesreproductive health offerings also include CytoChip, a flexible customized solution for mid-plex genotyping assays performed on the iScan System or HiScan, while the VeraCode GoldenGate genotyping arrays are well-suited for low-plex genotyping on the BeadXpress Reader.
Real-time PCR Platforms
The Eco Real-Time PCR System provides fast, accurate qPCR results. Its icon-driven user interface simplifies experimental design and setup, while a straightforward workflow streamlines operation, enabling the system to perform qPCR on 48 samples in less than 40 minutes. As our first entry into the qPCR market, we believe the smaller, lower-cost, full-featured Eco System will enable more scientists to use real-time PCR technology in their research.
Our Services
In addition to the products we supply to customers, we also provide sequencing and genotyping services through our CLIA-certified, CAP accreditedCAP-accredited laboratory.
FastTrack Services
One of the ways in which we compete and extend the reach of our systems in the genetic analysis market is to deliver FastTrack Servicesservices that leverage our proprietary technologies and the expertise of our scientists to perform genotyping and sequencing services for our customers. We began offering genotyping services to academic institutions, biotechnology, and pharmaceutical customers in 2002. The in-house molecular geneticists that make up our FastTrack Genotyping team help customers perform GWAS projects, linkage analysis, and fine mapping studies to meet their deadlines, employing a range of our products, including standard and custom GoldenGate, standard Infinium and Infinium HD, and iSelect Infinium assays. These projects range in size from a few hundred to over 10,000 samples.
10
After five years of building an infrastructure to support genotyping services, we expanded to deliver sequencing services in 2007. We continue to combine the power of our proprietary SBS technology, with the consultative and analytical capabilities of our FastTrack Sequencing team to execute high-value projects such as whole-genome sequencing, targeted resequencing, digital expression profiling, and small RNA discovery. Projects range from small sample sets requiring as little as one run, to large-scale projects such as de novo whole-genome sequencing that demand multiple instruments running in parallel for extended periods of time.
Service Partnership Programs
To complement our own service capabilities, we have developed partnered programs such as our Certified Service Providers (CSPro) and Illumina Genome Network (IGN), to create a world-wide network of Illumina technology-enabled service offerings that broaden our market reach. Illumina CSPro is a collaborative service partnership established between Illumina and leading genome centers and research laboratories to ensure the delivery of high-quality genetic analysis services. It provides a competitive advantage for service providers, while also ensuring that customers will receive Illumina data quality and service. To become a CSPro provider, participating laboratories must complete ana three-phased Illumina certification process and undergo recertification on an annual basis.process. There are over 5065 Illumina CSPro-certified organizations worldwide providing sequencing, genotyping, and gene expression services using our technologies and products.
Introduced in July 2010, the IGN links researchers interested in conducting large whole genome sequencing projects with leading institutes worldwide that possess our next-generation sequencing technology. The IGN provides a cost-effective and dependable way to complete large sequencing projects. The genome sequencing service network comprises CSPro-certified academicAll IGN partners are experienced and commercial organizations possessing 10well-published using Illumina technology, and each has completed Illumina’s Certified Service Provider (CSPro) certification. Each IGN partner possesses ten or more HiSeq 2000 or Genome Analyzerhigh-throughput Illumina sequencing systems, and committedproviding the scalability to providing industry-leading turnaround times of as few as 12 weeks for 50 samples.handle even the largest sequencing projects with rapid completion times. Current members includeinclude: the Broad Institute, British Columbia Cancer Agency’s Genome Science Centre, Cold Spring Harbor Laboratory, University of Washington Department of Genome Sciences, National Center for Genome Resources, (NCGR) in Santa Fe, New Mexico and the Macrogen Macrogen/Genomic Medicine Institute, in Seoul, Korea.and Illumina’s own FastTrack Services.
Individual Genome Sequencing
Intellectual Property
We have an extensive intellectual property portfolio, including, as of February 1, 2011,2013, ownership of, or exclusive licenses to, 214270 issued U.S. patents and 197172 pending U.S. patent applications, including seven11 allowed applications that have not yet issued as patents. Our issued patents include those directed to various aspects of our arrays, assays, oligo synthesis, sequencing technology, instruments, and chemical detection technologies, and have terms that expire between 20112013 and 2029.2030. We continue to file new patent applications to protect the full range of our technologies. We have filed or have been granted counterparts for many of these patents and applications in foreign countries.
We also rely upon trade secrets, know-how, copyright, and trademark protection, as well as continuing technological innovation and licensing opportunities to develop and maintain our competitive position. Our success will depend in part on our ability to obtain patent protection for our products and processes, to preserve our trade secrets, to enforce our patents, copyrights and trademarks, to operate without infringing the proprietary rights of third parties, and to acquire licenses related to enabling technology or products.
We are party to various exclusive and non-exclusive license agreements and other arrangements with third parties that grant us rights to use key aspects of our array and sequencing technologies, assay methods, chemical detection methods, reagent kits, and scanning equipment. We have exclusive licenses from Tufts University to patents that are directed to our BeadArray technology. These patents were filed by Dr. David Walt, who is a member of our board of directors, the Chairman of our Scientific Advisory Board, and one of our founders. Our exclusive licenses expire with the termination of the underlying patents, which will occur between 20112013 and 2020. We have additional nonexclusive license agreements with various third
11
parties for other components of our products. In most cases, the agreements remain in effect over the term of the underlying patents, may be terminated at our request without further obligation, and require that we pay customary royalties while the agreement is in effect.
Research and Development
We have made substantial investments in research and development since our inception. We have assembled a team of skilled scientists and engineers who are specialists in biology, chemistry, informatics, instrumentation, optical systems, software, manufacturing, and other related areas required to complete the development of our products. Our research and development efforts have focused primarily on the tasks required to optimize our sequencing, BeadArray, VeraCode, and oligo synthesis technologies and to support commercialization of the products and services derived from theseour technologies.
Our research and development expenses for 2010, 2009,fiscal 2012, 2011, and 2008 (inclusive of charges relating to share-based compensation of $25.42010 were $231.0 million $20.0, $196.9 million, and $14.1$177.9 million respectively) were $177.9 million, $140.6 million, and $100.0 million,, respectively. We expect research and development expense to increase during 20112013 as a result of the growth of our business and as we continue to expand our research and product development efforts.
Marketing and Distribution
Our current products address the genetic analysis portion of the life sciences market, in particular, experiments involving sequencing, SNP genotyping, and gene expression profiling. These experiments may be involved in many areas of biologic research, including basic human disease research, pharmaceutical drug discovery and development, pharmacogenomics, toxicogenomics, and animal and agricultural research. Our potential customers include leading genomic research centers, academic institutions, government laboratories, and clinical research organizations, as well as pharmaceutical, biotechnology, agrigenomics,agri-genomics, and consumer genomics companies. The genetic analysis market is relatively new and emerging and its size and speed of development will ultimately be driven by, among other items:
| the ability of the research community to extract medically valuable information from genomics and to apply that knowledge to multiple areas of disease-related research and treatment; | ||
the availability of sufficiently low cost, high-throughput research and analysis tools to enable the large amount of experimentation and analysis required to study genetic variation and biological function; and
the availability of government and private industry funding to perform the research required to extract medically relevant information from genomic analysis.
We market and distribute our products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region. In each of these areas, we have dedicated sales, service, and application support personnel responsible for expanding and managing their respective customer bases. In addition, in certain markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and South Africa we sell our products and provide services to customers through distributors that specialize in life science products. Likewise, in the United States we sell our qPCR portfolio (including the Eco Real-Time PCR System and associated reagents) through a distributor. We expect to continue to increase our sales and distribution resources during 20112013 and beyond as we launch a number of new products and expand the number of customers that can use our products.
Manufacturing
We manufacture sequencing and array platforms, reagent kits, scanning equipment, and oligos. Our manufacturing capacity for consumables and instruments has grown during 20102012 to support our increased
14
customer demand. We are also focused on continuing to enhance the quality and manufacturing yield of our BeadChips and flow cells, in particular. To continue to increase throughput and improve the quality and manufacturing yield as we increase the complexity of our products, we are exploring ways to continue increasing the level of automation in the manufacturing process. We adhere to access and safety standards required by federal, state, and local health ordinances, such as standards for the use, handling, and disposal of hazardous substances.
Raw Materials
Our manufacturing operations require a wide variety of raw materials, electronic and mechanical components, chemical and biochemical materials, and other supplies. We have multiple commercial sources for many of our components and supplies; however, there are some raw materials and components that we obtain from single source suppliers. To mitigate potential risks arising from single source suppliers, we believe that we can redesign our products for alternative components or
12
use alternative reagents, if required. In addition, while we generally attempt to keep our inventory at minimal levels, we purchase incremental inventory as circumstances warrant to protect our supply chain.
Competition
Although we believe that our products and services provide significant advantages over products and services currently available from other sources, we expect to continue to encounter intense competition from other companies that offer products and services for sequencing, SNP genotyping, gene expression, and molecular diagnostics markets. These include companies such as Affymetrix, Inc.; Agilent Technologies, Inc.; Beckman Coulter, Inc.; Complete Genomics, Inc.; Helicos BioSciences Corporation; General Electric Company; Life Technologies Corporation; Luminex Corporation; Pacific Biosciences of California, Inc.; QIAGEN N.V.; and Roche Diagnostics Corp.; and Sequenom, Inc., among others. Some of these companies have or will have substantially greater financial, technical, research, and other resources and larger, more established marketing, sales, distribution, and service organizations than we do. In addition, they may have greater name recognition than we do in the markets we address and in some cases a larger installed base of systems. Each of these markets is very competitive and we expect new competitors to emerge and the intensity of competition to increase. In order to effectively compete with these companies, we will need to demonstrate that our products have superior throughput, cost, and accuracy advantages over competing products.
Segment and Geographic Information
We currently sell our products to a number of customers outside the United States, including customers in other areas of North America, Europe, and the Asia-Pacific region. Shipments to customers outside the United States totaled $403.8$580.1 million, or 45%51% of our total revenue, during 2010,fiscal 2012, compared to $319.1$526.8 million, or 48%50%, and $293.2$403.8 million, or 51%45%, in 2009fiscal 2011 and 2008,2010, respectively. SalesThe U.S. dollar has been determined to customers outsidebe the functional currency of the United States were generally denominated in U.S. dollars. In 2008, we reorganized ourCompany’s international structureoperations due to establish more efficient channels among product development, product manufacturing, and sales. The reorganization increased our foreign subsidiaries’ anticipated dependence on the U.S. entity for management decisions, financial support, production assets, and inventory thereby making the foreign subsidiaries more of a direct and integral component of the U.S. entity’s operations. As a result, we reassessed the primary economic environment of our foreign subsidiaries and determined the subsidiaries are more U.S. dollar based, resulting in a U.S. dollar functional currency determination.subsidiaries. We expect that sales to international customers will continue to be an important and growing source of revenue. See note “13.“15. Segment Information,
15
Geographic Data, and Significant Customers” in Part II, Item 8 of thisForm 10-K for further information concerning our foreign and domestic operations.
Backlog
Our backlog was $299.0approximately $260 million and $227.6$251 million at December 30, 2012 and January 2, 2011 and January 3, 2010,1, 2012, respectively. Generally, our backlog consists of orders believed to be firm as of the balance sheet date; however, we may allow customers to make product substitutions as we launch new products. The timing of shipments depends on several factors, including agreed upon shipping schedules, which may span multiple quarters, and whether the product is catalog or custom. We expect an estimated 90%the majority of the backlog as of January 2, 2011December 30, 2012 to be shipped within the fiscal year ending January 1, 2012.December 29, 2013. Although we generally recognize revenue upon the transfer of title to a customer, we may be required to defer the recognition of revenue even after title transfer depending on the specific arrangement with a customer and the applicable accounting treatment. A material portion of our backlog at January 2, 2011 is associated with a large order we received from one customer at the end of 2009 for which we are using operating lease accounting that requires us to recognize revenue over a period of three years with the majority of that revenue recognized in 2011 and 2012.
Seasonality
Historically, customer purchasing patterns have not shown significant seasonal variation, although demand for our products is usually lowest in the first quarter of the calendar year and highest in the third quarter of the calendar year as a result, in part, of U.S. academic customers spending unused budget allocations before the end of the U.S. government’s fiscal year on September 30 of each year. However, this historical pattern has decreased during the past two years as a result, in part, of uncertainty concerning government and academic research funding and reduced usage of our consumable products during the summer vacation season.
13
Environmental Matters
We are committed to the protection of our employees and the environment. Our operations require the use of hazardous materials that subject us to a variety of federal, state, and local environmental and safety laws and regulations. We believe we are in material compliance with current applicable laws and regulations; however, we could be held liable for damages and fines should contamination of the environment or individual exposures to hazardous substances occur. In addition, we cannot predict how changes in these laws and regulations, or the development of new laws and regulations, will affect our business operations or the cost of compliance.
Government Regulation
The shorter 510(k) clearance process, which generally takes from three to six months after submission, but can take significantly longer, may be utilized if it is demonstrated that the new product is “substantially equivalent” to a similar product that has already been cleared by the FDA. The longer PMA process is much more costly, uncertain, and generally takes from nine months to two years after filing. Because we cannot ensurebe certain that any molecular diagnostic products that we develop will be subject to the shorter 510(k) clearance process, or will ultimately be approved at all, the regulatory approval process for such products may be significantly delayed and may be significantly more expensive than anticipated. If we fail to obtain, or experience significant delays in obtaining, regulatory approvals for molecular diagnostic products that we
16
develop, we may not be able to launch or successfully commercialize such products in a timely manner, or at all.
Changes to the current regulatory framework, including the imposition of additional or new regulations, could arise at any time during the development or marketing of our products, which may negatively affect our ability to obtain or maintain FDA or comparable regulatory approval of our products, if required.
In addition, the regulatory approval or clearance process required to design, manufacture, market, sell, and sellsupport our existing and future products that are intended for, and marketed and labeled as, “Research Use Only,” or RUO, is uncertain if such products are used or could be used, even without our consent, for the diagnosis of disease. If the FDA or other regulatory authorities assert that any of our RUO products are subject to regulatory clearance or approval, our business, financial condition, or results of operations could be adversely affected.
Employees
As of January 2, 2011,December 30, 2012, we had a total of approximately 2,1002,400 employees. None of our employees is represented by a labor union. We consider our employee relations to be positive. Our success will depend in large part upon our ability to attract and retain employees. In addition, we employ a number of temporary and contract employees. We face competition in this regard from other companies, research and academic institutions, government entities, and other organizations.
| ITEM 1A. | Risk Factors |
Our business is subject to various risks, including those described below. In addition to the other information included in thisForm 10-K, the following issues could adversely affect our operating results or our stock price.
Reduction or delay in research and development budgets and government funding may adversely affect our revenue.
A substantial portion of our revenue is derived from genomic research centers, academic institutions, government laboratories, and clinical research organizations, as well as pharmaceutical, biotechnology, agrigenomics, and consumer genomics companies, and their capital spending budgets can have a significant effect on the demand for our products and services. These budgets are based on a wide variety of factors, including the allocation of available resources to make purchases, funding from government sources, the spending priorities among various types of research equipment, and policies regarding capital expenditures during recessionary periods. Any decrease in capital spending or change in spending priorities of our customers could significantly reduce our revenue. Moreover, we have no control over the timing and amount of
14
purchases by our customers, and, as a result, revenue from these sources may vary significantly due to factors that can be difficult to forecast. Any delay or reduction in purchases by our customers or our inability to forecast fluctuations in demand could harm our future operating results.
The timing and amount of revenues from customers that rely on government and academic research funding may vary significantly due to factors that can be difficult to forecast, and there remains significant uncertainty concerning government and academic research funding worldwide as governments in the United States and Europe, in particular, focus on reducing fiscal deficits while at the same time confronting slowing economic growth. Funding for life science research has increased more slowly during the past several years compared to previous years and has declined in some countries. Government funding of research and development is subject to the political process, which is inherently fluid and unpredictable. Other programs, such as defense, entitlement programs, or general efforts to reduce budget deficits could be viewed by governments as a higher priority. These budgetary pressures may result in reduced allocations to government agencies that fund research and development activities, such as the U.S. National Institute of Health, or NIH. For instance, the significance and timing of anticipated reductions to the NIH budget from March 2013 may be significantly impacted by the sequestration provisions of the Budget Control Act of 2011 and whether these provisions remain in effect. Past proposals to reduce budget deficits have included reduced NIH and other research and development allocations. Any shift away from the funding of life sciences research and development or delays surrounding the approval of government budget proposals may cause our customers to delay or forego purchases of our products, which could adversely affect our business, financial condition, or results of operations.
We face intense competition, which could render our products obsolete, result in significant price reductions, or substantially limit the volume of products that we sell.
We compete with life sciences companies that design, manufacture, and market products for analysis of genetic variation and biological function and other applications using a wide-range of competing technologies. We anticipate that we will continue to face increased competition as existing companies develop new or improved products and as new companies enter the market with new technologies. One or more of our competitors may render our technology obsolete or uneconomical. Some of our competitors have greater financial and personnel resources, broader product lines, a more established customer base, and more experience in research and development than we do. Furthermore, life sciences and pharmaceutical companies, which are our potential customers and strategic partners, could also develop competing products. We believe that customers in our markets display a significant amount of loyalty to their initial supplier of a particular product; therefore, it may be difficult to generate sales to potential customers who have purchased products from competitors. To the extent we are unable to be the first to develop or supply new products, our competitive position may suffer.
The market for molecular diagnostics products is currently limited and highly competitive, with several large companies already having significant market share, intellectual property portfolios, and regulatory expertise. Established diagnostic companies also have an installed base of instruments in several markets, including clinical and reference laboratories, which could deter acceptance of our products. In addition, some of these companies have formed alliances with genomics companies that provide them access to genetic information that may be incorporated into their diagnostic tests.
Our acquisitions expose us to risks that could adversely affect our business, and wemay not achieve the anticipated benefits of acquisitions of businesses ortechnologies.
As part of our strategy to develop and identify new products, services, and technologies, we have made, and may continue to make, acquisitions of technologies, products, or businesses. Acquisitions involve numerous risks and operational, financial, and managerial challenges, including the following, any of which could adversely affect our business, financial condition, or results of operations:
difficulties in integrating new operations, technologies, products, and personnel;
lack of synergies or the inability to realize expected synergies and cost-savings;
difficulties in managing geographically dispersed operations;
underperformance of any acquired technology, product, or business relative to our expectations and the price we paid;
negative near-term impacts on financial results after an acquisition, including acquisition-related earnings charges;
the potential loss of key employees, customers, and strategic partners of acquired companies;
15
claims by terminated employees and shareholders of acquired companies or other third parties related to the transaction;
the issuance of dilutive securities, assumption or incurrence of additional debt obligations or expenses, or use of substantial portions of our cash;
diversion of management’s attention and company resources from existing operations of the business;
inconsistencies in standards, controls, procedures, and policies;
the impairment of intangible assets as a result of technological advancements, or worse-than-expected performance of acquired companies; and
assumption of, or exposure to, unknown contingent liabilities or liabilities that are difficult to identify or accurately quantify.
In addition, the successful integration of acquired businesses requires significant efforts and expense across all operational areas, including sales and marketing, research and development, manufacturing, finance, legal, and information technologies. There can be no assurance that any of the acquisitions we make will be successful or will be, or will remain, profitable. Our failure to successfully address the above risks may prevent us from achieving the anticipated benefits from any acquisition in a reasonable time frame, or at all.
Our success depends upon the continued emergence and growth of markets for analysis of genetic variation and biological function.
We design our products primarily for applications in the life sciences, diagnostic, agricultural, and pharmaceutical industries. The usefulness of our technologies depends in part upon the availability of genetic data and its usefulness in identifying or treating disease. We are focusing on markets for analysis of genetic variation and
17
biological function, namely sequencing, genotyping, and gene expression profiling. These markets are new and emerging, and they may not develop as quickly as we anticipate, or reach their full potential. Other methods of analysis of genetic variation and biological function may emerge and displace the methods we are developing. Also, researchers may not be able to successfully analyze raw genetic data or be able to convert raw genetic data into medically valuable information. For instance, demand for our microarray products may be adversely affected if researchers fail to find meaningful correlations between genetic variation, such as SNPs, and disease susceptibility through genome wide association studies. In addition, factors affecting research and development spending generally, such as changes in the regulatory environment affecting life sciences and pharmaceutical companies, and changes in government programs that provide funding to companies and research institutions, could harm our business. If useful genetic data is not available or if our target markets do not develop in a timely manner, demand for our products may grow at a slower rate than we expect, and we may not be able to sustain profitability.
If the quality of our products does not meet our customers’ expectations, then our reputation could suffer and ultimately oursales and operating earnings could be negativelyimpacted.
In the course of conducting our business, we must adequately address quality issues associated with our products and services, including defects in our engineering, design, and manufacturing processes, as well as defects in third-party components included in our products. Because our instruments and consumables are highly complex, the occurrence of defects may increase as we continue to introduce new products and services and as we rapidly scale up manufacturing to meet increased demand for our products and services. Although we have established internal procedures to minimize risks that may arise from product quality issues, there can be no assurance that we will be able to eliminate or mitigate occurrences of these issues and associated liabilities. In addition, identifying the root cause of quality issues, particularly those affecting reagents and third-party components, may be difficult, which increases the time needed to address quality issues as they arise and increases the risk that similar problems could recur. Finding solutions to quality issues can be expensive, and we may incur significant costs or lost revenue in connection with, for example, shipment holds, product recalls, and warranty or other service obligations. In addition, quality issues can impair our relationships with new or existing customers and adversely affect our brand image, and our reputation as a producer of high quality products could suffer, which could adversely affect our business, financial condition, or results of operations.
Our continued growth is dependent on continuously developing and commercializing newproducts.
Our target markets are characterized by rapid technological change, evolving industry standards, changes in customer needs, existing and emerging competition, strong price competition, and frequent new product introductions. Accordingly, our continued growth depends on continuously developing and commercializing new products and services, including improving
16
our existing products and services, in order to address evolving market requirements on a timely basis. If we fail to innovate or adequately invest in new technologies, our products and services will become dated, and we could lose our competitive position in the markets that we serve as customers purchase new products offered by our competitors. We believe that successfully introducing new products and technologies in our target markets on a timely basis provides a significant competitive advantage because customers make an investment of time in selecting and learning to use a new product and may be reluctant to switch once that selection is made.
To the extent that we fail to introduce new and innovative products, or such products are not accepted in the market or suffer significant delays in development, we may lose market share to our competitors, which will be difficult or impossible to regain. An inability, for technological or other reasons, to develop successfully develop and timely introduce new products could reduce our growth rate or otherwise have an adverse effect on our business. In the past, we have experienced, and are likely to experience in the future, delays in the development and introduction of new products. We cannot ensureThere can be no assurance that we will keep pace with the rapid rate of change in our markets or that our new products will adequately meet the requirements of the marketplace,
18
achieve market acceptance, or compete successfully with competing technologies. Some of the factors affecting market acceptance of new products and services include:
availability, quality, and price relative to competing products and services;
the functionality and performance of new and existing products and services;
the timing of introduction of new products or services relative to competing products and services;
scientists’ and customers’ opinions of the utility of new products or services;
citation of new products or services in published research;
regulatory trends and approvals; and
general trends in life sciences research and applied markets.
We may also have to write off excess or obsolete inventory if sales of our products are not consistent with our expectations or the market requirements for our products change due to technical innovations in the marketplace.
If we do not successfully manage the development, manufacturing, and launch of new products orservices, including product transitions, our financial results could be adverselyaffected.
We face risks associated with launching new products and pre-announcing products and services when the products or services have not been fully developed or tested. If our products and services are not able to deliver the performance or results expected by our target markets or are not delivered on a timely basis, our reputation and credibility may suffer. If we encounter development challenges or discover errors in our products late in our development cycle, we may delay ourthe product launch date. In addition, we may experience difficulty in managing or forecasting customer reactions, purchasing decisions, or transition requirements or programs (such as trade-in programs) with respect to newly launched products (or products in development) relative to our existing products, which could adversely affect sales of our existing products. The expenses or losses associated with unsuccessful product development or launch activities or lack of market acceptance of our new products could adversely affect our business, financial condition, or results of operations.
We depend on third-party manufacturers and suppliers for components and materialsused in our products, and if shipments from these manufacturers or suppliers aredelayed or interrupted, or if the quality of the components or materials supplied donot meet our requirements, we may not be able to launch, manufacture, or ship ourproducts in a timely manner, or at all.
The complex nature of our products requires customized, precision-manufactured components and materials that currently are available from a limited number of sources, and, in the case of some components
19
and materials, from only a single source. If deliveries from these vendors are delayed or interrupted for any reason, or if we are otherwise unable to secure a sufficient supply, we may not be able to obtain these components or materials on a timely basis or in sufficient quantities or qualities, or at all, in order to meet demand for our products. We may need to enter into contractual relationships with manufacturers for commercial-scale production of some of our products, or develop these capabilities internally, and we cannot ensurethere can be no assurance that we will be able to do this on a timely basis, in sufficient quantities, or on commercially reasonable terms. In addition, the lead time needed to establish a relationship with a new supplier can be lengthy, and we may experience delays in meeting demand in the event we must switch to a new supplier. The time and effort required to qualify a new supplier could result in additional costs, diversion of resources, or reduced manufacturing yields, any of which would negatively impact our operating results. Accordingly, we may not be able to establish or maintain reliable, high-volume manufacturing at commercially
17
reasonable costs or at all. In addition, the manufacture or shipment of our products may be delayed or interrupted if the quality of the components or materials supplied by our vendors does not meet our requirements. Current or future social and environmental regulations or critical issues, such as those relating to the sourcing of conflict minerals from the Democratic Republic of the Congo or the need to eliminate environmentally sensitive materials from our products, could restrict the supply of components and materials used in production or increase our costs. Any delay or interruption to our manufacturing process or in shipping our products could result in lost revenue, which would adversely affect our business, financial condition, or results of operations.
If we lose our key personnel or are unable to attract and retain additionalpersonnel, we may be unable to achieve our goals.
We are highly dependent on our management and scientific personnel, including Jay Flatley, our President and Chief Executive Officer. The loss of their services could adversely impact our ability to achieve our business objectives. In addition, the continued growth of our business depends on our ability to hire additional qualified personnel with expertise in molecular biology, chemistry, biological information processing, sales, marketing, and technical support. We compete for qualified management and scientific personnel with other life science companies, universities, and research institutions, particularly those focusing on genomics. Competition for these individuals, particularly in the San Diego and San Francisco area, is intense, and the turnover rate can be high. Failure to attract and retain management and scientific personnel would prevent us from pursuing collaborations or developing our products or technologies. Additionally, integration of acquired companies and businesses can be disruptive, causing key employees of the acquired business to leave. Further, we use stock options and restricted stock units to attract key personnel, incentivize them to remain with us, and align their interests with those of the Company by building long-term stockholder value. If our stock price decreases, the value of these equity awards decreases and therefore reduces a key employee’s incentive to stay.
If we are unable to increase our manufacturing capacity and develop and maintainoperation of our manufacturing capability, we may not be able to launch or supportour products in a timely manner, or at all.
We continue to rapidly increase our manufacturing capacity to meet the anticipated demand for our products. Although we have significantly increased our manufacturing capacity and we believe we have plans in place sufficient to ensure we have adequate capacity to meet our current business plan for 2011,plans, there are uncertainties inherent in expanding our manufacturing capabilities, and we may not be able to sufficiently increase our capacity in a timely manner. For example, manufacturing and product quality issues may arise as we increase production rates at our manufacturing facilities and launch new products. Also, we may not manufacture the right product mix to meet customer demand, especially as we introduce new products. As a result, we may experience difficulties in meeting customer, collaborator, and internal demand, in which case we could lose customers or be required to delay new product introductions, and demand for our products could decline. Additionally, in the past, we have experienced variations in manufacturing conditions and quality control issues that have temporarily reduced or suspended production of certain products. Due to the intricate nature of manufacturing complex instruments, consumables, and products that contain DNA, we may encounter similar or previously unknown manufacturing difficulties in the future that could significantly reduce production yields, impact our ability to launch or sell these products (or to produce them economically), prevent us from achieving expected performance levels, or cause us to set prices that hinder wide adoption by customers.
Additionally, we currently manufacture in a limited number of locations. Our manufacturing facilities are located in San Diego and Hayward, California; Madison, Wisconsin; Singapore; and Little Chesterford,Cambridge, United Kingdom. These areas are subject to natural disasters such as earthquakes, wildfires, or floods. If a natural disaster were to damage one of our facilities significantly or if other events were to cause our operations to fail, we may be unable to manufacture our products, provide our services, or develop new products.
Also, many of our manufacturing processes are automated and are controlled by our custom-designed Laboratory Information Management Systemlaboratory information management system (LIMS). Additionally, the decoding process in our array manufacturing requires significant network and storage infrastructure. If either our LIMS system or our networks or storage infrastructure were to fail for an extended period of time, it may adversely impact our ability to manufacture our products on a timely basis and could prevent us from achieving our expected shipments in any given period.
20
21
22
Any inability to effectively protect our proprietary technologies could harm ourcompetitive position.
Our success depends to a large extent on our ability to develop proprietary products and technologies and to obtain patents and maintain adequate protection of our intellectual property in the United States and other countries. If we do not protect our intellectual property adequately, competitors may be able to use our technologies and thereby erode our competitive advantage. The laws of some foreign countries do not protect proprietary rights to the same extent as the laws of the United States, and
18
many companies have encountered significant challenges in establishing and enforcing their proprietary rights outside of the United States. These challenges can be caused by the absence of rules and methods for the establishment and enforcement of intellectual property rights outside of the United States.
The patentproprietary positions of companies developing tools for the life sciences, genomics, agricultural, and pharmaceutical industries, including our patentproprietary position, generally are uncertain and involve complex legal and factual questions. We will be able to protect our proprietary rights from unauthorized use by third parties only to the extent that our proprietary technologies are covered by valid and enforceable patents or are effectively maintained as trade secrets. In addition, certain patent applications in the United States may be maintained in secrecy until the patents issue, and publication of discoveries in the scientific or patent literature tend to lag behind actual discoveries by several months. We intend to apply for patents covering our technologies and products as we deem appropriate. However, our patent applications may be challenged and may not result in issued patents or may be invalidated or narrowed in scope after they are issued. Questions as to inventorship or ownership may also arise. Any finding that our patents or applications are unenforceable could harm our ability to prevent others from practicing the related technology, and a finding that others have inventorship or ownership rights to our patents and applications could require us to obtain certain rights to practice related technologies, which may not be available on favorable terms, if at all. Furthermore, as issued patents expire, we may lose some competitive advantage as others develop competing products, and, as a result, we may lose revenue.
In addition, our existing patents and any future patents we obtain may not be sufficiently broad to prevent others from practicing our technologies or from developing competing products. There is also the risk that othersproducts and may independently develop similar or alternative technologies or design around our patented technologies. Also, our patents maytherefore fail to provide us with any competitive advantage. We may need to initiate lawsuits to protect or enforce our patents, or litigate against third party claims, which would be expensive, and, if we lose, may cause us to lose some of our intellectual property rights and reduce our ability to compete in the marketplace. Furthermore, these lawsuits may divert the attention of our management and technical personnel. There is also the risk that others may independently develop similar or alternative technologies or design around our patented technologies. In that regard, certain patent applications in the United States may be maintained in secrecy until the patents issue, and publication of discoveries in the scientific or patent literature tend to lag behind actual discoveries by several months.
We also rely upon trade secrets and proprietary know-how protection for our confidential and proprietary information, and we have taken security measures to protect this information. These measures, however, may not provide adequate protection for our trade secrets, know-how, or other confidential information. Among other things, we seek to protect our trade secrets and confidential information by entering into confidentiality agreements with employees, collaborators, and consultants. There can be no assurance that any confidentiality agreements that we have with our employees, collaborators, and consultants will provide meaningful protection for our trade secrets and confidential information or will provide adequate remedies in the event of unauthorized use or disclosure of such information. Accordingly, there also can be no assurance that our trade secrets will not otherwise become known or be independently developed by competitors.
Litigation, other proceedings, or third party claims of intellectual propertyinfringement could require us to spend significant time and money and could preventus from selling our products or services.
Our success depends, in part, on our non-infringement of the patents or proprietary rights of third parties. Third parties have asserted and may in the future assert that we are employing their proprietary technology without authorization. As we enter new markets or introduce new products, we expect that competitors will likely claim that our products infringe their intellectual property rights as part of a business strategy to impede our successful entry into those markets.competition. In addition, third parties may have obtained and may in the future obtain patents allowing them to claim that the use of our technologies infringes these patents. We could incur substantial costs and divert the attention of our management and technical personnel in defending ourselves against any of these claims. Any adverse ruling or perception of an adverse ruling in defending ourselves against these claims could have an adverse impact on our stock price, which may be disproportionate to the actual import of the ruling itself. Furthermore, parties making claims against us may be able to obtain injunctive or other relief, which effectively could block our ability to develop further, commercialize, or sell products or services, and could result in the award of substantial damages against us. In the event of a successful infringement claim against us, we may be required to pay damages and obtain one or more licenses from third parties, or be prohibited from selling certain products or services. In addition, we may be unable to obtain these licenses at a reasonable cost, if at all. We could therefore incur substantial costs related to royalty payments for licenses obtained from third parties, which could negatively affect our gross margins. In addition, we could encounter delays in product introductions while we attempt to develop alternative methods or products. Defense of any lawsuit or failure to obtain any of these licenses on favorable terms could prevent us from commercializing products, and the prohibition of sale of any of our products or services could adversely affect our ability to grow or maintain profitability.
Our products, if used for the diagnosis of disease, could be subject to governmentregulation, and the regulatory approval and maintenance process for such products maybe expensive, time-consuming, and uncertain both in timing and in outcome.
19
Products are not subject to FDA clearance or approval if they are not intended to be used for the diagnosis of disease. However, as we expand our product line to encompass products that are intended to be used for the diagnosis of disease, certain of our products will become subject to regulation by the FDA, or comparable agencies of other countries, including requirements for regulatory clearance or approval of such products before they can be marketed. Such regulatory approval processes or clearances may be expensive, time-consuming, and uncertain, and our failure to obtain or comply with such approvals and clearances could have an adverse effect on our business, financial condition, or operating results. In addition, changes to the current regulatory framework, including the imposition of additional or new regulations, could arise at any time during the development or marketing of our products, which may negatively affect our ability to obtain or maintain FDA or comparable regulatory approval of our products, if required.
Molecular diagnostic products, in particular, depending on their intended use, may be regulated as medical devices by the FDA and comparable agencies of other countries and may require either receiving clearance from the FDA following a pre-market notification process or premarket approval from the FDA, in each case prior to marketing. Obtaining the requisite regulatory approvals can be expensive and may involve considerable delay. If we fail to obtain, or experience significant delays in obtaining, regulatory approvals for molecular diagnostic products that we develop, we may not be able to launch or successfully commercialize such products in a timely manner, or at all.
In addition, the regulatory approval or clearance process required to design, manufacture, market, sell, and support our existing and future products that are intended for, and marketed and labeled as, “Research Use Only,” or RUO, is uncertain if such products are used or could be used, even without our consent, for the diagnosis of disease. If the FDA or other regulatory authorities assert that any of our RUO products are subject to regulatory clearance or approval, our business, financial condition, or results of operations could be adversely affected.
Doing business internationally creates operational and financial risks for ourbusiness.
Conducting and launching operations on an international scale requires close coordination of activities across multiple jurisdictions and time zones and consumes significant management resources. If we fail to coordinate and manage these activities effectively, including the risks noted below, our business, financial condition, or results of operations could be adversely affected. We are focused on expanding our international operations in key markets. We have sales offices located internationally throughout Europe, the Asia-Pacific region, and Brazil, as well as manufacturing facilities in the United Kingdom and Singapore. During 2010,2012, the majority of our sales to international customers andwere denominated in foreign currencies while the majority of our purchases of raw materials from international suppliers were denominated in U.S. dollars. Shipments to customers outside the United States comprised 45%51%, 48%50%, and 51%45% of our total revenue for thefiscal years ended January 2, 2012, 2011 January 3, 2010,, and December 28, 2008,2010, respectively. We intend to continue to expand our international presence by selling to customers located outside of the United States and we expect the total amount ofnon-U.S. sales to continue to grow.
International sales entail a variety of risks, including:
longer payment cycles and difficulties in collecting accounts receivable outside of the United States;
longer sales cycles due to the volume of transactions taking place through public tenders;
currency exchange fluctuations;
challenges in staffing and managing foreign operations;
tariffs and other trade barriers;
unexpected changes in legislative or regulatory requirements of foreign countries into which we sell our products;
difficulties in obtaining export licenses or in overcoming other trade barriers and restrictions resulting in delivery delays; and
significant taxes or other burdens of complying with a variety of foreign laws.
Changes in the value of the relevant currencies may affect the cost of certain items required in our operations. Changes in currency exchange rates may also affect the relative prices at which we are able sell products in the same market. Our revenues from international customers may be negatively impacted as increases in the U.S. dollar relative to our international customers local currency could make our products more expensive, impacting our ability to compete. Our costs of materials from international suppliers may increase if in order to continue doing business with us they raise their prices as the value of the U.S. dollar decreases relative to their local currency. Foreign policies and actions regarding currency valuation could result in actions by the United States and other countries to offset the effects of such fluctuations. The recent global financial downturn
20
has led to a high level of volatility in foreign currency exchange rates and that level of volatility may continue, which could adversely affect our business, financial condition, or results of operations.
We are subject to risks related to taxation in multiple jurisdictions and the possible loss of the tax deduction on our outstanding convertible notes.jurisdictions.
We are subject to income taxes in both the United States and numerous foreign jurisdictions. Significant judgments based on interpretations of existing tax laws or regulations are required in determining the provision for income taxes. Our effective income tax rate could be adversely affected by various factors, including, but not limited to, changes in the mix of earnings in tax jurisdictions with different statutory tax rates, changes in the valuation of deferred tax assets and liabilities, changes in existing tax laws or tax rates, changes in the level of non-deductible expenses (including share-based compensation), changes in our future levels of research and development spending, mergers and acquisitions, or the result of examinations by various tax authorities. Although we believe our tax estimates are reasonable, if the IRSU.S. Internal Revenue Service or other taxing authority disagrees with the positions taken by the Company on its tax returns, we could have additional tax liability, including interest and penalties. If material, payment of such additional amounts upon final adjudication of any disputes could have a material impact on our results of operations and financial position.
25
Our business has grown rapidly, with total revenues increasing from $73.5 million for the year ended January 1, 2006 to $1.15 billion for the year ended December 30, 2012 and with the number of employees increasing from 375 to approximately 2,400 during the same period. We expect to continue to experience substantial growth in order to achieve our operating plans. The continued global expansion of our business and addition of new personnel may place a strain on our management and operational systems. Our ability to effectively manage our operations and growth requires us to continue to expend funds to enhance our operational, financial, and management controls, reporting systems, and procedures and to attract and retain sufficient numbers of talented employees on a global basis. If we are unable to scale up and implement improvements to our manufacturing process and control systems in an efficient or timely manner, or if we encounter deficiencies in existing systems and controls, then we will not be able to make available the products required to successfully commercialize our technology. Our future operating results will depend on the ability of our management to continue to implement and improve our research, product development, manufacturing, sales and marketing, and customer support programs, enhance our operational and financial control systems, expand, train, and manage our employee base, integrate acquired businesses, and effectively address new issues related to our growth as they arise. There can be no assurance that we will be able to manage our recent or any future expansion or acquisition successfully, and any inability to do so could be adversely affected.affect our business, financial condition, or results of operations.
Our operating results may vary significantly from period to period, and we may not beable to sustain operating profitability.
Our revenue is subject to fluctuations due to the timing of sales of high-value products and services, the effects of new product launches and related promotions, the timing and availability of our customers’ funding, the impact of seasonal spending patterns, the timing and size of research projects our customers perform, the timing of our customers’ funding, changes in overall spending levels in the life sciences industry, and other unpredictable factors that may affect customer ordering patterns. Given the difficulty in predicting the timing and magnitude of sales for our products and services, we may experiencequarter-to-quarter fluctuations in revenue resulting in the potential for a sequential decline in quarterly revenue. While we anticipate future growth, there is some uncertainty as to the timing of revenue recognition on a quarterly basis. This is because a substantial portion of our quarterly revenue is typically recognized in the last month of a quarter and because the pattern for revenue generation during that month is normally not linear, with a concentration of orders in the final week of the quarter. In light of that, our revenue cut-off and recognition procedures, together with our manufacturing and shipping operations, may experience increased pressure and demand during the time period shortly before the end of a fiscal quarter.
A large portion of our expenses isare relatively fixed, including expenses for facilities, equipment, and personnel. In addition, we expect operating expenses to continue to increase significantly in absolute dollars, and we expect that our research and development and selling and marketing expenses will increase at a higher rate in the future as a result of the development and launch of new products. Accordingly, our ability to sustain profitability will depend, in part, on the rate of growth, if any, of our revenue and on the level of our expenses, and if revenue does not grow as anticipated, we may not be able to maintain annual or quarterly profitability. Any significant delays in the commercial launch of our products, unfavorable sales trends in our existing product lines, or impacts from the other factors mentioned above, could adversely affect our future revenue growth or cause a sequential decline in quarterly revenue. In addition, non-cash share-based compensation expense and expenses related to prior and future acquisitions are also likely to continue to adversely affect our future profitability. Due to the
21
possibility of significant fluctuations in our revenue and expenses, particularly from quarter to quarter, we believe that quarterly comparisons of our operating results are not a good indication of our future performance. If our operating results fluctuate or do not meet the expectations of stock market analysts and investors, our stock price could decline.
From time to time, we receive large orders that have a significant effect on our operating results in the period in which the order is recognized as revenue. The timing of such orders is difficult to predict, and the timing of revenue recognition from such orders may affect period to period changes in net sales. As a result, our operating results could vary materially from quarter to quarter based on the receipt of such orders and their ultimate recognition as revenue.
Changes in accounting standards and subjective assumptions, estimates, and judgmentsby management related to complex accounting matters could significantly affect ourfinancial results or financial condition.
Generally accepted accounting principles and related accounting pronouncements, implementation guidelines, and interpretations with regard to a wide range of matters that are relevant to our business, such as revenue recognition, asset impairment and fair value determinations, inventories, business combinations and intangible asset valuations, and litigation, are highly complex and involve many subjective assumptions, estimates, and judgments. Changes in these rules or their interpretation or changes in underlying assumptions, estimates, or judgments could significantly change our reported or expected financial performance or financial condition.
Ethical, legal, and social concerns related to the use of genetic information couldreduce demand for our products or services.
Our products may be used to provide genetic information about humans, agricultural crops, and other living organisms. The information obtained from our products could be used in a variety of applications, which may have underlying ethical, legal, and social concerns regarding privacy and the appropriate uses of the resulting information, including thepreimplantation genetic screening of embryos, prenatal genetic testing, genetic engineering or modification of agricultural products, or testing genetic predisposition for certain medical conditions.conditions, particularly for those that have no known cure. Governmental authorities could, for social or other purposes, call for limits on or regulation of the use of genetic testing or prohibit testing for genetic predisposition to certain conditions, particularly for those that have no known cure. Similarly, such concerns may lead individuals to refuse to use genetics tests even if permissible. These and other ethical, legal, and social concerns about genetic testing may limit market acceptance of our technology for certain applications or reduce the potential markets for our technology, either of which could have an adverse effect on our business, financial condition, or results of operations.
Our strategic equity investments may result in losses.
We periodically make strategic equity investments in various public and private companies with businesses or technologies that may complement our business. The market values of these strategic equity investments may fluctuate due to market conditions and other conditions over which we have no control.Other-than-temporary declines in the market price and valuations of the securities that we hold in other companies would require us to record losses in proportion to our ownership interest. This could result in future charges to our earnings. It is uncertain whether or not we will realize any long-term benefits associated with these strategic investments.
Security breaches and other disruptions could compromise our information and expose us to liability, which would cause our business and reputation to suffer.
In the ordinary course of our business, we collect and store sensitive data, including intellectual property, our proprietary business information, and that of our customers, and personally identifiable information of our customers and employees, in our data centers and on our networks. The secure maintenance of this information is important to our operations and business strategy. Despite our security measures, our information technology and infrastructure may be vulnerable to attacks by hackers or breached due to employee error, malfeasance or other disruptions. Any such breach could compromise our networks and the information stored there could be accessed, publicly disclosed, lost, or stolen. Any such access, disclosure, or other loss of information could result in legal claims or proceedings, liability under laws that protect the privacy of personal information, and damage to our reputation.
Conversion of our outstanding convertible notes may result in losses.
As of January 2, 2011,December 30, 2012, we had $390.0$40 million aggregate principal amount of convertible notes due 2014 and $920 million aggregate principal amount of convertible notes due 2016 outstanding. The notes are convertible into cash, and if applicable, shares of our common stock under certain circumstances, including trading price conditions related to our common
22
stock. If the trading price of our common stock remains significantly above the conversion price of $21.83 per share with respect to convertible notes due 2014 and $83.55 with respect to convertible notes due 2016, we expect that the noteholders will elect to convert the applicable notes. Upon conversion, we are required to record a gain or loss for the difference between the fair value of the notes to be extinguished and their corresponding net carrying value. The fair value of the notes to be extinguished depends on our current incremental borrowing rate. The net carrying value of our notes has an implicit interest rate of 8.27%.8.3% with respect to convertible notes due 2014 and 4.5% with respect to convertible notes due 2016. If our incremental borrowing rate at the time of conversion is lower than the implied interest rate of the notes, we will record a loss in our consolidated statement of income during the period in which the notes are converted.
Our Certificate of Incorporation and Bylaws include anti-takeover provisions that may make it difficult for another company to acquire control of us or limit the price investors might be willing to pay for our stock.
Certain provisions of our Certificate of Incorporation and Bylaws could delay the removal of incumbent directors and could make it more difficult to successfully complete a merger, tender offer, or proxy contest involving us. These provisions include our Preferred Shares Rights Agreement, commonly known as a “poison pill” and provisions in our Certificate of Incorporation that give our Board the ability to issue preferred stock and determine the rights and designations of the preferred stock at any time without stockholder approval. The rights of the holders of our common stock will be subject to, and may be adversely affected by, the rights of the holders of any preferred stock that may be issued in the future. The issuance of preferred stock, while providing flexibility in connection with possible acquisitions and other corporate purposes, could have the effect of making it more difficult for a third party to acquire, or of discouraging a third party from acquiring, a majority of our outstanding voting stock. In addition, the staggered terms of our board of directors could have the effect of delaying or deferring a change in control.
In addition, certain provisions of the Delaware General Corporation Law (“DGCL”), including Section 203 of the DGCL, may have the effect of delaying or preventing changes in the control or management of Illumina. Section 203 of the DGCL provides, with certain exceptions, for waiting periods applicable to business combinations with stockholders owning at least 15% and less than 85% of the voting stock (exclusive of stock held by directors, officers, and employee plans) of a company.
The above factors may have the effect of deterring hostile takeovers or otherwise delaying or preventing changes in the control or management of Illumina, including transactions in which our stockholders might otherwise receive a premium over the fair market value of our common stock.
| Unresolved Staff Comments. |
None.
27
| Properties. |
The following chart summarizes the facilities we lease as of January 2, 2011,December 30, 2012, including the location and size of each principal facility, and their designated use. We believe our facilities are adequate for our current and near-term needs, and that we will be able to locate additional facilities as needed.
| Approximate | Lease | |||||||||
| Location | Square Feet | Operation | Expiration Dates | |||||||
| San Diego, CA | 314,000 | R&D, Manufacturing, Storage, | 2011 – 2023 | |||||||
| Distribution and Administrative | ||||||||||
| Hayward, CA | 109,000 | R&D, Manufacturing and Administrative | 2013 – 2014 | |||||||
| Singapore | 61,000 | Manufacturing and Administrative | 2013 – 2015 | |||||||
| Eindhoven, the Netherlands | 54,000 | Distribution and Administrative | 2011 – 2015 | |||||||
| Little Chesterford, United Kingdom | 41,500 | R&D, Manufacturing and Administrative | 2024 | |||||||
| Other | 34,000 | R&D, Manufacturing, Sales and Administrative | 2011 – 2014 | |||||||
| Approximate | Lease | ||||||
| Location | Square Feet | Operation | Expiration Dates | ||||
| San Diego, CA | 502,000 | R&D, Manufacturing, Warehouse, | 2015 – 2031 | ||||
| Distribution, and Administrative | |||||||
| Hayward, CA | 109,000 | R&D, Manufacturing, and Administrative | 2013 – 2014 | ||||
| Singapore | 87,000 | Manufacturing and Administrative | 2013 – 2015 | ||||
| Eindhoven, the Netherlands | 42,000 | Distribution and Administrative | 2015 | ||||
| Cambridge, United Kingdom | 66,000 | R&D, Manufacturing, and Administrative | 2021 - 2024 | ||||
| Madison, WI | 27,000 | R&D, Manufacturing, and Administrative | 2018 | ||||
| Other | 19,000 | R&D, Manufacturing, Sales, and Administrative | 2013 - 2015 | ||||
23
| Legal Proceedings. |
On November 24, 2010, Syntrix Biosystems, Inc. filed suit against us in the United States District Court for the Western District of Washington at Tacoma (Case No. C10-5870-BHS) alleging that we willfully infringed U.S. Patent No. 6,951,682 by selling our BeadChip array products, and that we misappropriated Syntrix’s trade secrets. Fact and expert discovery is complete in the case. In November and December 2012, we filed motions for summary judgment that the patent is not infringed and is invalid, and that Syntrix’s trade secrets claims are barred by various statutes of limitation. Syntrix filed a motion for summary judgment that the patent is valid. On January 30, 2013, the court granted our motion for summary judgment on Syntrix’s trade secret claims, and dismissed those claims from the case. The court denied Syntrix’s motion for summary judgment on validity, and denied our motion for summary judgment for non-infringement and invalidity. A trial is scheduled to begin on February 26, 2013.
We have thoroughly investigated Syntrix’s claims and believe the claims are without merit. While we believe there is no legal basis for the alleged liability, we cannot estimate the possible loss or range of possible loss as there are significant legal and factual issues to be resolved. For example, each party has filed motions seeking to exclude portions of the other party’s expert testimony and to preclude the other party from introducing certain other evidence at trial. In addition to post-trial briefing, the parties would likely engage in appellate motion practice, the result of which is also unpredictable and could significantly affect the outcome of the case.
Not applicable.
24
PART II
| Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities. |
Market Information
Our common stock has been quoted on The NASDAQ Global Select Market under the symbol “ILMN” since July 28, 2000. Prior to that time, there was no public market for our common stock. The following table sets forth, for the fiscal periods indicated, the quarterly high and low sales prices per share of our common stock as reported on The NASDAQ Global Select Market.
| 2010 | 2009 | |||||||||||||||
| High | Low | High | Low | |||||||||||||
| First Quarter | $ | 40.90 | $ | 29.76 | $ | 38.95 | $ | 23.29 | ||||||||
| Second Quarter | 45.72 | 36.70 | 39.92 | 33.17 | ||||||||||||
| Third Quarter | 50.93 | 41.15 | 41.56 | 30.73 | ||||||||||||
| Fourth Quarter | 66.59 | 47.70 | 44.07 | 25.59 | ||||||||||||
| 2012 | 2011 | ||||||||||||||
| High | Low | High | Low | ||||||||||||
| First Quarter | $ | 55.39 | $ | 28.72 | $ | 74.12 | $ | 61.87 | |||||||
| Second Quarter | 53.00 | 37.77 | 76.81 | 65.41 | |||||||||||
| Third Quarter | 49.27 | 38.92 | 79.40 | 39.82 | |||||||||||
| Fourth Quarter | 57.00 | 44.78 | 40.53 | 25.57 | |||||||||||
Stock Performance Graph
The graph below compares the cumulative total stockholder returns on our common stock for the last five fiscal years with the cumulative total stockholder returns on the NASDAQ Composite Index and the NASDAQ Biotechnology Index for the same period. The graph assumes that $100 was invested on January 1, 2006December 30, 2007 in our common stock and in each index and that all dividends were reinvested. No cash dividends have been declared on our common stock. Stockholder returns over the indicated period should not be considered indicative of future stockholder returns.
and NASDAQ Biotechnology Index
25
Holders
As of February 4, 2011January 31, 2013 we had 348224 record holders of our common stock.
Dividends
We have never paid cash dividends and have no present intention to pay cash dividends in the foreseeable future. In addition, the indentureThe indentures for our 0.625% convertible senior notes due 2014 and 0.25% convertible senior notes due 2016, which notes are convertible into
29
cash and, in certain circumstances, shares of our common stock, requiresrequire us to increase the conversion rate applicable to the notes if we pay any cash dividends.
Purchases of Equity Securities by the Issuer
| Total Number of | Approximate Dollar | |||||||||||||||
| Shares Purchased as | Value of Shares | |||||||||||||||
| Total Number of | Part of Publicly | that May Yet Be | ||||||||||||||
| Shares | Average Price | Announced | Purchased Under | |||||||||||||
| Period | Purchased(1) | Paid per Share(1) | Programs(1) | the Programs(1) | ||||||||||||
| October 4 – October 31, 2010 | 160,517 | $ | 49.84 | 160,517 | $ | 176,002,121 | ||||||||||
| November 1 – November 28, 2010 | 139,738 | 57.25 | 139,738 | 168,002,146 | ||||||||||||
| November 29, 2010 – January 2, 2011 | 188,747 | 63.58 | 188,747 | 156,002,505 | ||||||||||||
| Total | 489,002 | $ | 57.86 | 489,002 | $ | 156,002,505 | ||||||||||
| Period | Total Number of Shares Purchased (1) | Average Price Paid per Share | Total Number of Shares Purchased as Part of Publicly Announced Programs | Approximate Dollar Value of Shares that May Yet Be Purchased Under the Programs | |||||||||
| October 1, 2012 - October 28, 2012 | 97,289 | $ | 51.39 | 97,289 | $ | 187,518,994 | |||||||
| October 29, 2012 - November 25, 2012 | 207,558 | 48.18 | 207,558 | 177,519,092 | |||||||||
| November 26, 2012 - December 30, 2012 | 190,921 | 52.38 | 190,921 | 167,519,168 | |||||||||
| Total | 495,768 | $ | 50.43 | 495,768 | $ | 167,519,168 | |||||||
____________
| (1) | All shares purchased during the fiscal quarter ended |
Sales of Unregistered Securities
None during the fourthfiscal quarter ended December 30, 2012.
26
| Selected Financial Data. |
The following table sets forth selected historical consolidated financial data for each of our last five fiscal years during the period ended January 2, 2011.December 30, 2012.
Statement of Operations Data
| Years Ended | ||||||||||||||||||||
| January 2, | January 3, | December 28, | December 30, | December 31, | ||||||||||||||||
| 2011 | 2010 | 2008 | 2007 | 2006 | ||||||||||||||||
| (52 weeks) | (53 weeks) | (52 weeks) | (52 weeks) | (52 weeks) | ||||||||||||||||
| (In thousands, except per share data) | ||||||||||||||||||||
| Total revenue | $ | 902,741 | $ | 666,324 | $ | 573,225 | $ | 366,799 | $ | 184,586 | ||||||||||
| Income (loss) from operations(1),(2) | 211,654 | 125,597 | 80,457 | (301,201 | ) | 37,812 | ||||||||||||||
| Net income (loss) | 124,891 | 72,281 | 39,416 | (287,305 | ) | 39,968 | ||||||||||||||
| Net income (loss) per share: | ||||||||||||||||||||
| Basic | $ | 1.01 | $ | 0.59 | $ | 0.34 | $ | (2.65 | ) | $ | 0.45 | |||||||||
| Diluted | $ | 0.87 | $ | 0.53 | $ | 0.30 | $ | (2.65 | ) | $ | 0.41 | |||||||||
| Shares used in calculating net income (loss) per share: | ||||||||||||||||||||
| Basic | 123,581 | 123,154 | 116,855 | 108,308 | 89,002 | |||||||||||||||
| Diluted | 143,433 | 137,096 | 133,607 | 108,308 | 97,508 | |||||||||||||||
| Years Ended | |||||||||||||||||||
December 30, 2012 (52 weeks) | January 1, 2012 (52 weeks) | January 2, 2011 (52 weeks) | January 3, 2010 (53 weeks) | December 28, 2008 (52 weeks) | |||||||||||||||
| (In thousands, except per share data) | |||||||||||||||||||
| Total revenue | $ | 1,148,516 | $ | 1,055,535 | $ | 902,741 | $ | 666,324 | $ | 573,225 | |||||||||
| Income from operations | 200,752 | 199,461 | 211,654 | 125,597 | 80,457 | ||||||||||||||
| Net income | 151,254 | 86,628 | 124,891 | 72,281 | 39,416 | ||||||||||||||
| Net income per share: | |||||||||||||||||||
| Basic | $ | 1.23 | $ | 0.70 | $ | 1.01 | $ | 0.59 | $ | 0.34 | |||||||||
| Diluted | $ | 1.13 | $ | 0.62 | $ | 0.87 | $ | 0.53 | $ | 0.30 | |||||||||
| Shares used in calculating net income per share: | |||||||||||||||||||
| Basic | 122,999 | 123,399 | 123,581 | 123,154 | 116,855 | ||||||||||||||
| Diluted | 133,693 | 138,937 | 143,433 | 137,096 | 133,607 | ||||||||||||||
Balance Sheet Data
| January 2, | January 3, | December 28, | December 30, | December 31, | ||||||||||||||||
| 2011 | 2010 | 2008 | 2007 | 2006 | ||||||||||||||||
| (In thousands) | ||||||||||||||||||||
| Cash, cash equivalents and short-term investments(2),(3),(4),(5) | $ | 894,289 | $ | 693,527 | $ | 640,075 | $ | 386,082 | $ | 130,804 | ||||||||||
| Working capital | 723,881 | 540,354 | 483,113 | 397,040 | 159,950 | |||||||||||||||
| Total assets | 1,839,113 | 1,429,937 | 1,327,171 | 929,981 | 300,584 | |||||||||||||||
| Long-term debt, current portion(5) | 311,609 | 290,202 | 276,889 | 16 | — | |||||||||||||||
| Long-term debt, less current portion(5) | — | — | — | 258,007 | — | |||||||||||||||
| Total stockholders’ equity(1),(2),(3),(4) | 1,197,675 | 864,248 | 798,667 | 353,927 | 247,342 | |||||||||||||||
| December 30, 2012 | January 1, 2012 | January 2, 2011 | January 3, 2010 | December 28, 2008 | |||||||||||||||
| (In thousands) | |||||||||||||||||||
| Cash, cash equivalents and short-term investments(1),(2),(3) | $ | 1,350,204 | $ | 1,189,568 | $ | 894,289 | $ | 693,527 | $ | 640,075 | |||||||||
| Working capital | 1,482,477 | 1,317,698 | 723,881 | 540,354 | 483,113 | ||||||||||||||
| Total assets | 2,566,085 | 2,195,840 | 1,839,113 | 1,429,937 | 1,327,171 | ||||||||||||||
| Long-term debt, current portion(1) | 36,967 | — | 311,609 | 290,202 | 276,889 | ||||||||||||||
| Long-term debt, less current portion(1) | 805,406 | 807,369 | — | — | — | ||||||||||||||
| Total stockholders’ equity(2),(3) | 1,318,581 | 1,075,215 | 1,197,675 | 864,248 | 798,667 | ||||||||||||||
In addition to the following notes, see Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations”Operations,” and Item 8, “Financial Statements and Supplementary Data”Data,” for further information regarding our consolidated results of operations and financial position for periods reported therein and for known factors that will impact comparability of future results.
| (1) | During 2011, we issued $920.0 million principal amount of |
| (2) | For the |
27
| (3) | In August 2008, a total of 8,050,000 shares were sold to the public at a public offering price of $43.75 per share, raising net proceeds to us of $342.7 million. | |
| Management’s Discussion and Analysis of Financial Condition and Results of Operations. |
Business Overview and Outlook. High level discussion of our operating results and significant known trends that affect our business.
Results of Operations. Detailed discussion of our revenues and expenses.
Liquidity and Capital Resources. Discussion of key aspects of our statements of cash flows, changes in our financial position, and our financial commitments.
Off-Balance Sheet Arrangements. We have no significant off-balance sheet arrangements.
Contractual Obligations. Tabular disclosure of known contractual obligations as of December 30, 2012.
Critical Accounting Policies and Estimates. Discussion of significant changes since our most recent Annual Report on Form 10-K that we believe are important to understanding the assumptions and judgments underlying our financial statements.
This MD&A discussion contains forward-looking statements. Seestatements that involve risks and uncertainties. Please see “Special Note Regarding Forward-Looking Statements” for additional factors relating to such statements, and see “Risk Factors” in Item 1A of this report for a discussion of certain risk factors applicable to our business, financial condition, and results of operations. Operating results are not necessarily indicative of results that may occur in future periods.
Business Overview and Outlook
This overview and outlook provides a high level discussion of our operating results and significant known trends that affect our business. We believe that an understanding of these trends is important to understanding our financial results for the periods being reported herein as well as our future financial performance. This summary is not intended to be exhaustive, nor is it intended to be a substitute for the detailed discussion and analysis provided elsewhere in this Annual Report on Form 10-K.
About Illumina
We are a leading developer, manufacturer, and marketer of life science tools and integrated systems for the analysis of genetic variation and function. Using our proprietary technologies, we provide a comprehensive line of genetic analysis solutions, with products and services that serveaddress a broad range of highly interconnected markets, including sequencing, genotyping, gene expression, and moleculargenomic-based diagnostics. Our customers include
31
leading genomic research centers, academic institutions, government laboratories, and clinical research organizations, as well as pharmaceutical, biotechnology, agrigenomics, and consumer genomics companies.companies, and in vitro fertilization clinics.
Our broad portfolio of systems,instruments, consumables, and analysis tools are designed to simplify and accelerate genetic analysis. This portfolio addresses the full range of genomic complexity, price points, and throughputs, enabling researchers to select the best solution for their scientific challenge. In 2007, through our acquisition of Solexa, Inc., we acquired our proprietary sequencing by synthesis (SBS) technology that is at the heart of our leading-edge sequencing instruments. These systems can be used to efficiently perform a range of nucleic acid (DNA, RNA) analyses on large numbers of samples. For more focused studies, our array-based solutions provide ideal tools to perform genome-wide association studies (GWAS) involving single-nucleotide polymorphism (SNP) genotyping and copy number variation (CNV) analyses, as well as gene expression profiling and other DNA, RNA, and protein studies.
In 2012 and early 2013, we took significant steps to support our goal to be the leader in genomic-based diagnostics by acquiring BlueGnome Ltd. (BlueGnome) in September 2012 and signing a definitive agreement to acquire Verinata Health, Inc. (Verinata) in January 2013. BlueGnome is a leading provider of solutions for the screening of genetic abnormalities associated with developmental delay, cancer, and infertility, and BlueGnome’s offerings enhance our ability to establish integrated solutions in reproductive health and cancer. Upon completion of the Verinata acquisition, we will further strengthen our diagnostic focus on reproductive health by having access to Verinata’s verifi® prenatal test, the broadest non-invasive prenatal test (NIPT) available today for high-risk pregnancies, and what we believe to be the most comprehensive intellectual propert
28
y portfolio in the NIPT industry. To further enhance our genetic analysis workflows, in January 2011 we acquired Epicentre Technologies Corporation (Epicentre), a leading provider of nucleic acid sample preparation reagents and specialty enzymes for sequencing and microarray applications. In 2010, through our acquisition of Helixis, Inc., we expanded our portfolio to include real-time polymerase chain reaction (PCR), one of the most widely used technologies in life sciences. Our new Eco Real-Time PCR System provides researchers with an affordable, full-featured system to perform targeted validation studies.
Our financial results have been, and will continue to be, impacted by several significant trends, which are described below. While these trends are important to understanding and evaluating our financial results, this discussion should be read in conjunction with our consolidated financial statements and the notes thereto in Item 1, Part I of this report, and the other transactions, events, and trends discussed in “Risk Factors” in Item 1A, Part I of this report may also materially impact our business operations and financial results.report.
Funding Environment
There remains significant uncertainty concerning government and academic research funding worldwide as governments in the United States and Europe, in particular, focus on reducing fiscal deficits while at the same time confronting slow economic growth. We believe this uncertainty will continue in 2013, which could lead to purchasing delays and could negatively impact our business.
While many of our customers receive funding from government agencies to purchase our products or services, we are increasingly less dependent on government funding. In fiscal 2012, approximately 30% of our total revenue came from commercial customers who are not reliant on government agencies for funding, and it is our strategy to diversify our customer base to increase further the portion of our revenue from commercial customers over time. However, we estimate that approximately one-third of our total revenue continues to be derived, directly or indirectly, from funding provided by the U.S. National Institute of Health (NIH). In fiscal 2012, the NIH budget increased 1% as compared to fiscal 2011 levels. NIH funding for the first quarter of 2013 will be subject to the continuing resolution that was signed into law by President Obama and funds the NIH at 90% of budget. The significance and timing of any reductions to the NIH budget from March 2013 may be significantly impacted by the sequestration provisions of the Budget Control Act of 2011 and by whether these provisions remain in effect. In addition, the U.S. Department of Health and Human Services (HHS), of which the NIH is a part, has the ability to reallocate funds within its budget to spare the NIH from the full effect of HHS budget reductions. We further believe that allocations within the NIH budget will continue to favor genetic analysis tools generally and, in particular, research programs that utilize next-generation sequencing.
Next-Generation Sequencing
Our sequencing instrument portfolio primarily includes the HiSeq product family and MiSeq. We began full commercial shipments in the fourth quarter of the launch, a substantial number2012 of our customers who previously purchased the Genome Analyzerannounced HiSeq 2500 sequencing system, ordered the HiSeq 2000 to replace their existing sequencer with this new system. As a result of strong demand, both from customers who desired to trade-in their existing Genome Analyzers and new customers who ordered the HiSeq 2000, our manufacturing capacity was constrained throughout all of 2010. During the year we significantly increased our manufacturing capacity for the HiSeq 2000 to meet growing demand. We now believe that we have increased our capacity to the point where we can begin reducing our backlog and fulfilling new orders in a more timely manner. Additionally, in the first half of 2011, we expect to further enhance the performance of the HiSeq 2000. We believe that these enhancements will enablewhich allows customers to sequence wholean entire human genomes for less than $5,000genome in consumable costs. As we continue to make improvements that reduce the cost ofapproximately a day. Our MiSeq sequencing we believe that more customers will use the HiSeq 2000, which generates more revenue per instrument time than the Genome Analyzer. We believe that this will increase our consumable pull-through, whichsystem is a measure of the annual consumable revenue generated from each instrument in the installed base.
32
As a complement to advances innext-generation sequencing, technology, we believe microarrays offer a cheaper,less expensive, faster, and morehighly accurate technology for use when genetic content is already known. The information content of microarrays is fixed and reproducible. As such, microarrays provide repeatable, standardized assays for certain subsets of nucleotide bases within the overall genome. During 2010, microarray product sales As the cost of sequencing continues to decrease, we believe that life science researchers will migrate certain whole genome array studies to sequencing over the next few years; however, we expect this decline to be offset by demand from customers in applied and translational markets.
29
Financial Overview
Financial highlights for 2012 include the following:
Net revenue increased as by 9% during 2012 compared to 2009, led by:
Gross Margin
33
In 2012, we completed the relocation of our headquarters that started in 2011 and global expansion.incurred $26.3 million in headquarter relocation expense, which primarily included a cease-use loss upon vacating our prior headquarters, double rent expense during the transition to the new facility, and the accretion of interest expense on the related lease exit liability. We do not expect to incur significant additional headquarter relocation expense other than the accretion of interest expense on lease exit liability.
In 2012, we also incurred $23.1 million in expenses associated with the unsolicited tender offer for shares of our common stock commenced by CKH Acquisition Corp. and Roche Holding Ltd. (together, “Roche”) in early 2012. We anticipate incurring additional advisory expenses through mid-2013.
32.1% in 2012, as compared to 34.9% in 2011. The provision for income taxes is dependent on the mix of earnings in tax jurisdictions with different statutory tax rates and the other factors discussed in the risk factor “We are subject to risks related to taxation in multiple jurisdictions and the possible loss of the tax deduction on our outstanding convertible notes”jurisdictions” in Item 1A of thisForm 10-K. report. For 20112013 and beyond, we anticipate increased earnings in higher tax jurisdictions, which may adversely impact the provision for income taxes.taxes to increase in absolute dollars but the effective tax rate to trend lower than the U.S. federal statutory rate as the portion of our earnings subject to lower statutory tax rates increases.
We ended 2012 with cash, cash equivalents, and beyond.short-term investments totaling $1.35 billion.
30
Results of Operations
To enhance comparability, the following table sets forth audited consolidated statement of operations data for the years ended December 30, 2012, January 1, 2012, and January 2, 2011 January 3, 2010 and December 28, 2008 stated as a percentage of total revenue.
| 2010 | 2009 | 2008 | ||||||||||
| Revenue: | ||||||||||||
| Product revenue | 93 | % | 94 | % | 93 | % | ||||||
| Service and other revenue | 7 | 6 | 7 | |||||||||
| Total revenue | 100 | 100 | 100 | |||||||||
| Cost of revenue: | ||||||||||||
| Cost of product revenue | 30 | 29 | 34 | |||||||||
| Cost of service and other revenue | 2 | 2 | 2 | |||||||||
| Amortization of intangible assets | 1 | 1 | 2 | |||||||||
| Impairment of manufacturing equipment | — | — | 1 | |||||||||
| Total cost of revenue | 33 | 32 | 39 | |||||||||
| Gross profit | 67 | 68 | 61 | |||||||||
| Operating expense: | ||||||||||||
| Research and development | 20 | 21 | 17 | |||||||||
| Selling, general and administrative | 24 | 26 | 26 | |||||||||
| Acquisition related (gain) expense, net | (1 | ) | 2 | 4 | ||||||||
| Total operating expense | 43 | 49 | 47 | |||||||||
| Income from operations | 24 | 19 | 14 | |||||||||
| Other income (expense): | ||||||||||||
| Interest income | 1 | 2 | 2 | |||||||||
| Interest expense | (3 | ) | (4 | ) | (4 | ) | ||||||
| Other (expense) income, net | (1 | ) | — | 1 | ||||||||
| Total other expense, net | (3 | ) | (2 | ) | (1 | ) | ||||||
| Income before income taxes | 21 | 17 | 13 | |||||||||
| Provision for income taxes | 7 | 6 | 6 | |||||||||
| Net income | 14 | % | 11 | % | 7 | % | ||||||
34
| 2012 | 2011 | 2010 | ||||||
| Revenue: | ||||||||
| Product revenue | 91.9 | % | 93.5 | % | 93.3 | % | ||
| Service and other revenue | 8.1 | 6.5 | 6.7 | |||||
| Total revenue | 100.0 | 100.0 | 100.0 | |||||
| Cost of revenue: | ||||||||
| Cost of product revenue | 27.6 | 29.2 | 30.1 | |||||
| Cost of service and other revenue | 3.8 | 2.5 | 2.4 | |||||
| Amortization of acquired intangible assets | 1.2 | 1.1 | 0.9 | |||||
| Total cost of revenue | 32.6 | 32.8 | 33.4 | |||||
| Gross profit | 67.4 | 67.2 | 66.6 | |||||
| Operating expense: | ||||||||
| Research and development | 20.1 | 18.7 | 19.7 | |||||
| Selling, general and administrative | 24.9 | 24.8 | 24.4 | |||||
| Headquarter relocation expense | 2.3 | 4.0 | — | |||||
| Unsolicited tender offer related expense | 2.0 | — | — | |||||
| Restructuring charges | 0.4 | 0.8 | — | |||||
| Acquisition related expense (gain), net | 0.2 | 0.1 | (0.9 | ) | ||||
| Total operating expense | 49.9 | 48.4 | 43.2 | |||||
| Income from operations | 17.5 | 18.8 | 23.4 | |||||
| Other income (expense): | ||||||||
| Cost-method investment related gain (loss), net | 4.0 | — | (1.1 | ) | ||||
| Interest income | 1.4 | 0.7 | 0.9 | |||||
| Interest expense | (3.3 | ) | (3.3 | ) | (2.7 | ) | ||
| Other (expense) income, net | (0.2 | ) | (3.7 | ) | — | |||
| Total other income (expense), net | 1.9 | (6.3 | ) | (2.9 | ) | |||
| Income before income taxes | 19.4 | 12.5 | 20.5 | |||||
| Provision for income taxes | 6.2 | 4.4 | 6.7 | |||||
| Net income | 13.2 | % | 8.1 | % | 13.8 | % | ||
Our fiscal year is the 52 or 53 weeks ending the Sunday closest to December 31, with quarters of 13 or 14 weeks ending the Sunday closest to March 31, June 30, September 30, and December 31. The yearyears ended December 30, 2012, January 1, 2012, and January 2, 2011 was were 52 weeks, and the year ended January 3, 2010 was 53 weeks.respectively.
Revenue
| 2010 | 2009 | Change | % Change | |||||||||||||
| (In thousands) | ||||||||||||||||
| Product revenue | $ | 842,510 | $ | 627,240 | $ | 215,270 | 34 | % | ||||||||
| Service and other revenue | 60,231 | 39,084 | 21,147 | 54 | ||||||||||||
| Total revenue | $ | 902,741 | $ | 666,324 | $ | 236,417 | 35 | % | ||||||||
| Total gross profit | $ | 601,540 | $ | 453,875 | $ | 147,665 | 33 | % | ||||||||
| Total gross margin | 66.6 | % | 68.1 | % | ||||||||||||
| 2012 - 2011 | 2011 - 2010 | ||||||||||||||||||||||||
| (Dollars in thousands) | 2012 | 2011 | Change | % Change | 2010 | Change | % Change | ||||||||||||||||||
| Product revenue | $ | 1,055,826 | $ | 987,280 | $ | 68,546 | 7 | % | $ | 842,510 | $ | 144,770 | 17 | % | |||||||||||
| Service and other revenue | 92,690 | 68,255 | 24,435 | 36 | 60,231 | 8,024 | 13 | ||||||||||||||||||
| Total revenue | $ | 1,148,516 | $ | 1,055,535 | $ | 92,981 | 9 | % | $ | 902,741 | $ | 152,794 | 17 | % | |||||||||||
Product revenue consists primarily of revenue from the sale of consumables and instruments. Services and other revenue consists primarily of instrument service contract revenue as well as sequencing and genotyping service revenue.
31
2012 Compared to 2011
Consumables revenue increased$133.5 million, or 22%, to $729.3 million in 2012 compared to $595.8 million in 2011. The increase was primarily attributable to increased sales of sequencing consumables, driven by higher consumable sales per HiSeq instrument and the growth in both the HiSeq and MiSeq installed base.
Instrument revenue decreased$58.8 million, or 16%, to $314.3 million in 2012 compared to $373.1 million in 2011, driven by a decrease in HiSeq shipments, partially offset by a full year of MiSeq shipments in 2012 as compared to less than two quarters of shipments in 2011.
Revenue in 2011 reflects the impact of discounts provided to customers under our Genome Analyzer trade-in program. The estimated incremental sales incentive provided under this trade-in program was approximately $11.1 million, based on the total discount provided from list price in excess of our average discount on HiSeq 2000 sales during the period. The Genome Analyzer trade-in program was completed in Q4 2011. See “Revenue Recognition” in note “1. Summary of Significant Accounting Policies” in Part II, Item 8, of this Form 10-K for additional information on the Genome Analyzer trade-in program.
The increase in service and other revenue in 2012 compared to 2011 was driven by an increase in our instrument service contract revenue as a result of our growing installed base as well as an increase in our genotyping and sequencing service revenue.
2011 Compared to 2010
Consumables revenue increased $113.7$90.8 million, or 29%18%, to $595.8 million in 2011 compared to $505.0 million for 2010 comparedin 2010. The increase was primarily attributable to $391.3 millionincreased sales of sequencing consumables, which accounted for 2009. Microarray consumable revenue, which constituted more than half of our total consumableconsumables revenue increased $28.3 million primarily attributable to growth in sales of our Infinium BeadChips, which constituted a majority of our microarray consumable sales. Sales volume of our Infinium BeadChip products increased on a per sample basis during 2010 compared to 2009. The average selling price per sample, however, declined due to a change in product mix primarily attributable to growth in sales of our focused content arrays and a number of large sample volume purchase orders that incurred higher discounts. Revenue from sequencing consumables increased $85.4 million due to2011, driven by growth in the installed base of our sequencing systems.systems, partially offset by a decrease in the consumable revenue per sequencing instrument.
Revenue from HiSeq 2000 sales in 2011 and 2010 was impacted by discounts provided to customers under our Genome Analyzer trade-in program. The estimated incremental sales incentive provided under this trade-in program was approximately $11.1 million and $47.8 million in 2011 and 2010, respectively. See “Revenue Recognition” in note “1. Organization and Summary of Significant Accounting Policies” in Part II, Item 8, of thisForm 10-K for additional information on the Genome Analyzer trade-in program.
The impact ofincrease in service and other revenue in 2011 compared to 2010 was primarily driven by an increase in our instrument service contract revenue resulting from our expanded installed base and an increase in sequencing services.
Gross Margin
| 2012 - 2011 | 2011 - 2010 | ||||||||||||||||||||||||
| (Dollars in thousands) | 2012 | 2011 | Change | % Change | 2010 | Change | % Change | ||||||||||||||||||
| Total gross profit | $ | 773,528 | $ | 709,098 | $ | 64,430 | 9 | % | $ | 601,540 | $ | 107,558 | 18 | % | |||||||||||
| Total gross margin | 67.4 | % | 67.2 | % | 66.6 | % | |||||||||||||||||||
2012 Compared to 2011
Gross profit in 2012 increased in comparison to 2011 primarily due to higher sales. Gross margin improved in 2012 due in large part to the promotional programsshift in sales mix from instruments to consumables, which have a higher margin than instruments. This improvement was partially offset by a legal settlement charge recorded to cost of sales in 2012. In addition, instrument sales in 2011 were affected by promotional discounts provided to customers on HiSeq 2000 sales, including the Genome Analyzer trade-in program. Based on the estimated amount of incremental sales incentive provided, the Genome Analyzer trade-in
32
program negatively impacted our gross margin by approximately 1.1% in 2011. This trade-in program was completed in Q4 2011.
2011 Compared to 2010
Gross margin increased in 2011 compared to 2010. During the period, the gross margin of our instrument sales improved, marginsprimarily driven by an increase in average selling price per instrument as our Genome Analyzer trade-in program was substantially completed in the first half of 2011. The Genome Analyzer trade-in program negatively impacted our gross margin by approximately 1.1% and 5.3% in 2011 and 2010, respectively, based on the estimated amount of incremental sales incentive provided. The gross margin of our consumable sales also increased as we experienced a shift in sales mix from lower gross margin microarray consumables to higher gross margin sequencing consumables, primarily attributabledue to improved overhead absorptionthe expansion of our sequencing instrument installed base. The improvements in gross margins were partially offset by the negative impact from higher stock compensation expense and higher amortization expense of acquired intangible assets included in cost of revenue.
Operating Expense
| 2012 - 2011 | 2011 - 2010 | ||||||||||||||||||||||||
| (Dollars in thousands) | 2012 | 2011 | Change | % Change | 2010 | Change | % Change | ||||||||||||||||||
| Research and development | $ | 231,025 | $ | 196,913 | $ | 34,112 | 17 | % | $ | 177,947 | $ | 18,966 | 11 | % | |||||||||||
| Selling, general and administrative | 285,991 | 261,843 | 24,148 | 9 | 220,454 | 41,389 | 19 | ||||||||||||||||||
| Headquarter relocation expense | 26,328 | 41,826 | (15,498 | ) | (37 | ) | — | 41,826 | 100 | ||||||||||||||||
| Unsolicited tender offer related expense | 23,136 | — | 23,136 | 100 | — | — | — | ||||||||||||||||||
| Restructuring charges | 3,522 | 8,136 | (4,614 | ) | (57 | ) | — | 8,136 | 100 | ||||||||||||||||
| Acquisition related expense (gain), net | 2,774 | 919 | 1,855 | 202 | (8,515 | ) | 9,434 | (111 | ) | ||||||||||||||||
| Total operating expense | $ | 572,776 | $ | 509,637 | $ | 63,139 | 12 | % | $ | 389,886 | $ | 119,751 | 31 | % | |||||||||||
2012 Compared to 2011
Research and development expense increased by $34.1 million, or 17%, in 2012 from 2011, primarily due to a $21.4 million impairment loss recognized for IPR&D recorded as a result of a prior acquisition and increased volumespersonnel expenses as we continue to increase our investment in projects to develop and commercialize new products. In addition, we incurred increased facilities expenses in 2012 as the rental fees for our current headquarters are higher than our prior facility.
Selling, general and administrative expense increased by $24.1 million in 2012 from 2011. The increase is primarily driven by a $15.8 million increase in personnel expenses associated with increased headcount, and a $9.5 million increase in legal and other consulting fees. Personnel expenses included salaries, share-based compensation, and benefits. These increases in expense were partially offset by a $2.3 million decrease in bad debt expense, as certain customer bankruptcies impacted us in 2011. In addition, we had the benefit of decreased costsa $2.3 million legal settlement gain recorded in selling, general and administrative expenses in 2011.
In Q3 2012, we completed the relocation of our headquarters that started in 2011. During 2012, we incurred $26.3 million in additional headquarter relocation expense, primarily consisting of cease-use loss associated with chemistry improvements.vacating our prior headquarters, double rent expense during the transition to our new facility, and accretion of interest expense on the lease exit liability. Headquarter relocation expense recorded in 2011 consisted of accelerated depreciation and rent expense on the new facility during the transition period of occupying both the current and new facility.
During Q1 2012, CKH Acquisition Corporation and Roche Holding Ltd. (together, “Roche”) made an unsolicited tender offer to purchase all outstanding shares of our common stock for up to $51.00 per share. During 2012, we recorded $23.1 million of expenses incurred in relation to Roche’s unsolicited tender offer, consisting primarily of legal, advisory, and other professional fees.
In late 2011, we announced restructuring plans to reduce our global workforce and to consolidate certain facilities. As a result of the restructuring effort, we recorded additional restructuring charges of $3.5 million during 2012, comprised primarily of separation and other employee costs.
33
Acquisition related expense (gain), net in 2012 consisted of acquisition transaction costs of $0.8 million and changes in fair value of contingent consideration of $2.0 million. Acquisition related expense (gain), net in 2011 consisted of gains related to changes in fair value of contingent consideration offset by acquired in-process research and development of $5.4 million related to a milestone payment for a prior acquisition.
| 2010 | 2009 | Change | % Change | |||||||||||||
| (In thousands) | ||||||||||||||||
| Research and development | $ | 177,947 | $ | 140,616 | $ | 37,331 | 27 | % | ||||||||
| Selling, general and administrative | 220,990 | 176,337 | 44,653 | 25 | ||||||||||||
| Acquisition related (gain) expense, net | (9,051 | ) | 11,325 | (20,376 | ) | (180 | ) | |||||||||
| Total operating expense | $ | 389,886 | $ | 328,278 | $ | 61,608 | 19 | % | ||||||||
2011 Compared to 2010
The increase in research and development expensesexpense in 2011 from 2010 was primarily attributable to a $25.9 millionan increase in personnel expenses includingof $17.5 million associated with increased average headcount during 2011 and an increase of $2.9 million in research and development supplies. Personnel expenses included salaries, non-cash share-based compensation, and benefits, and an increase in other non-personnel expenses of $13.3 million comprised mostly of lab and production supplies expenses. These increases were primarily attributable to investments in new product development and commercialization along with projects to sustain and optimize our existing product portfolio.benefits.
The increase in selling, general and administrative expensesexpense in 2011 from 2010 was primarily attributable to a $31.8 millionan increase in personnel expenses including salaries, non-cash share-based compensation, and benefits,of $33.5 million associated with the growth of our business and anduring the period. The remaining increase was primarily driven by a $4.0 million increase in outside servicebad debt expenses as a result of $9.7customer bankruptcies, and a $3.7 million increase in supplies, repairs, and maintenance expenses. These increases were partially offset by a legal settlement gain of $2.3 million, representing the payment we received to settle an outstanding commercial dispute.
In 2011, we relocated our headquarters to another facility in San Diego, California and incurred $41.8 million in headquarter relocation expense, which included a cease-use loss upon vacating our prior headquarters, accelerated depreciation of certain property and equipment, and double rent expense during the transition to the new facility.
In Q4 2011, we announced a restructuring plan to reduce our global workforce by approximately 200 employees, or approximately 8%, and to consolidate certain facilities. As a result of the restructuring effort, we recorded a restructuring charge of $8.1 million during Q4 2011, comprised mostlyprimarily of legalseverance pay and marketing expenses.other employee separation costs.
Other Income (Expense), Net
| 2012 - 2011 | 2011 - 2010 | ||||||||||||||||||||||||
| (Dollars in thousands) | 2012 | 2011 | Change | % Change | 2010 | Change | % Change | ||||||||||||||||||
| Cost-method investment related gain (loss), net | $ | 45,911 | $ | — | $ | 45,911 | 100 | % | $ | (10,309 | ) | $ | 10,309 | (100 | )% | ||||||||||
| Interest income | 16,208 | 7,052 | 9,156 | 130 | 8,378 | (1,326 | ) | (16 | ) | ||||||||||||||||
| Interest expense | (37,779 | ) | (34,790 | ) | (2,989 | ) | 9 | (24,598 | ) | (10,192 | ) | 41 | |||||||||||||
| Other (expense) income, net | (2,484 | ) | (38,678 | ) | 36,194 | (94 | ) | 254 | (38,932 | ) | (15,328 | ) | |||||||||||||
| Total other income (expense), net | $ | 21,856 | $ | (66,416 | ) | $ | 88,272 | (133 | )% | $ | (26,275 | ) | $ | (40,141 | ) | 153 | % | ||||||||
2012 Compared to 2011
During the former shareholdersfourth quarter of 2012, we recognized a gain of $48.6 million on the sale of our minority ownership interest in deCODE Genetics, a cost-method investment. We also recorded an impairment loss of $2.7 million on another cost-method investment that was determined to be other-than-temporarily impaired.
Interest income increased in 2012 primarily due to a $6.0 million recovery of a company we acquired in 2008. During 2009, acquisition related (gain) expense, net, included acquired in-process researchpreviously impaired note receivable and development charges of $11.3 million related to milestone payments made to the former shareholders of the company we acquired in 2008.
| 2010 | 2009 | Change | % Change | |||||||||||||
| (In thousands) | ||||||||||||||||
| Interest income | $ | 8,378 | $ | 11,029 | $ | (2,651 | ) | (24 | )% | |||||||
| Interest expense | (24,598 | ) | (23,718 | ) | (880 | ) | 4 | |||||||||
| Other (expense) income, net | (10,055 | ) | 1,217 | (11,272 | ) | (926 | ) | |||||||||
| Total other expense, net | $ | (26,275 | ) | $ | (11,472 | ) | $ | (14,803 | ) | 129 | % | |||||
Other (expense) income, net, in 2012 primarily consisted of foreign exchange losses. Other (expense) income, net, in 2011 primarily consisted of a $37.6 million loss on the extinguishment of debt recorded on conversions of our 0.625% convertible senior notes due 2014.
34
2011 Compared to 2010
The decrease in interest income in 2011 compared to 2010 was primarily attributabledriven by lower interest rates, despite the increase in our cash, cash equivalents and short-term investment balance during the period. Interest expense increased during the period primarily due to the accretion of discount on our $920.0 million 0.25% convertible senior notes due 2016 issued in the first half of 2011, partially offset by the decrease in interest expense associated with the repayment of $349.9 million in principal for the 0.625% convertible senior notes due 2014 during 2011.
Other (expense) income, net, in 2011 primarily consisted of a loss of $37.6 million on the extinguishment of debt recorded on conversions of our 0.625% convertible senior notes due 2014 and a $1.1 million foreign exchange loss recorded during the period. The loss on extinguishment of debt was calculated as the difference between the carrying amount of the converted notes and their fair value as of the settlement dates. Other (expense) income, net, in 2010 primarily consisted of a $13.2 million impairment charge recorded in Q4 2010 related to the impairment of a cost-method investment and a related note receivable, (see note “5. Impairment” in Part II, Item 8 of thisForm 10-K for additional information on this impairment) partially offset by a $2.9 million gain recognized in Q2 2010 on the acquisition of Helixis, Inc., which representedrecorded for the difference between the carrying value of our cost-methoda cost method investment in Helixis, Inc. prior to the acquisition and the fair value of that investment at the time of acquisition.acquisition, and foreign exchange gains.
Cost-method investment related gain (loss), net, in 2010 consisted of a $13.2 million impairment charge recorded on a cost-method investment and a related note receivable, partially offset by a $2.9 million gain on acquisition of a previous investee.
Provision for Income Taxes
| 2012 - 2011 | 2011 - 2010 | ||||||||||||||||||||||||
| (Dollars in thousands) | 2012 | 2011 | Change | % Change | 2010 | Change | % Change | ||||||||||||||||||
| Income before income taxes | $ | 222,608 | $ | 133,045 | $ | 89,563 | 67 | % | $ | 185,379 | $ | (52,334 | ) | (28 | )% | ||||||||||
| Provision for income taxes | 71,354 | 46,417 | 24,937 | 54 | 60,488 | (14,071 | ) | (23 | ) | ||||||||||||||||
| Net income | $ | 151,254 | $ | 86,628 | $ | 64,626 | 75 | % | $ | 124,891 | $ | (38,263 | ) | (31 | )% | ||||||||||
| Effective tax rate | 32.1 | % | 34.9 | % | 32.6 | % | |||||||||||||||||||
2012 Compared to 2011
Our effective tax rate was 32.1% for 2012. The variance from the U.S. statutory rate of 35% was primarily attributable to the change in the mix of earnings in tax jurisdictions with different statutory rates. Our future effective tax rate may vary from the U.S statutory tax rate due to the change in the mix of earnings in tax jurisdictions with different statutory rates, benefits related to tax credits, and the tax impact of non-deductible expenses and other permanent differences between income before income taxes and taxable income. The effective tax rate in 2011 closely approximated the U.S. statutory rate because a significant portion of our earnings were subject to U.S. taxation.
| 2010 | 2009 | Change | % Change | |||||||||||||
| (In thousands) | ||||||||||||||||
| Income before income taxes | $ | 185,379 | $ | 114,125 | $ | 71,254 | 62 | % | ||||||||
| Provision for income taxes | $ | 60,488 | $ | 41,844 | $ | 18,644 | 45 | % | ||||||||
| Effective tax rate | 32.6 | % | 36.7 | % | ||||||||||||
2011 Compared to 2010
The decreaseeffective tax rate in 2011 closely approximated the U.S. statutory rate because a significant portion of our earnings was subject to U.S. taxation. The increase in the effective tax rate in 2011 from 2010 was primarily attributable to the gainlower non-taxable gains recorded on the changes in fair value of contingent consideration related to prior acquisitions and higher nondeductible acquired IPR&D charges recorded in 2011.
Liquidity and Capital Resources
At December 30, 2012, we had approximately $434.0 million in cash and cash equivalents, a $131.0 million increase from last year, due to the factors described in the “Cash Flow Summary” below. Our primary source of liquidity has been cash flows from operations. Our ability to generate cash from operations provides us with the financial flexibility we need to meet operating, investing, and financing needs. Cash and cash equivalents held by our foreign subsidiaries at December 30, 2012 were approximately $265.5 million. It is our intention to indefinitely reinvest all current and future foreign earnings in foreign subsidiaries.
Historically, we have liquidated our short-term investments and/or issued debt and equity securities to finance our business needs as a supplement to cash provided by operating activities. At December 30, 2012, we have $916.2 million in
35
short-term investments. Our short-term investments include marketable securities consisting of debt securities in government-sponsored entities, corporate debt securities, and U.S. Treasury notes.
In 2011, we issued $920.0 million in principal amount of convertible senior notes that mature on March 15, 2016 (2016 notes). We pay 0.25% interest per annum on the principal amount of the 2016 notes semi-annually in arrears in cash on March 15 and September 15 of each year. In 2007, we issued $400.0 million in principal of convertible senior notes that mature on February 15, 2014 (2014 notes). We pay 0.625% interest per annum on the principal amount of the 2014 notes semi-annually in arrears in cash on February 15 and August 15 of each year. Additional information about the convertible notes, including their conversion features, is described in note “7. Convertible Senior Notes” in Part II, Item 8, of this Form 10-K. As of December 30, 2012, the principal amounts of our 2016 notes and 2014 notes were $920.0 million and $40.1 million, respectively. Our commitment of interest payment on these outstanding notes is $8.4 million on an annual basis.
Our primary short-term needs for capital, which are subject to change, include expenditures related to:
support of commercialization efforts related to our current and future products, including expansion of our direct sales force and field support resources both in the United States and abroad;
acquisitions of equipment and other fixed assets for use in our current and future manufacturing and research and development facilities;
repurchases of our outstanding common stock;
the continued advancement of research and development efforts;
potential strategic acquisitions and investments; and
the expansion needs of our facilities, including costs of leasing additional facilities.
In 2012, we acquired BlueGnome for total cash and other consideration of $95.5 million, which included $7.5 million in fair value of contingent cash consideration. In 2011, we acquired Epicentre for total cash and other consideration of $71.4 million, which included $4.6 million in the fair value of contingent consideration relatedsettled in stock and $7.4 million in the fair value of contingent cash consideration.
Our Board of Directors has authorized several common stock repurchase programs. In 2012, we used $82.5 million to repurchase our outstanding shares under these programs. As of December 30, 2012, we had authorization from our Board of Directors to repurchase to an additional $167.5 million of our common stock.
During 2011, we used $314.3 million of the net proceeds from the issuance of our 2016 notes to purchase 4.9 million shares of our common stock in privately negotiated transactions concurrently with the issuance. We also used part of the net proceeds for the extinguishment of $349.9 million principal amount of our 2014 notes upon conversion. We used the remaining net proceeds for other general corporate purposes, which included acquisitions and purchases of our common stock.
We expect that our revenue and the resulting operating income, as well as the status of each of our new product development programs, will significantly impact our cash management decisions.
We anticipate that our current cash, cash equivalents and short-term investments, together with cash provided by operating activities will be sufficient to fund our near term capital and operating needs for at least the next 12 months, including the pending acquisition of Helixis, Inc. that is excluded from taxable incomeVerinata. Operating needs include the planned costs to operate our business, including amounts required to fund working capital and a decrease in nondeductible acquired IPR&D recognized for financial reporting purposes in 2010 as compared to 2009.
capital expenditures. Our fiscal year is 52 or 53 weeks ending the Sunday closest to December 31, with quarters of 13 or 14 weeks ending the Sunday closest to March 31, June 30, September 30, and December 31. The year ended January 3, 2010 was 53 weeksfuture capital requirements and the year ended December 28, 2008 was 52 weeks.
| 2009 | 2008 | Change | % Change | |||||||||||||
| (In thousands) | ||||||||||||||||
| Product revenue | $ | 627,240 | $ | 532,390 | $ | 94,850 | 18 | % | ||||||||
| Service and other revenue | 39,084 | 40,835 | (1,751 | ) | (4 | ) | ||||||||||
| Total revenue | $ | 666,324 | $ | 573,225 | $ | 93,099 | 16 | % | ||||||||
| Total gross profit | $ | 453,875 | $ | 353,094 | $ | 100,781 | 29 | % | ||||||||
| Total gross margin | 68.1 | % | 61.6 | % | ||||||||||||
our ability to successfully commercialize and further develop our technologies and create innovative products in our markets;
scientific progress in our research and development programs and the magnitude of those programs;
competing technological and market developments; and
the need to enter into collaborations with other companies or acquire other companies or technologies to enhance or complement our product and service offerings.
36
Cash flow Summary
| (In thousands) | 2012 | 2011 | 2010 | ||||||||
| Net cash provided by operating activities | $ | 291,873 | $ | 358,140 | $ | 272,573 | |||||
| Net cash used in investing activities | (150,012 | ) | (400,999 | ) | (285,053 | ) | |||||
| Net cash (used in) provided by financing activities | (10,755 | ) | 97,016 | 116,474 | |||||||
| Effect of exchange rate changes on cash and cash equivalents | (103 | ) | (126 | ) | 320 | ||||||
| Net increase in cash and cash equivalents | $ | 131,003 | $ | 54,031 | $ | 104,314 | |||||
Operating Activities
Cash provided by operating activities in 2012 consisted of net income of $151.3 million primarily attributable plus net adjustments to lower salesnet income of whole-genome genotyping arrays partially$158.6 million, offset by growth in focused content arrays. The decline was driven by customers delaying the start of new GWAS in anticipation of new and rare variant content from the 1000 Genome Project, order delays directly related to stimulus funding under the Recovery Act, and the impact of reduced foundation funding at a few key customers. Sales volume for our Infinium BeadChip product lines, which constituted a majority of our microarray consumable sales, was relatively flat on a sample basis during 2009 compared to 2008. The average selling price per sample, however, declined due to a change in product mix attributablenet operating assets of $18.0 million. The primary non-cash expenses added back to growthnet income included share-based compensation of $94.3 million, depreciation and amortization expenses related to property and equipment and acquired intangible assets of $63.8 million, impairment of IPR&D of $21.4 million, and the accretion of the debt discount of $35.0 million. The adjustments to net income also included $20.8 million in incremental tax benefit related to share-based compensation, $45.9 million in net cost-method investment related gain, and $6.0 million in recovery of a previously impaired note receivable. The main drivers in the saleschange in net operating assets included increases in accounts receivable, inventory, accounts payable, and accrued liabilities.
Cash provided by operating activities in 2011 consisted of our focused content arrays coupled with lower salesnet income of whole-genome genotyping arrays.
37
| 2009 | 2008 | Change | % Change | |||||||||||||
| (In thousands) | ||||||||||||||||
| Research and development | $ | 140,616 | $ | 99,963 | $ | 40,653 | 41 | % | ||||||||
| Selling, general and administrative | 176,337 | 148,014 | 28,323 | 19 | ||||||||||||
| Acquisition related (gain) expense, net | 11,325 | 24,660 | (13,335 | ) | (54 | ) | ||||||||||
| Total operating expense | $ | 328,278 | $ | 272,637 | $ | 55,641 | 20 | % | ||||||||
| 2009 | 2008 | Change | % Change | |||||||||||||
| (In thousands) | ||||||||||||||||
| Interest income | $ | 11,029 | $ | 12,519 | $ | (1,490 | ) | (12 | )% | |||||||
| Interest expense | (23,718 | ) | (22,210 | ) | (1,508 | ) | 7 | |||||||||
| Other income (expense), net | 1,217 | 1,921 | (704 | ) | (37 | ) | ||||||||||
| Total other expense, net | $ | (11,472 | ) | $ | (7,770 | ) | $ | (3,702 | ) | 48 | % | |||||
38
| 2009 | 2008 | Change | % Change | |||||||||||||
| (In thousands) | ||||||||||||||||
| Income before income taxes | $ | 114,125 | $ | 72,687 | $ | 41,438 | 57 | % | ||||||||
| Provision for income taxes | $ | 41,844 | $ | 33,271 | $ | 8,573 | 26 | % | ||||||||
| Effective tax rate | 36.7 | % | 45.8 | % | ||||||||||||
| 2010 | 2009 | 2008 | ||||||||||
| (In thousands) | ||||||||||||
| Net cash provided by operating activities | $ | 272,573 | $ | 172,191 | $ | 87,882 | ||||||
| Net cash used in investing activities | (285,053 | ) | (256,569 | ) | (277,249 | ) | ||||||
| Net cash provided by (used in) financing activities | 116,474 | (98,862 | ) | 337,672 | ||||||||
| Effect of exchange rate changes on cash and cash equivalents | 320 | 849 | 3,778 | |||||||||
| Net increase (decrease) in cash and cash equivalents | $ | 104,314 | $ | (182,391 | ) | $ | 152,083 | |||||
Cash provided by operating activities in 2010 consistsconsisted of net income of $124.9 million plus net non-cash adjustments to net income of $149.8$150.1 million and, offset by a $2.1$2.4 million decrease in net operating assets. The primary non-cash expenses added back to net income included share based compensation of $71.6 million, depreciation and amortization expenses related to property and equipment and intangible assets of $42.0 million, and the amortizationaccretion of the debt discount on our convertible notes totaling $21.4 million. The adjustments to net income also included $42.4 million in incremental tax benefit related to share-based compensation. The main drivers in the change in net operating assets included increases in accounts receivable, inventory, accounts payable and accrued liabilities. These increases were primarily related to the growth
Investing Activities
Cash used in investing activities totaled $150.0 million in 2012. We purchased $925.5 million of available-for-sale securities and $898.8 million of our business.available-for-sale securities matured or were sold during the period. We used $15.9 million for purchases of strategic investments and $12.2 million for purchases of intangible assets. We also paid net cash of $83.2 million for acquisitions, and invested $68.8 million in capital expenditures primarily associated with the purchase of manufacturing and servicing equipment, leasehold improvements, and information technology equipment and systems. We received $50.8 million in proceeds from a sale of a cost-method investment as well as $6.0 million from the recovery of a note receivable previously impaired.
Cash used in investing activities totaled $285.0$401.0 million in 2010. During the year we:
39
Cash used in investing activities totaled $285.1 million in 2010. During the year we purchased $846.2 million of available-for-sale securities, and $688.6 million of our facilitiesavailable-for-sale securities matured or were sold. We also paid net cash of $98.2 million for acquisitions, sold trading securities totaling $54.9 million, used $49.8 million for capital expenditures
37
primarily associated with the purchase of manufacturing equipment and infrastructure atfor additional production capacity and rental and loaner instruments, and made strategic investments totaling $27.7 million.
Financing Activities
Cash used in financing activities totaled $10.8 million in 2012. We received $54.4 million in proceeds from the issuance of common stock through the exercise of stock options and warrants and under our San Diego, Haywardemployee stock purchase plan. We used $82.5 million to repurchase our common stock in 2012. In addition, we received $20.8 million in incremental tax benefit related to share-based compensation.
Cash provided by financing activities totaled $97.0 million in 2011. We received $903.5 million in proceeds from the issuance of $920.0 million of our 0.25% convertible senior notes due 2016, net of issuance discounts, of which $349.9 million was used to repay the principal amount of our 0.625% convertible senior notes due 2014 upon conversions in 2011. We used $570.4 million in repurchases of our common stock. We also received $67.5 million in proceeds from the issuance of our common stock through the exercise of stock options and UK locations.warrants and under our employee stock purchase plan. In addition, we received $46.4 million in incremental tax benefit related to share-based compensation.
Cash provided by financing activities totaled $116.5 million in 2010. We received $118.0 million in proceeds from the issuance of our common stock through the exercise of stock options and warrants and under our Employee Stock Purchase Plan.employee stock purchase plan. We also received $42.4 million in incremental tax benefit related to stock options exercised. These increases wereshare-based compensation. Cash provided by these activities was partially offset by common stock repurchases of $44.0 million.
40
Off-Balance Sheet Arrangements
We do not participate in any transactions that generate relationships with unconsolidated entities or financial partnerships, such as entities often referred to as structured finance or special purpose entities, which would have been established for the purpose of facilitating off-balance sheet arrangements or other contractually narrow or limited purposes. During the fiscal year ended January 2, 2011,December 30, 2012, we were not involved in any “off-balance sheet arrangements” within the meaning of the rules of the SEC.Securities and Exchange Commission.
Contractual Obligations
Contractual obligations represent future cash commitments and liabilities under agreements with third parties, and exclude orders for goods and services entered into in the normal course of business that are not enforceable or legally binding. The following table represents our contractual obligations as of January 2, 2011,December 30, 2012, aggregated by type (amounts in thousands):
| Payments Due by Period(1) | ||||||||||||||||||||
| Less Than | More Than | |||||||||||||||||||
| Contractual Obligation | Total | 1 Year | 1 – 3 Years | 3 – 5 Years | 5 Years | |||||||||||||||
| Debt obligations(2) | $ | 398,530 | $ | 2,437 | $ | 4,875 | $ | 391,218 | $ | — | ||||||||||
| Operating leases | 499,261 | 13,965 | 37,737 | 40,985 | 406,574 | |||||||||||||||
| Amounts due under executive deferred compensation plan | 5,272 | 5,272 | — | — | — | |||||||||||||||
| Total | $ | 903,063 | $ | 21,674 | $ | 42,612 | $ | 432,203 | $ | 406,574 | ||||||||||
| Payments Due by Period(1) | ||||||||||||||||||||
| Less Than | More Than | |||||||||||||||||||
| Contractual Obligation | Total | 1 Year | 1 – 3 Years | 3 – 5 Years | 5 Years | |||||||||||||||
| Debt obligations(2) | $ | 968,551 | $ | 2,551 | $ | 44,850 | $ | 921,150 | $ | — | ||||||||||
| Operating leases | 515,207 | 27,676 | 47,167 | 47,276 | 393,088 | |||||||||||||||
| Purchase obligations | 12,276 | 8,908 | 3,368 | — | — | |||||||||||||||
| Amounts due under executive deferred compensation plan | 12,071 | 12,071 | — | — | — | |||||||||||||||
| Total | $ | 1,508,105 | $ | 51,206 | $ | 95,385 | $ | 968,426 | $ | 393,088 | ||||||||||
| (1) | The table excludes |
| (2) | Debt obligations include the principal amount of our convertible senior notes due 2016 and 2014, as well as interest payments |
41
38
maturity can result in repayments of the principal amounts sooner than the scheduled repayments as indicated in the table. See note “7. Convertible Senior Notes” in Part II, Item 8 of this Form 10-K for further discussion of the terms of the convertible senior notes.
Critical Accounting Policies and Estimates
The preparation of financial statements in accordance with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in our consolidated financial statements and accompanying notes. Management bases its estimates on historical experience, market and other conditions, and various other assumptions it believes to be reasonable. Although these estimates are based on management’s best knowledge of current events and actions that may impact us in the future, the estimation process is, by its nature, uncertain given that estimates depend on events over which we may not have control. If market and other conditions change from those that we anticipate, our consolidated financial statements may be materially affected. In addition, if our assumptions change, we may need to revise our estimates, or take other corrective actions, either of which may also have a material effect on our consolidated financial statements.
We believe that the following critical accounting policies and estimates have a higher degree of inherent uncertainty and require our most significant judgments. In addition, had we used estimates different from any of these, our consolidated financial statements could have been materially different from those presented. Members of our senior management have discussed the development and selection of our critical accounting policies and estimates, and our disclosure regarding them, with the audit committee of our board of directors. Our accounting policies are more fully described in note “1. Organization and Significant Accounting Policies” in Part II, Item 8 of thisForm 10-K.
Revenue Recognition
Our revenue is generated primarily from the sale of products and services. Product revenue primarily consists of sales of instruments and consumables used in genetic analysis. Service and other revenue primarily consists of revenue received for performingfrom instrument service contract sales, genotyping and sequencing services, extended warranty sales, and amounts earned under research agreements with government grants, which are recognized in the period during which the related costs are incurred. The timing of revenue recognition and the amount of revenue actually recognized in each case depends upon a variety of factors, including the specific terms of each arrangement and the nature of our deliverables and obligations. Determination of the appropriate amount of revenue recognized involves significant judgments and estimates and actual results may differ from our estimates.
We recognize revenue when persuasive evidence of an arrangement exists, delivery has occurred or services have been rendered, the seller’s price to the buyer is fixed or determinable, and collectibility is reasonably assured. In instances where final acceptance of the product or system is required, revenue is deferred until all the acceptance criteria have been met. All revenue is recorded net of any discounts.
Revenue for product sales is recognized generally upon transfer of title to the customer, provided that no significant obligations remain and collection of the receivable is reasonably assured. Revenue forfrom instrument service contracts is recognized as the services are rendered, typically evenly over the contract term. Revenue from genotyping and sequencing services is recognized when earned, which is generally at the time the genotyping or sequencing analysis data is made available to the customer or agreed upon milestones are reached.
In order to assess whether the price is fixed or determinable, we evaluate whether refund rights exist. If there are refund rights or payment terms based on future performance, we defer revenue recognition until the price becomes fixed or determinable. We assess collectibility based on a number of factors, including past transaction history with the customer and the creditworthiness of the customer. If we determine that collection of a payment is not reasonably assured, revenue recognition is deferred until receipt of payment.
We regularly enter into contracts where revenue is derived from multiple deliverables including any mix of products or services. These products or services are generally delivered within a short time frame, approximately three to six months, of the contract execution date. Revenue recognition for contracts with multiple deliverables is based on the individual units of accounting determined to exist in the contract. A delivered item is considered a separate unit of accounting when the delivered item has value to the customer on a stand-alone basis. Items are considered to have stand-alone value when they are sold separately by any vendor or when the customer could resell the item on a stand-alone basis.
For transactions entered into in 2009 and 2010,with multiple deliverables, consideration is allocated at the inception of the contract to all deliverables based on their relative selling price. The relative selling price for each deliverable is determined using vendor specific objective
39
evidence (VSOE) of selling price or third-party evidence of selling price if VSOE does not exist. If neither VSOE nor third-party evidence exists, we use best estimate of the selling price for the deliverable.
In order to establish VSOE of selling price, we must regularly sell the product or service on a standalone basis with a substantial majority priced within a relatively narrow range. VSOE of selling price is usually the midpoint of that range. If there are not a sufficient number of standalone sales and VSOE of selling price cannot be determined, then we consider whether third party evidence can be used to establish selling price. Due to the lack of similar products and services sold by other companies within the industry, we have rarely established selling price using third-party evidence. If neither VSOE nor third party evidence of selling price exists, we determine our best estimate of selling price using average selling prices over a rolling12-month period coupled with an assessment of current market conditions. If the product or service has no history of sales or if the sales volume is not sufficient, we rely upon prices set by our pricing committee adjusted for applicable discounts. We recognize revenue for delivered elements only when we determine there are no uncertainties regarding customer acceptance.
In the first quarter of 2010, we offered an incentive with the launch of the HiSeq 2000 that enabled existing Genome Analyzer customers to trade in their Genome Analyzer and receive a discount on the purchase of a HiSeq 2000. The incentive was limited to customers who had purchased a Genome Analyzer as of the date of the announcement and was the first significant trade-in program we have offered. The Genome Analyzer trade-in program was completed in 2011. We will accountaccounted for HiSeq 2000 discounts related to the Genome Analyzer trade-in program in the period in whichas reductions to revenue upon recognition of the HiSeq 2000 sales revenue, which is recognized.later than the date the trade-in program was launched.
Investments
We determineinvest in various types of securities, including debt securities in government-sponsored entities, corporate debt securities, and U.S. treasury securities. As of December 30, 2012, we have $916.2 million in short-term investments. In accordance with the accounting standard for fair value measurements, we classify our investments as Level 1, 2, or 3 within the fair value hierarchy. Fair values determined by Level 1 inputs utilize quoted prices (unadjusted) in active markets for identical assets that we have the ability to access. Fair values determined by Level 2 inputs utilize data points that are observable such as quoted prices, interest rates and yield curves. Fair values determined by Level 3 inputs utilize unobservable data points for the asset.
As discussed in note “6. Fair Value Measurements” in Part II, Item 8 of this Form 10-K, a majority of our security holdings have been classified as Level 2. These securities have been initially valued at the transaction price and subsequently valued utilizing a third party service provider who assesses the fair value using inputs other than quoted prices that are observable either directly or indirectly, such as yield curve, volatility factors, credit spreads, default rates, loss severity, current market and contractual prices for the underlying instruments or debt, broker and dealer quotes, as well as other relevant economic measures. We perform certain procedures to corroborate the fair value of our assetsthese holdings, and liabilities based on the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value maximize the use of observable inputsprocess, we apply judgments and minimize the use of unobservable inputs. We use a fair value hierarchy with three levels of inputs, of which the first two are considered observable and the last unobservable, to measure fair value:
43
Allowance for Doubtful Accounts
We maintain an allowance for doubtful accounts for estimated losses resulting from the inability of our customers to make required payments. We evaluate the collectibility of our accounts receivable based on a combination of factors. We regularly analyze customer accounts, review the length of time receivables are outstanding, review historical loss rates and assess current economic trends that may impact the level of credit losses in the future. Our gross trade accounts receivables totaled $219.3 million and the allowance for doubtful accounts was $4.3 million at December 30, 2012. Our allowance for doubtful accounts has generally been adequate to cover our actual credit losses. However, since we cannot reliably predict future changes in the financial stability of our customers, and we may need to increase our reserves if the financial conditions of our customers deteriorate.
40
Inventory Valuation
Inventories are stated at lower of cost or market. We record adjustments to inventory for potentially excess, obsolete, or impaired goods in order to state inventory at net realizable value. We must make assumptions about future demand, market conditions, and the release of new products that will supersede old ones. We regularly review inventory for excess and obsolete products and components, taking into account product life cycles, quality issues, historical experience, and usage forecasts. IfOur gross inventory totaled $178.6 million and the cumulative adjustment for potentially excess and obsolete inventory was $19.9 million at December 30, 2012. Historically, our inventory adjustment has been adequate to cover our losses. However, if actual market conditions are less favorable than anticipated, additional inventory adjustments could be required.
Contingencies
We are subject to legal proceedings primarily relatedinvolved in various lawsuits and claims arising in the ordinary course of business, including actions with respect to intellectual property, employment, and contractual matters. We routinely assess the likelihood of adverse judgments or outcomes toIn connection with these matters, as well as rangeswe assess, on a regular basis, the probability and range of possible loss based on the developments in these matters. A liability is recorded in the financial statements if it is believed to be probable losses, tothat a loss has been incurred and the extent losses areamount of the loss can be reasonably estimable. If losses are probableestimated. Because litigation is inherently unpredictable and reasonably estimable, we will record a liability and an expense for the estimated loss. Disclosure for specific legalunfavorable resolutions could occur, assessing contingencies is provided ifhighly subjective and requires judgments about future events. We regularly review outstanding legal matters to determine the likelihoodadequacy of occurrence is probablethe liabilities accrued and the exposure is considered material to the consolidated financial statements. In making determinationsrelated disclosures in consideration of likely outcomes of litigation matters, management considers many factors. These factors, which include, but are not limited to, past history, scientific and other evidence, and the specifics and status of each matter. We may change our estimates if our assessment of the various factors changes whichand the amount of ultimate loss may result in the recording of an accrual or a changediffer from our estimates, resulting in a previously recorded accrual. Predicting the outcomematerial effect on our business, financial condition, results of claims and litigation, and estimating related costs and exposure involves substantial uncertainties that could cause actual costs to vary materially from estimates and accruals.operations, and/or cash flows.
Business Combinations
Under the acquisition method of accounting, we allocate the fair value of the total consideration transferred to the tangible and identifiable intangible assets acquired and liabilities assumed based on their estimated fair values on the date of acquisition. The fair values assigned, defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between willing market participants, are based on estimates and assumptions determined by management. We record the excess consideration over the aggregate fair value of tangible and intangible assets, net of liabilities assumed, as goodwill. These valuations require us to make significant estimates and assumptions, especially with respect to intangible assets.
In connection with certain of our acquisitions, additional contingent consideration is earned by the sellers upon completion of certain future performance milestones. Prior to fiscal year 2009, the Company recognized contingent consideration as an additional element of the cost of the acquisition, generally goodwill, when the contingency was resolved beyond a reasonable doubt and the additional consideration was issued or became issuable. Due to changes in the accounting standards regarding business combinations, for all acquisitions consummated on or after December 29, 2008,In these cases, a liability is recorded on the acquisition date for an estimate of the acquisition date fair value of the contingent consideration by applying the income approach utilizing
44
variable factorsinputs such as anticipated future cash flows, risk-free adjusted discount rates, and nonperformance risk. Any change in the fair value of the contingent consideration subsequent to the acquisition date is recognized in acquisition related expense (gain) expense,, net, a component of operating expenses, in theour consolidated statements of income. This method requires significant management judgment, including the probability of achieving certain future milestones and discount rates. Future changes in our estimates could result in expenses or gains.
Management typically uses athe discounted cash flow method to value our acquired intangible assets. This method requires significant management judgment to forecast future operating results and establish residual growth rates and discount factors. The estimates we use to value and amortize intangible assets are consistent with the plans and estimates that we use to manage our business and are based on available historical information and industry estimates and averages. If the subsequent actual results and updated projections of the underlying business activity change compared with the assumptions and projections used to develop these values, we could experience impairment charges. In addition, we have estimated the economic lives of certain acquired assets and these lives are used to calculate depreciation and amortization expense. If our estimates of the economic lives change, depreciation or amortization expenses could be accelerated or slowed.
Intangible Assets and Other Long-Lived Assets — Impairment Assessments
We estimateregularly perform reviews to determine if the fair valuecarrying values of our long-lived assets are impaired. A review of identifiable intangible assets and other long-lived assets that have finite useful lives wheneveris performed when an event or change in circumstances indicates thatoccurs indicating the carrying valuepotential for impairment. If indicators of impairment exist, we assess the recoverability of the asset may not be recovered through undiscounted future operating cash flows.affected long-lived assets and compare their fair values to the respective carrying amounts.
41
In order to estimate the fair value of purchasedidentifiable intangible assets and other long-lived assets, that have finite useful lives, we estimate the present value of future cash flows from those assets. The key assumptions that we use in our discounted cash flow model are the amount and timing of estimated future cash flows to be generated by the asset over an extended period of time and a rate of return that considers the relative risk of achieving the cash flows, the time value of money, and other factors that a willing market participant would consider. Significant judgment is required to estimate the amount and timing of future cash flows and the relative risk of achieving those cash flows. We had a total of $129.9 million in net property and equipment and $70.0 million in net intangible assets on our balance sheet at January 2, 2011.
Assumptions and estimates about future values and remaining useful lives are complex and often subjective. They can be affected by a variety of factors, including external factors such as industry and economic trends, and internal factors such as changes in our business strategy and our internal forecasts. For example, if our future operating results do not meet current forecasts or if we experience a sustained decline in our market capitalization that is determined to be indicative of a reduction in fair value of one or more of our reporting units, we may be required to record future impairment charges for purchased intangible assets. Impairment charges could materially decrease our future net income and result in lower asset values on our balance sheet.
Share-Based Compensation
We are required to measure and recognize compensation expense for all share-based payments made to employees and directors based on estimated fair value. We estimate the fair value of stock options granted and stock purchases under our employee stock purchase plan using the Black-Scholes-Merton (BSM) option-pricing model. The fair value of our restricted stock units is based on the market price of our common stock on the date of grant.
The determination of fair value of share-based awards using the BSM model requires the use of certain estimates and highly judgmental assumptions that affect the amount of share-based compensation expense recognized in our consolidated statements of income. These include estimates of the expected volatility of our stock price, expected life of an award, expected dividends, and the risk-free interest rate. We determine the volatility of our stock price by equally weighing the historical and implied volatility of our common stock. The historical volatility of our common stock over the most recent period is generally commensurate with the estimated expected life of our stock awards, adjusted for the impact of unusual fluctuations not reasonably
45
expected to recur, and other relevant factors. Implied volatility is calculated from the implied market volatility of exchange-traded call options on our common stock. The expected life of an award is based on historical forfeiture experience, exercise activity, and on the terms and conditions of the stock awards. We determined expected dividend yield to be 0% given we have never declared or paid any cash dividends on our common stock and we currently do not anticipate paying such cash dividends. The risk-free interest rate is based upon U.S. Treasury securities with remaining terms similar to the expected term of the share-based awards. We amortize the fair value of share-based compensation on a straight-line basis over the requisite service periods of the awards. If any of the assumptions used in the BSM model change significantly, share-based compensation expense may differ materially from what we have recorded in the current period.
Warranties
We generally provide a one-year warranty on instruments. Additionally, we provide a warranty on consumables through the expiration date, which generally ranges from six to twelve months after the manufacture date. We establish an accrual for estimated warranty expenses based on historical experience as well as anticipated product performance. We periodically review the adequacy of our warranty reserve, and adjust, if necessary, the warranty percentage and accrual based on actual experience and estimated costs to be incurred. If our estimates of warranty obligation change or if actual product performance is below our expectations we may incur additional warranty expense.
Cease-Use Loss upon Exit of Facility
In 2012, we completed the relocation of our headquarters to a new facility in San Diego, California, and recorded headquarter relocation expense of $26.3 million, the majority of which was attributable to a cease-use loss recorded upon vacating our prior headquarter facility. The lease on our prior headquarter facility expires in 2023. The cease-use loss is calculated as the present value of the remaining lease obligation offset by estimated sublease rental receipts during the remaining lease period, adjusted for deferred items and leasehold improvements. In calculating the cease-use loss, management is required to make significant judgments to estimate the present value of future cash flows from the assumed sublease. The key assumptions that we use in our discounted cash flow model include the amount and timing of estimated sublease rental receipts, and the risk-adjusted discount rate. These assumptions are subjective in nature and the actual future cash flows could differ from our estimates, resulting in significant adjustments to the cease-use loss recorded.
42
Income Taxes
Our provision for income taxes, deferred tax assets and liabilities, and reserves for unrecognized tax benefits reflect our best assessment of estimated future taxes to be paid. Significant judgments and estimates based on interpretations of existing tax laws or regulations in the U.S.United States and the numerous foreign jurisdictions where we are subject to income tax are required in determining our provision for income taxes. Changes in tax laws, statutory tax rates, and estimates of the company’s future taxable income could impact the deferred tax assets and liabilities provided for in the consolidated financial statements and would require an adjustment to the provision for income taxes.
Deferred tax assets are regularly assessed to determine the likelihood they will be recovered from future taxable income. A valuation allowance is established when we believe it is more likely than not the future realization of all or some of a deferred tax asset will not be achieved. In evaluating our ability to recover deferred tax assets within the jurisdiction which they arise, we consider all available positive and negative evidence. Factors reviewed include the cumulative pre-tax book income for the past three years, scheduled reversals of deferred tax liabilities, our history of earnings and reliable forecasting,reliability of our forecasts, projections of pre-tax book income over the foreseeable future, and the impact of any feasible and prudent tax planning strategies. Based on the available evidence as of January 2, 2011,December 30, 2012, we were not able to conclude it is more likely than not certain U.S. and foreign deferred tax assets will be realized. Therefore, we recorded a valuation allowance of $1.9$1.8 million and $3.1 million against certain U.S. and foreign deferred tax assets, respectively.assets.
We recognize the impact of a tax position in our financial statements only if that position is more likely than not of being sustained upon examination by taxing authorities, based on the technical merits of the position. Tax authorities regularly examine our returns in the jurisdictions in which we do business and we regularly assess the tax risk of the company’s return filing positions. Due to the complexity of some of the uncertainties, the ultimate resolution may result in payments that are materially different from our current estimate of the tax liability. These differences, as well as any interest and penalties, will be reflected in the provision for income taxes in the period in which they are determined.
| Quantitative and Qualitative Disclosures about Market Risk. |
Interest Rate Sensitivity
Our investment portfolio is exposed to market risk forfrom changes in interest rates. The fair market value of fixed rate securities may be adversely impacted by fluctuations in interest rates while income earned on floating rate securities may decline as a result of decreases in interest rates. Under our current policies, we do
46
not use interest rate derivative instruments to manage exposure to interest rate changes. We attempt to ensure the safety and preservation of our invested principal funds by limiting default risk, market risk, and reinvestment risk. We mitigate default risk by investing in investment grade securities. We have historically maintained a relatively short average maturity for our investment portfolio, and we believe a hypothetical 100 basis point adverse move in interest rates along the entire interest rate yield curve would not materially affect the fair value of our interest sensitive financial instruments. In addition, if a 100 basis point change in overall interest rates were to occur in 2011,2013, our interest income would change by approximately $8.9$13.5 million in relation to amounts we would expect to earn, based on our cash, cash equivalents, and short-term investments as of January 2, 2011.December 30, 2012.
Changes in interest rates may also impact gains or losses from the conversion of our outstanding convertible senior notes. As of January 2,During 2011, we had $390.0issued $920 million in aggregate principal amount of our 0.25% convertible senior notes outstanding. Thedue 2016. At our election, the notes are convertible into cash, and if applicable, shares of our common stock, or a combination of cash and shares of our common stock in each case under certain circumstances, including trading price conditions related to our common stock. If the trading price of our common stock remains significantlyreaches a price for a sustained period at 130% above the conversion price of $21.83 per share, we expect that noteholders$83.55, the notes will elect to convert the notes.become convertible. Upon conversion, we are required to record a gain or loss for the difference between the fair value of the debt to be extinguished and its corresponding net carrying value. The fair value of the debt to be extinguished depends on our currentthen-current incremental borrowing rate. The net carrying value of the notes has an implicit interest rate of 8.27%. If our incremental borrowing rate at the time of conversion is higher or lower than the implied interest rate of the notes, we will record a gain or loss in our consolidated statement of income during the period in which the notes are converted. The implicit interest rate for the notes is 4.5%. An incremental borrowing rate that is a hypothetical 100 basis points lower than the implicit interest rate upon conversion of $100 million aggregate principal amount of the notes would result in a loss of approximately $3.5 million.$3.0 million.
43
Market Price Sensitive Instruments
In order to reduce potential equity dilution, in connection with the issuance (and potential conversion) of our 0.625% convertible senior notes due 2014, we entered into convertible note hedge transactions, entitling us to purchase up to 18,322,32018,322,000 shares of our common stock at a strike price of $21.83 per share, subject to adjustment. In addition, we sold to the hedge transaction counterparties warrants exercisable on a net-share basis, for up to 18,322,32018,322,000 shares of our common stock at a strike price of $31.435 per share, subject to adjustment. The anti-dilutive effect of the note hedge transactions, if any, could be partially or fully offset to the extent the trading price of our common stock exceeds the strike price of the warrants on the exercise dates of the warrants, which occur during 2014, assuming the warrants are exercised.
Foreign Currency Exchange Risk
We conduct a portion of our business in currencies other than the entity’scompany’s U.S. dollar functional currency. These transactions give rise to monetary assets and liabilities that are denominated in currencies other than the entity’s functional currency.U.S. dollar. The value of these monetary assets and liabilities are subject to changes in currency exchange rates from the time the transactions are originated until settlement in cash. Our foreign currency exposures are primarily concentrated in the Euro, Yen, British pound sterling, Australian dollar, and Singapore dollar. Both realized and unrealized gains or losses on the value of these monetary assets and liabilities are included in the determination of net income. We recorded a $3.7 millionnet currency exchange gainloss for the fiscal year ended December 30, 2012 on business transactions, net of hedging transactions, of $1.0 million for each of the years ended January 2, 2011 and January 3, 2010, which are included in other (expense) income, net, in theour consolidated statements of income.
We use forward exchange contracts to manage a portion of the foreign currency exposure risk for foreign subsidiaries with monetary assets and liabilities denominated in currencies other than the entity’s functional currency.U.S. dollar. We only use derivative financial instruments to reduce foreign currency exchange rate risks; we do not hold any derivative financial instruments for trading or speculative purposes. We primarily use forward exchange contracts to hedge foreign currency exposures, and they generally have terms of one month or less. Realized and unrealized gains or losses on the value of financial contracts entered into to hedge the exchange rate exposure of these monetary assets and liabilities are also included in the determination of net income, as they have not been designated for hedge accounting. These contracts, which settle monthly, effectively fix the exchange rate at which these specific monetary assets and liabilities will be settled, so that gains or losses on the forward contracts offset the losses or gains from changes in the value of the underlying monetary assets and liabilities. At January 2, 2011, we had $20.0 millionAs ofDecember 30, 2012, the total notional amount of outstanding forward contracts in place for foreign currency forward contracts outstanding to hedge foreign currency risk.purchases was approximately $51.2 million.
48
44
| Financial Statements and Supplementary Data. |
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
| Page | ||||
49
45
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
The Board of Directors and Stockholders of
Illumina, Inc.
We have audited the accompanying consolidated balance sheets of Illumina, Inc. as of December 30, 2012 and January 2, 2011 and January 3, 2010,1, 2012, and the related consolidated statements of income, comprehensive income, stockholders’ equity, and cash flows for each of the three fiscal years in the period ended January 2, 2011.December 30, 2012. Our audits also included the financial statement schedule listed in the Index at Item 15. These financial statements and schedule are the responsibility of the Company’s management. Our responsibility is to express an opinion on these financial statements and schedule based on our audits.
We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.
In our opinion, the financial statements referred to above present fairly, in all material respects, the consolidated financial position of Illumina, Inc. at December 30, 2012 and January 2, 2011 and January 3, 2010,1, 2012, and the consolidated results of its operations and its cash flows for each of the three fiscal years in the period ended January 2, 2011,December 30, 2012, in conformity with U.S. generally accepted accounting principles. Also, in our opinion, the related financial statement schedule, when considered in relation to the basic financial statements taken as a whole, presents fairly in all material respects the information set forth therein.
We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), Illumina, Inc.’s internal control over financial reporting as of January 2, 2011,December 30, 2012, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission and our report dated February 28, 201115, 2013 expressed an unqualified opinion thereon.
/s/ EErnstRNST & YoungYOUNG LLP
San Diego, California
February 28, 201115, 2013
50
46
ILLUMINA, INC.
CONSOLIDATED BALANCE SHEETS
(in thousands, except par value)
| January 2, | January 3, | |||||||
| 2011 | 2010 | |||||||
| (In thousands) | ||||||||
ASSETS | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 248,947 | $ | 144,633 | ||||
| Short-term investments | 645,342 | 548,894 | ||||||
| Accounts receivable, net | 165,598 | 157,751 | ||||||
| Inventory, net | 142,211 | 92,776 | ||||||
| Deferred tax assets, current portion | 19,378 | 20,021 | ||||||
| Prepaid expenses and other current assets | 36,922 | 17,515 | ||||||
| Total current assets | 1,258,398 | 981,590 | ||||||
| Property and equipment, net | 129,874 | 117,188 | ||||||
| Goodwill | 278,206 | 213,452 | ||||||
| Intangible assets, net | 70,024 | 43,788 | ||||||
| Deferred tax assets, long-term portion | 39,497 | 47,371 | ||||||
| Other assets | 63,114 | 26,548 | ||||||
| Total assets | $ | 1,839,113 | $ | 1,429,937 | ||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 66,744 | $ | 52,781 | ||||
| Accrued liabilities | 156,164 | 98,253 | ||||||
| Long-term debt, current portion | 311,609 | 290,202 | ||||||
| Total current liabilities | 534,517 | 441,236 | ||||||
| Other long-term liabilities | 28,531 | 24,656 | ||||||
| Commitments and contingencies | ||||||||
| Conversion option subject to cash settlement | 78,390 | 99,797 | ||||||
| Stockholders’ equity: | ||||||||
| Preferred stock, $0.01 par value, 10,000,000 shares authorized, no shares issued at January 2, 2011 and January 3, 2010 | — | — | ||||||
| Common stock, $0.01 par value, 320,000,000 shares authorized, 151,512,837 shares issued at January 2, 2011, 143,544,265 shares issued at January 3, 2010 | 1,516 | 1,436 | ||||||
| Additional paid-in capital | 1,891,288 | 1,637,751 | ||||||
| Accumulated other comprehensive income | 1,765 | 2,830 | ||||||
| Accumulated deficit | (155,335 | ) | (280,226 | ) | ||||
| Treasury stock, at cost (24,904,564 shares at January 2, 2011 and 24,068,450 shares at January 3, 2010) | (541,559 | ) | (497,543 | ) | ||||
| Total stockholders’ equity | 1,197,675 | 864,248 | ||||||
| Total liabilities and stockholders’ equity | $ | 1,839,113 | $ | 1,429,937 | ||||
| December 30, 2012 | January 1, 2012 | ||||||
| ASSETS | |||||||
| Current assets: | |||||||
| Cash and cash equivalents | $ | 433,981 | $ | 302,978 | |||
| Short-term investments | 916,223 | 886,590 | |||||
| Accounts receivable, net | 214,975 | 173,886 | |||||
| Inventory | 158,718 | 128,781 | |||||
| Deferred tax assets, current portion | 30,451 | 23,188 | |||||
| Prepaid expenses and other current assets | 32,700 | 29,196 | |||||
| Total current assets | 1,787,048 | 1,544,619 | |||||
| Property and equipment, net | 166,167 | 143,483 | |||||
| Goodwill | 369,327 | 321,853 | |||||
| Intangible assets, net | 130,196 | 106,475 | |||||
| Deferred tax assets, long-term portion | 40,183 | 19,675 | |||||
| Other assets | 73,164 | 59,735 | |||||
| Total assets | $ | 2,566,085 | $ | 2,195,840 | |||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | |||||||
| Current liabilities: | |||||||
| Accounts payable | $ | 65,727 | $ | 49,806 | |||
| Accrued liabilities | 201,877 | 177,115 | |||||
| Long-term debt, current portion | 36,967 | — | |||||
| Total current liabilities | 304,571 | 226,921 | |||||
| Long-term debt | 805,406 | 807,369 | |||||
| Other long-term liabilities | 134,369 | 80,613 | |||||
| Commitments and contingencies | |||||||
| Conversion option subject to cash settlement | 3,158 | 5,722 | |||||
| Stockholders’ equity: | |||||||
| Preferred stock, $0.01 par value, 10,000 shares authorized, no shares issued and outstanding at December 30, 2012 and January 1, 2012 | — | — | |||||
| Common stock, $0.01 par value: 320,000 shares authorized; 170,171 shares issued and 123,943 outstanding at December 30, 2012; 166,707 shares issued and 122,041 outstanding at January 1, 2012 | 1,703 | 1,668 | |||||
| Additional paid-in capital | 2,419,831 | 2,249,900 | |||||
| Accumulated other comprehensive income | 2,123 | 2,117 | |||||
| Retained earnings (accumulated deficit) | 82,547 | (68,707 | ) | ||||
| Treasury stock, 46,228 shares and 44,665 shares at cost at December 30, 2012 and January 1, 2012, respectively | (1,187,623 | ) | (1,109,763 | ) | |||
| Total stockholders’ equity | 1,318,581 | 1,075,215 | |||||
| Total liabilities and stockholders’ equity | $ | 2,566,085 | $ | 2,195,840 | |||
See accompanying notes to consolidated financial statements
47
ILLUMINA, INC.
(In thousands, except per share amounts)
| Years Ended_ | ||||||||||||
| January 2, | January 3, | December 28, | ||||||||||
| 2011 | 2010 | 2008 | ||||||||||
| (In thousands, except per share amounts) | ||||||||||||
| Revenue: | ||||||||||||
| Product revenue | $ | 842,510 | $ | 627,240 | $ | 532,390 | ||||||
| Service and other revenue | 60,231 | 39,084 | 40,835 | |||||||||
| Total revenue | 902,741 | 666,324 | 573,225 | |||||||||
| Cost of revenue: | ||||||||||||
| Cost of product revenue | 271,997 | 190,714 | 192,868 | |||||||||
| Cost of service and other revenue | 21,399 | 15,055 | 12,756 | |||||||||
| Amortization of intangible assets | 7,805 | 6,680 | 10,438 | |||||||||
| Impairment of manufacturing equipment | — | — | 4,069 | |||||||||
| Total cost of revenue | 301,201 | 212,449 | 220,131 | |||||||||
| Gross profit | 601,540 | 453,875 | 353,094 | |||||||||
| Operating expense: | ||||||||||||
| Research and development | 177,947 | 140,616 | 99,963 | |||||||||
| Selling, general and administrative | 220,990 | 176,337 | 148,014 | |||||||||
| Acquisition related (gain) expense, net | (9,051 | ) | 11,325 | 24,660 | ||||||||
| Total operating expense | 389,886 | 328,278 | 272,637 | |||||||||
| Income from operations | 211,654 | 125,597 | 80,457 | |||||||||
| Other income (expense): | ||||||||||||
| Interest income | 8,378 | 11,029 | 12,519 | |||||||||
| Interest expense | (24,598 | ) | (23,718 | ) | (22,210 | ) | ||||||
| Other (expense) income, net | (10,055 | ) | 1,217 | 1,921 | ||||||||
| Total other expense, net | (26,275 | ) | (11,472 | ) | (7,770 | ) | ||||||
| Income before income taxes | 185,379 | 114,125 | 72,687 | |||||||||
| Provision for income taxes | 60,488 | 41,844 | 33,271 | |||||||||
| Net income | $ | 124,891 | $ | 72,281 | $ | 39,416 | ||||||
| Net income per basic share | $ | 1.01 | $ | 0.59 | $ | 0.34 | ||||||
| Net income per diluted share | $ | 0.87 | $ | 0.53 | $ | 0.30 | ||||||
| Shares used in calculating basic net income per share | 123,581 | 123,154 | 116,855 | |||||||||
| Shares used in calculating diluted net income per share | 143,433 | 137,096 | 133,607 | |||||||||
| Years Ended | |||||||||||
| December 30, 2012 | January 1, 2012 | January 2, 2011 | |||||||||
| Revenue: | |||||||||||
| Product revenue | $ | 1,055,826 | $ | 987,280 | $ | 842,510 | |||||
| Service and other revenue | 92,690 | 68,255 | 60,231 | ||||||||
| Total revenue | 1,148,516 | 1,055,535 | 902,741 | ||||||||
| Cost of revenue: | |||||||||||
| Cost of product revenue | 317,283 | 308,228 | 271,997 | ||||||||
| Cost of service and other revenue | 43,552 | 26,118 | 21,399 | ||||||||
| Amortization of acquired intangible assets | 14,153 | 12,091 | 7,805 | ||||||||
| Total cost of revenue | 374,988 | 346,437 | 301,201 | ||||||||
| Gross profit | 773,528 | 709,098 | 601,540 | ||||||||
| Operating expense: | |||||||||||
| Research and development | 231,025 | 196,913 | 177,947 | ||||||||
| Selling, general and administrative | 285,991 | 261,843 | 220,454 | ||||||||
| Headquarter relocation expense | 26,328 | 41,826 | — | ||||||||
| Unsolicited tender offer related expense | 23,136 | — | — | ||||||||
| Restructuring charges | 3,522 | 8,136 | — | ||||||||
| Acquisition related expense (gain), net | 2,774 | 919 | (8,515 | ) | |||||||
| Total operating expense | 572,776 | 509,637 | 389,886 | ||||||||
| Income from operations | 200,752 | 199,461 | 211,654 | ||||||||
| Other income (expense): | |||||||||||
| Cost-method investment related gain (loss), net | 45,911 | — | (10,309 | ) | |||||||
| Interest income | 16,208 | 7,052 | 8,378 | ||||||||
| Interest expense | (37,779 | ) | (34,790 | ) | (24,598 | ) | |||||
| Other (expense) income, net | (2,484 | ) | (38,678 | ) | 254 | ||||||
| Total other income (expense), net | 21,856 | (66,416 | ) | (26,275 | ) | ||||||
| Income before income taxes | 222,608 | 133,045 | 185,379 | ||||||||
| Provision for income taxes | 71,354 | 46,417 | 60,488 | ||||||||
| Net income | $ | 151,254 | $ | 86,628 | $ | 124,891 | |||||
| Net income per basic share | $ | 1.23 | $ | 0.70 | $ | 1.01 | |||||
| Net income per diluted share | $ | 1.13 | $ | 0.62 | $ | 0.87 | |||||
| Shares used in calculating basic net income per share | 122,999 | 123,399 | 123,581 | ||||||||
| Shares used in calculating diluted net income per share | 133,693 | 138,937 | 143,433 | ||||||||
See accompanying notes to consolidated financial statements
48
ILLUMINA, INC.
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
(In thousands)
| Years Ended | ||||||||||||
| December 30, 2012 | January 1, 2012 | January 2, 2011 | ||||||||||
| Net income | $ | 151,254 | $ | 86,628 | $ | 124,891 | ||||||
| Unrealized gain (loss) on available-for-sale securities, net of deferred tax | 6 | 352 | (1,065 | ) | ||||||||
| Total comprehensive income | $ | 151,260 | $ | 86,980 | $ | 123,826 | ||||||
See accompanying notes to the consolidated financial statements.
49
ILLUMINA, INC.
CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
| Accumulated | ||||||||||||||||||||||||||||||||
| Additional | Other | Total | ||||||||||||||||||||||||||||||
| Common Stock | Paid-In | Comprehensive | Accumulated | Treasury Stock | Stockholders’ | |||||||||||||||||||||||||||
| Shares | Amount | Capital | Income | Deficit | Shares | Amount | Equity | |||||||||||||||||||||||||
| (In thousands) | ||||||||||||||||||||||||||||||||
| Balance as of December 30, 2007 | 125,608 | $ | 1,256 | $ | 994,869 | $ | 1,347 | $ | (391,923 | ) | (14,819 | ) | $ | (251,622 | ) | $ | 353,927 | |||||||||||||||
| Components of comprehensive income: | ||||||||||||||||||||||||||||||||
| Net income | — | — | — | — | 39,416 | — | — | 39,416 | ||||||||||||||||||||||||
Unrealized gain onavailable-for-sale securities, net of deferred tax | — | — | — | 920 | — | — | — | 920 | ||||||||||||||||||||||||
| Foreign currency translation adjustment | — | — | (16 | ) | 155 | — | — | — | 139 | |||||||||||||||||||||||
| Comprehensive income | 40,475 | |||||||||||||||||||||||||||||||
| Issuance of common stock in conjunction with secondary offering, net of issuance costs | 8,050 | 80 | 342,570 | — | — | — | — | 342,650 | ||||||||||||||||||||||||
| Issuance of common stock under employee stock plans | 4,923 | 49 | 44,281 | — | — | — | — | 44,330 | ||||||||||||||||||||||||
| Warrants exercised | 356 | 4 | 2,987 | — | — | — | — | 2,991 | ||||||||||||||||||||||||
| Share-based compensation | — | — | 47,695 | — | — | — | — | 47,695 | ||||||||||||||||||||||||
| Incremental tax benefit related to stock options exercised | — | — | 18,501 | — | — | — | — | 18,501 | ||||||||||||||||||||||||
| Repurchases of common stock | — | — | — | — | — | (3,109 | ) | (70,785 | ) | (70,785 | ) | |||||||||||||||||||||
| Remeasurement of convertible debt | — | — | 18,883 | — | — | — | — | 18,883 | ||||||||||||||||||||||||
| Balance as of December 28, 2008 | 138,937 | 1,389 | 1,469,770 | 2,422 | (352,507 | ) | (17,928 | ) | (322,407 | ) | 798,667 | |||||||||||||||||||||
| Components of comprehensive income: | ||||||||||||||||||||||||||||||||
| Net income | — | — | — | — | 72,281 | — | — | 72,281 | ||||||||||||||||||||||||
Unrealized gain onavailable-for-sale securities, net of deferred tax | — | — | — | 408 | — | — | — | 408 | ||||||||||||||||||||||||
| Comprehensive income | 72,689 | |||||||||||||||||||||||||||||||
| Issuance of common stock | 3,569 | 36 | 39,343 | — | — | — | — | 39,379 | ||||||||||||||||||||||||
| Warrants exercised | 954 | 10 | 7,566 | — | — | — | — | 7,576 | ||||||||||||||||||||||||
| Share-based compensation | — | — | 60,813 | — | — | — | — | 60,813 | ||||||||||||||||||||||||
| Incremental tax benefit related to stock options exercised | — | — | 39,319 | — | — | — | — | 39,319 | ||||||||||||||||||||||||
| Repurchases of common stock | — | — | — | — | — | (6,140 | ) | (175,136 | ) | (175,136 | ) | |||||||||||||||||||||
| Remeasurement of convertible debt | 84 | 1 | 20,940 | — | — | — | — | 20,941 | ||||||||||||||||||||||||
| Balance as of January 3, 2010 | 143,544 | 1,436 | 1,637,751 | 2,830 | (280,226 | ) | (24,068 | ) | (497,543 | ) | 864,248 | |||||||||||||||||||||
| Components of comprehensive income: | ||||||||||||||||||||||||||||||||
| Net income | — | — | — | — | 124,891 | — | — | 124,891 | ||||||||||||||||||||||||
Unrealized loss onavailable-for-sale securities, net of deferred tax | — | — | — | (1,065 | ) | — | — | — | (1,065 | ) | ||||||||||||||||||||||
| Comprehensive income | 123,826 | |||||||||||||||||||||||||||||||
| Issuance of common stock | 6,391 | 64 | 101,952 | — | — | — | — | 102,016 | ||||||||||||||||||||||||
| Warrants exercised | 1,578 | 16 | 16,013 | — | — | — | — | 16,029 | ||||||||||||||||||||||||
| Share-based compensation | — | — | 71,725 | — | — | — | — | 71,725 | ||||||||||||||||||||||||
| Incremental tax benefit related to stock options exercised | — | — | 42,445 | — | — | — | — | 42,445 | ||||||||||||||||||||||||
| Repurchases of common stock | — | — | — | — | — | (836 | ) | (44,016 | ) | (44,016 | ) | |||||||||||||||||||||
| Remeasurement of convertible debt | — | — | 21,402 | — | — | — | — | 21,402 | ||||||||||||||||||||||||
| Balance as of January 2, 2011 | 151,513 | $ | 1,516 | $ | 1,891,288 | $ | 1,765 | $ | (155,335 | ) | (24,904 | ) | $ | (541,559 | ) | $ | 1,197,675 | |||||||||||||||
| Additional | Accumulated Other | Retained Earnings | Total | ||||||||||||||||||||||||||
| Common Stock | Paid-In | Comprehensive | (Accumulated | Treasury Stock | Stockholders’ | ||||||||||||||||||||||||
| Shares | Amount | Capital | Income | Deficit) | Shares | Amount | Equity | ||||||||||||||||||||||
| (In thousands) | |||||||||||||||||||||||||||||
| Balance as of January 3, 2010 | 143,544 | 1,436 | 1,637,751 | 2,830 | (280,226 | ) | (24,068 | ) | (497,543 | ) | 864,248 | ||||||||||||||||||
| Net income | — | — | — | — | 124,891 | — | — | 124,891 | |||||||||||||||||||||
| Unrealized loss on available-for-sale securities, net of deferred tax | — | — | — | (1,065 | ) | — | — | — | (1,065 | ) | |||||||||||||||||||
| Issuance of common stock, net of repurchases | 7,969 | 80 | 117,965 | — | — | (836 | ) | (44,016 | ) | 74,029 | |||||||||||||||||||
| Share-based compensation | — | — | 71,725 | — | — | — | — | 71,725 | |||||||||||||||||||||
| Incremental tax benefit related to share-based compensation | — | — | 42,445 | — | — | — | — | 42,445 | |||||||||||||||||||||
| Reclassification of conversion option subject to cash settlement | — | — | 21,402 | — | — | — | — | 21,402 | |||||||||||||||||||||
| Balance as of January 2, 2011 | 151,513 | 1,516 | 1,891,288 | 1,765 | (155,335 | ) | (24,904 | ) | (541,559 | ) | 1,197,675 | ||||||||||||||||||
| Net income | — | — | — | — | 86,628 | — | — | 86,628 | |||||||||||||||||||||
| Unrealized gain on available-for-sale securities, net of deferred tax | — | — | — | 352 | — | — | — | 352 | |||||||||||||||||||||
| Issuance of common stock, net of repurchases | 15,194 | 152 | 104,268 | — | — | (19,990 | ) | (572,207 | ) | (467,787 | ) | ||||||||||||||||||
| Convertible note, equity portion, net of tax and issuance costs | — | — | 155,366 | — | — | — | — | 155,366 | |||||||||||||||||||||
| Tax impact from the issuance of convertible debt | — | — | (59,427 | ) | — | — | — | — | (59,427 | ) | |||||||||||||||||||
| Tax benefit related to conversions of convertible debt | — | — | 11,409 | — | — | — | — | 11,409 | |||||||||||||||||||||
| Reclassification of conversion option subject to cash settlement | — | — | 7,667 | — | — | — | — | 7,667 | |||||||||||||||||||||
| Share-based compensation | — | — | 92,153 | — | — | — | — | 92,153 | |||||||||||||||||||||
| Net incremental tax benefit related to share-based compensation | — | — | 43,122 | — | — | — | — | 43,122 | |||||||||||||||||||||
| Equity based contingent compensation | — | — | 3,457 | — | — | — | — | 3,457 | |||||||||||||||||||||
| Issuance of treasury stock | — | — | 597 | — | — | 229 | 4,003 | 4,600 | |||||||||||||||||||||
| Balance as of January 1, 2012 | 166,707 | $ | 1,668 | $ | 2,249,900 | $ | 2,117 | $ | (68,707 | ) | (44,665 | ) | $ | (1,109,763 | ) | $ | 1,075,215 | ||||||||||||
| Net income | — | — | — | — | 151,254 | — | — | 151,254 | |||||||||||||||||||||
| Unrealized gain on available-for-sale securities, net of deferred tax | — | — | — | 6 | — | — | — | 6 | |||||||||||||||||||||
| Issuance of common stock, net of repurchases | 3,464 | 35 | 55,106 | — | — | (1,875 | ) | (83,306 | ) | (28,165 | ) | ||||||||||||||||||
| Reclassification of conversion option subject to cash settlement | — | — | 2,565 | — | — | — | — | 2,565 | |||||||||||||||||||||
| Share-based compensation | — | — | 94,385 | — | — | — | — | 94,385 | |||||||||||||||||||||
| Net incremental tax benefit related to share-based compensation | — | — | 17,015 | — | — | — | — | 17,015 | |||||||||||||||||||||
| Equity based contingent compensation | — | — | 6,306 | — | — | — | — | 6,306 | |||||||||||||||||||||
| Issuance of treasury stock | — | — | (5,446 | ) | — | — | 312 | 5,446 | — | ||||||||||||||||||||
| Balance as of December 30, 2012 | 170,171 | $ | 1,703 | $ | 2,419,831 | $ | 2,123 | $ | 82,547 | (46,228 | ) | $ | (1,187,623 | ) | $ | 1,318,581 | |||||||||||||
See accompanying notes to consolidated financial statements
53
50
ILLUMINA, INC. CONSOLIDATED STATEMENTS OF CASH FLOWS (In thousands) | |||||||||||
| Years Ended | |||||||||||
| December 30, 2012 | January 1, 2012 | January 2, 2011 | |||||||||
| Cash flows from operating activities: | |||||||||||
| Net income | $ | 151,254 | $ | 86,628 | $ | 124,891 | |||||
| Adjustments to reconcile net income to net cash provided by operating activities: | |||||||||||
| Depreciation expense | 48,249 | 55,575 | 34,204 | ||||||||
| Amortization of acquired intangible assets | 15,541 | 12,689 | 7,805 | ||||||||
| Share-based compensation expense | 94,324 | 92,092 | 71,645 | ||||||||
| Accretion of debt discount | 35,004 | 32,173 | 21,407 | ||||||||
| Cease-use loss | 22,367 | 23,638 | — | ||||||||
| Contingent compensation expense | 6,306 | 3,457 | — | ||||||||
| Incremental tax benefit related to share-based compensation | (20,783 | ) | (46,354 | ) | (42,445 | ) | |||||
| Deferred income taxes | (21,698 | ) | 19,227 | 48,696 | |||||||
| Change in fair value of contingent consideration | 1,975 | (4,500 | ) | (10,376 | ) | ||||||
| Cost-method investment related (gain) loss, net | (45,911 | ) | — | 10,309 | |||||||
| Recovery of previously impaired note receivable | (6,000 | ) | — | — | |||||||
| Impairment of in-process research and development | 21,438 | — | — | ||||||||
| Loss on extinguishment of debt | — | 37,611 | — | ||||||||
| Other | 7,780 | 10,877 | 8,811 | ||||||||
| Changes in operating assets and liabilities: | |||||||||||
| Accounts receivable | (34,441 | ) | (7,011 | ) | (7,844 | ) | |||||
| Inventory | (23,707 | ) | 22,152 | (48,583 | ) | ||||||
| Prepaid expenses and other current assets | (3,062 | ) | (2,016 | ) | 2,554 | ||||||
| Other assets | (2,903 | ) | (4,004 | ) | (3,566 | ) | |||||
| Accounts payable | 15,112 | (21,097 | ) | 23,150 | |||||||
| Accrued liabilities | 24,388 | 38,945 | 32,028 | ||||||||
| Other long-term liabilities | 6,640 | 8,058 | (113 | ) | |||||||
| Net cash provided by operating activities | 291,873 | 358,140 | 272,573 | ||||||||
| Cash flows from investing activities: | |||||||||||
| Purchases of available-for-sale securities | (925,478 | ) | (1,310,269 | ) | (846,208 | ) | |||||
| Sales of available-for-sale securities | 733,326 | 900,884 | 539,161 | ||||||||
| Maturities of available-for-sale securities | 165,424 | 160,007 | 149,450 | ||||||||
| Sales and maturities of trading securities | — | — | 54,900 | ||||||||
| Net cash paid for acquisitions | (83,156 | ) | (58,302 | ) | (98,211 | ) | |||||
| Purchases of strategic investments | (15,938 | ) | (13,769 | ) | (27,677 | ) | |||||
| Purchases of property and equipment | (68,781 | ) | (77,800 | ) | (49,818 | ) | |||||
| Cash paid for intangible assets | (12,228 | ) | (1,750 | ) | (6,650 | ) | |||||
| Proceeds from sale of strategic investment | 50,819 | — | — | ||||||||
| Recovery of previously impaired note receivable | 6,000 | — | — | ||||||||
| Net cash used in investing activities | (150,012 | ) | (400,999 | ) | (285,053 | ) | |||||
| Cash flows from financing activities: | |||||||||||
| Payments on current portion of long-term debt | — | (349,874 | ) | — | |||||||
| Payments on acquisition related contingent consideration liability | (3,374 | ) | — | — | |||||||
| Proceeds from issuance of convertible notes | — | 903,492 | — | ||||||||
| Incremental tax benefit related to share-based compensation | 20,783 | 46,354 | 42,445 | ||||||||
| Common stock repurchases | (82,522 | ) | (570,406 | ) | (44,016 | ) | |||||
| Proceeds from the exercise of warrants | — | 5,512 | 16,029 | ||||||||
| Proceeds from issuance of common stock | 54,358 | 61,938 | 102,016 | ||||||||
| Net cash (used in) provided by financing activities | (10,755 | ) | 97,016 | 116,474 | |||||||
| Effect of exchange rate changes on cash and cash equivalents | (103 | ) | (126 | ) | 320 | ||||||
| Net increase in cash and cash equivalents | 131,003 | 54,031 | 104,314 | ||||||||
| Cash and cash equivalents at beginning of year | 302,978 | 248,947 | 144,633 | ||||||||
| Cash and cash equivalents at end of year | $ | 433,981 | $ | 302,978 | $ | 248,947 | |||||
51
ILLUMINA, INC. CONSOLIDATED STATEMENTS OF CASH FLOWS — (Continued) (In thousands) | |||||||||||
| Years Ended | |||||||||||
| December 30, 2012 | January 1, 2012 | January 2, 2011 | |||||||||
| Supplemental cash flow information: | |||||||||||
| Cash paid for interest | $ | 2,551 | $ | 2,481 | $ | 2,437 | |||||
| Cash paid for income taxes | $ | 74,037 | $ | 9,806 | $ | 31,566 | |||||
| Unsettled short-term investments purchase | $ | 9,154 | $ | — | $ | — | |||||
| Years Ended | ||||||||||||
| January 2, | January 3, | December 28, | ||||||||||
| 2011 | 2010 | 2008 | ||||||||||
| (In thousands) | ||||||||||||
| Cash flows from operating activities: | ||||||||||||
| Net income | $ | 124,891 | $ | 72,281 | $ | 39,416 | ||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Acquired in-process research and development | 1,325 | 11,325 | 24,660 | |||||||||
| Amortization of intangible assets | 7,805 | 6,680 | 10,438 | |||||||||
| Amortization of debt discount | 21,407 | 20,286 | 18,883 | |||||||||
| Change in fair value of contingent consideration | (10,376 | ) | — | — | ||||||||
| Impairment of cost-method investment | 13,223 | — | — | |||||||||
| Gain on acquisition | (2,914 | ) | — | — | ||||||||
| Depreciation expense | 34,204 | 24,504 | 17,285 | |||||||||
| Share-based compensation expense | 71,645 | 60,811 | 47,688 | |||||||||
| Incremental tax benefit related to stock options exercised | (42,445 | ) | (39,319 | ) | (18,501 | ) | ||||||
| Deferred income taxes | 48,696 | 29,704 | 31,533 | |||||||||
| Impairment of manufacturing equipment | — | — | 4,069 | |||||||||
| Other non-cash adjustments | 7,239 | 1,721 | 803 | |||||||||
| Changes in operating assets and liabilities: | ||||||||||||
| Accounts receivable | (7,844 | ) | (18,578 | ) | (57,672 | ) | ||||||
| Inventory | (48,583 | ) | (20,557 | ) | (19,560 | ) | ||||||
| Prepaid expenses and other current assets | 2,554 | (3,429 | ) | 2,322 | ||||||||
| Other assets | (3,566 | ) | (2,670 | ) | (1,815 | ) | ||||||
| Accounts payable | 23,150 | 11,778 | 4,840 | |||||||||
| Accrued liabilities | 32,028 | 19,997 | 31,716 | |||||||||
| Other long-term liabilities | (113 | ) | 814 | 6,313 | ||||||||
| Litigation settlements payable | — | — | (54,536 | ) | ||||||||
| Unrealized gain (loss) on foreign exchange | 247 | (3,157 | ) | — | ||||||||
| Net cash provided by operating activities | 272,573 | 172,191 | 87,882 | |||||||||
| Cash flows from investing activities: | ||||||||||||
Purchases ofavailable-for-sale securities | (846,208 | ) | (694,487 | ) | (568,707 | ) | ||||||
Sales and maturities ofavailable-for-sale securities | 688,611 | 514,216 | 411,817 | |||||||||
| Sales and maturities of trading securities | 54,900 | 1,000 | — | |||||||||
| Net cash paid for acquisitions | (98,211 | ) | (1,325 | ) | (24,666 | ) | ||||||
| Purchases of investments | (27,677 | ) | (19,900 | ) | — | |||||||
| Purchases of property and equipment | (49,818 | ) | (52,673 | ) | (59,693 | ) | ||||||
| Cash paid for intangible assets | (6,650 | ) | (3,400 | ) | (36,000 | ) | ||||||
| Net cash used in investing activities | (285,053 | ) | (256,569 | ) | (277,249 | ) | ||||||
| Cash flows from financing activities: | ||||||||||||
| Payments on current portion of long-term debt | — | (10,000 | ) | (15 | ) | |||||||
| Incremental tax benefit related to stock options exercised | 42,445 | 39,319 | 18,501 | |||||||||
| Common stock repurchases | (44,016 | ) | (175,136 | ) | (70,785 | ) | ||||||
| Proceeds from secondary offering, net of issuance cost | — | — | 342,650 | |||||||||
| Proceeds from the exercise of warrants | 16,029 | 7,576 | 2,991 | |||||||||
| Proceeds from issuance of common stock | 102,016 | 39,379 | 44,330 | |||||||||
| Net cash provided by (used in) financing activities | 116,474 | (98,862 | ) | 337,672 | ||||||||
| Effect of exchange rate changes on cash and cash equivalents | 320 | 849 | 3,778 | |||||||||
| Net increase (decrease) in cash and cash equivalents | 104,314 | (182,391 | ) | 152,083 | ||||||||
| Cash and cash equivalents at beginning of period | 144,633 | 327,024 | 174,941 | |||||||||
| Cash and cash equivalents at end of period | $ | 248,947 | $ | 144,633 | $ | 327,024 | ||||||
| Supplemental disclosures of cash flow information: | ||||||||||||
| Cash paid for interest | $ | 2,437 | $ | 2,437 | $ | 2,553 | ||||||
| Cash paid (refunded) for income taxes | $ | 31,566 | $ | 10,361 | $ | (1,653 | ) | |||||
See accompanying notes to consolidated financial statements
54
52
ILLUMINA, INC.
Unless the context requires otherwise, references in this report to “Illumina,” “we,” “us,” the “Company,” and “our” refer to Illumina, Inc. and its consolidated subsidiaries.
| 1. | Organization and Summary of Significant Accounting Policies |
Organization and Business
Illumina, Inc. (the Company) is a leading developer, manufacturer, and marketer of life science tools and integrated systems for the analysis of genetic variation and biological function. Using the Company’sits proprietary technologies, Illumina provides a comprehensive line of genetic analysis solutions, with products and services that serveaddress a broad range of highly interconnected markets, including sequencing, genotyping, gene expression, and moleculargenomic-based diagnostics. The Company’s customers include leading genomic research centers, academic institutions, government laboratories, and clinical research organizations, as well as pharmaceutical, biotechnology, agrigenomics, and consumer genomics companies.companies, and in vitro fertilization clinics.
Basis of Presentation
The consolidated financial statements of the Company have been prepared in conformity with U.S. generally accepted accounting principles (GAAP) and include the accounts of the Company and its wholly-owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.
Fiscal Year
The Company’s fiscal year is 52 or 53 weeks ending the Sunday closest to December 31, with quarters of 13 or 14 weeks ending the Sunday closest to March 31, June 30, September 30, and December 31. The yearyears ended December 30, 2012, January 1, 2012, and January 2, 2011 was were 52 weeks; the year ended January 3, 2010 was 53 weeks; the year ended December 28, 2008 was 52 weeks. weeks, respectively.
Use of Estimates
The preparation of financial statements requires that management make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, expenses, and related disclosuredisclosures of contingent assets and liabilities. Actual results could differ from those estimates.
Reclassifications
Certain prior period amounts have been reclassified to conform to the current period presentation.
Segment Information
The Company is organized in two business operating segments thefor purposes of recording and reporting our financial results: Life Sciences Business Unit and Diagnostics Business Unit.Diagnostics. The Life Sciences Business Unitoperating segment includes all products and services that are primarily related to the research market, namely the product lines based on the Company’s sequencing, BeadArray, VeraCode, and real-time polymerase chain reaction (PCR) technologies, and thetechnologies. The Diagnostics Business Unitoperating segment focuses on the emerging opportunity in molecular diagnostics.clinical and personalized application of our products and services for such uses as diagnosing disease, identifying genetic abnormalities, and identifying effective treatment therapies, with an initial emphasis on reproductive health and cancer. During all periods presented, the CompanyDiagnostics operating segment had limited activity relatedbeen immaterial to the Diagnostics Business Unit.financial statements as a whole. Accordingly, the Company’s operating results for both unitssegments are reported on an aggregate basis as one reportable segment during these periods.segment. The Company will begin reporting in two reportable segments once revenues,revenue, operating profit or loss, or assetsasset of the Diagnostics Business Unit exceed operating segment exceeds 10% of the consolidated amounts.
Acquisitions
55
53
ILLUMINA, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)
or impaired. Post-acquisition adjustments related to business combination deferred tax asset valuation allowances and the additional consideration is issued or becomes issuable, in accordance with the accounting guidance effective at the acquisition date. This results in additional IPR&D charges in periods subsequent to the acquisitionliabilities for uncertain tax positions are recorded in acquisition related (gain) expense, net.current period income tax expense.
Cash Equivalents and Short-Term Investments
Cash equivalents are comprised of short-term, highly liquid investments with maturities of 90 days or less at the date of purchase.
Short-term investments consist of U.S. Treasurytreasury securities, debt securities in U.S. government-sponsored entities, and U.S. government agency securities, corporate notes and bonds, and commercial paper.debt securities. Management classifies short-term investments asavailable-for-sale at the time of purchase and reevaluatesevaluates such classification as of each balance sheet date. All short-term investments are recorded at estimated fair value. Unrealized gains and losses foravailable-for-sale securities are included in accumulated other comprehensive income, a component of stockholders’ equity. The Company evaluates its investments to assess whether those with unrealized loss positions are other than temporarily impaired. Impairments are considered to be other than temporary if they are related to deterioration in credit risk or if it is likely that the Company will sell the securities before the recovery of their cost basis. Realized gains and losses and declines in value judged to be other than temporary are determined based on the specific identification method and are reported in other (expense) income, net in the consolidated statements of income.
Fair Value Measurements
The Company determines the fair value of its assets and liabilities based on the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most
56
advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value maximize the use of observable inputs and minimize the use of unobservable inputs. The Company uses a fair value hierarchy with three levels of inputs, of which the first two are considered observable and the last unobservable, to measure fair value:
Level 1 — Quoted prices in active markets for identical assets or liabilities. Level 2 —Inputs, other than Level 1, that are observable, either directly or indirectly, such as | ||
| January 2, 2011 | ||||||||||||||||
| Level 1 | Level 2 | Level 3 | Total | |||||||||||||
| Assets: | ||||||||||||||||
| Money market funds (cash equivalent) | $ | 148,822 | $ | — | $ | — | $ | 148,822 | ||||||||
| Debt securities in government sponsored entities | — | 261,697 | — | 261,697 | ||||||||||||
| Corporate debt securities | — | 330,758 | — | 330,758 | ||||||||||||
| U.S. Treasury securities | 52,887 | — | — | 52,887 | ||||||||||||
| Total assets measured at fair value | $ | 201,709 | $ | 592,455 | $ | — | $ | 794,164 | ||||||||
| Liability: | ||||||||||||||||
| Acquisition related contingent consideration liability | $ | — | $ | — | $ | 3,738 | $ | 3,738 | ||||||||
| January 3, 2010 | ||||||||||||||||
| Level 1 | Level 2 _ | Level 3 | Total | |||||||||||||
| Assets: | ||||||||||||||||
| Money market funds (cash equivalent) | $ | 81,153 | $ | — | $ | — | $ | 81,153 | ||||||||
| Debt securities in government sponsored entities | — | 289,701 | — | 289,701 | ||||||||||||
| Corporate debt securities | — | 192,821 | — | 192,821 | ||||||||||||
| Auction rate securities | — | — | 54,900 | 54,900 | ||||||||||||
| U.S. Treasury securities | 11,472 | — | — | 11,472 | ||||||||||||
| Total assets measured at fair value | $ | 92,625 | $ | 482,522 | $ | 54,900 | $ | 630,047 | ||||||||
57
The carrying amounts of financial instruments such as cash and cash equivalents, accounts receivable, prepaid expenses and other current assets, accounts payable, and accrued liabilities, excluding acquisition related contingent consideration as a resultliabilities, approximate the related fair values due to the short-term maturities of changes in these significant inputs could have a significant effect on the consolidated statements of income and the financial position in the period of the change.instruments.
| Contingent | ||||
| Consideration | ||||
| Liability | ||||
| (Level 3 Measurement) | ||||
| Balance at January 3, 2010 | $ | — | ||
| Acquisition of Helixis | 14,114 | |||
| Gain recorded in acquisition related (gain) expense, net | (10,376 | ) | ||
| Balance at January 2, 2011 | $ | 3,738 | ||
Accounts Receivable
Trade accounts receivable are recorded at the net invoice value and are not interest bearing. The Company considers receivables past due based on the contractual payment terms. The Company reviews its exposure to amounts receivable and reserves specific amountsreceivables if collectibility is no longer reasonably assured. The Company also reserves a percentage of its trade receivable balance based on collection history and current economic trends that might impact the level of future credit losses. The Company re-evaluates such reserves on a regular basis and adjusts its reserves as needed.
Concentrations of Risk
The Company operates in markets that are highly competitive and rapidly changing. Significant technological changes, shifting customer needs, the emergence of competitive products or services with new capabilities, and other factors could negatively impact the Company’s operating results. A significant portion of the Company’s customers consist of university and research institutions that management believes are, to some degree, directly or indirectly supported by the United States Government. A significant change in current research funding, particularly with respect to the National Institutes of Health, could have a material adverse impact on the Company’s future revenues and results of operations.
The Company is also subject to risks related to its financial instruments including its cash and cash equivalents, investments, and accounts receivable. Most of the Company’s cash and cash equivalents as of January 2, 2011December 30, 2012 were deposited with U.S. financial institutions, in the United States.either domestically or with their foreign branches. The Company’s investment policy
54
restricts the amount of credit exposure to any one issuer to 5% of the portfolio at the time of purchase and to any one industry sector, as defined by Bloomberg classifications, to 25% of the portfolio at the time of purchase. There is no limit to the percentage of the portfolio that may be maintained in U.S. treasury obligations,securities, debt securities in U.S. government agencies,government-sponsored entities, and money market funds. The Company performs a regular review of customer activity and associated credit risks and do not require collateral or enter into netting arrangements. The Company has historically not experienced significant credit losses from investments and accounts receivable.
The Company’s products require customized components that currently are available from a limited number of sources. The Company obtains certain key components included in its products from single vendors.
The Company performs a regular review of customer activity and associated credit risks and does not require collateral or enter into netting arrangements. Shipments to customers outside the United States comprised 45%51%, 48%50%, and 51%45% of the Company’s revenue for the years ended December 30, 2012, January 1, 2012, and January 2, 2011 January 3, 2010, and December 28, 2008,, respectively. Customers outside the United States represented 59%54% and 46%52% of the Company’s gross trade accounts receivable balance as of December 30, 2012 and January 2, 2011 and January 3, 2010,1, 2012, respectively. Sales to territories outside of the United States are generally denominated in U.S. dollars.
International sales entail a variety of risks, including currency exchange fluctuations, longer payment cycles, and greater difficulty in accounts receivable collection. The Company is also subject to general geopolitical risks, such as political, social and economic instability, and changes in diplomatic and trade relations. The risks of international sales are mitigated in part by the extent to which sales are geographically distributed. The Company has historically not experienced significant credit losses from investments and accounts receivable. Approximately 18% of the Company’s revenue is derived from European countries other than the United Kingdom. As the credit and economic conditions in certain southern European countries continue to deteriorate, the Company regularly reviews its accounts receivable outstanding in these countries and assesses the allowance for doubtful accounts accordingly. As of December 30, 2012, outstanding accounts receivables beyond standard payment terms from these countries accounted for approximately 5% of the Company’s accounts receivable balance, and the Company has not experienced significant difficulties in collecting the accounts receivable outstanding in these countries.
Inventory
Inventory is stated at the lower of cost (on a first in, first out basis) or market. Inventory includes raw materials and finished goods that may be used in the research and development process and such items are expensed as consumed or expired. Provisions for slow moving, excess, and obsolete inventories are estimated based on product life cycles, quality issues, historical experience, and usage forecasts.
Property and Equipment
Property and equipment are stated at cost, subject to review of impairment, and depreciated over the estimated useful lives of the assets (generally three to seven years)years) using the straight-line method. Amortization of leasehold improvements is computedrecorded over the shorter of the lease term or the estimated useful life of the related assets. Maintenance and repairs are charged to operations as incurred. When assets are sold, or otherwise disposed of, the cost and related accumulated depreciation are removed from the accounts and any gain or loss is included in operating expense.
Goodwill, Intangible Assets and Other Long-Lived Assets
Goodwill, which has an indefinite useful life, represents the excess of cost over fair value of net assets acquired. The change in the carrying value of goodwill during the year ended January 2, 2011December 30, 2012 was due to goodwill recorded in connection with acquisitions consummated in the year. Intangible assets include acquired technology, customer relationships, other license agreements, and licensed technology (capitalized as part of the Affymetrix litigation). The cost of identified intangible assetsBlueGnome acquisition. Goodwill is amortized on a straight-line basis over periods ranging from three to ten years.
55
The Company’s identifiable intangible assets that haveare typically comprised of acquired core technologies, licensed technologies, IPR&D, customer relationships, and trade names. The cost of all identifiable intangible assets with finite lives is amortized on a straight-line basis over the assets’ respective estimated useful lives and other long-lived assetslives.
IPR&D, which also has an indefinite useful life, is performed whenreviewed for impairment at least annually, or more frequently if an event occurs indicating the potential for impairment. The IPR&D impairment test requires the Company to assess the fair value of the asset as compared to its carrying value and record an impairment charge if the carrying value exceeds the fair value. The Company performed its annual impairment test of its IPR&D in the second fiscal quarter of 2012 and recorded $21.4 million in impairment charges within research and development expenses in the consolidated statements of income. Resources previously assigned to the research project were re-directed with no plans for additional investments to be made to the project in the foreseeable future.
The Company regularly performs reviews to determine if any event has occurred that may indicate its intangible assets with finite useful lives and other long-lived assets are potentially impaired. If indicators of impairment exist, the Company assessesperforms an impairment test to assess the recoverability of the affected long-lived assets by determining whether the carrying amount of such assets exceeds the undiscounted expected future cash flows. If impairment is indicated,the affected assets are not recoverable, the Company comparesestimates the carrying amount to the estimated fair value of the assetassets and adjustsrecords an impairment loss if the carrying value of the asset accordingly.assets exceeds the fair value. Factors that would necessitate anindicate potential impairment assessment include a significant decline in the Company’s stock price
59
and market capitalization compared to its net book value, significant changes in the ability of a particular asset to generate positive cash flows, and significant changes in the Company’s strategic business objectives and utilization of a particular asset. The Company performed quarterly reviews of its intangible assets with finite useful lives and other long-lived assets and noted no indications of impairment for the asset.year ended December 30, 2012.
Reserve for Product Warranties
The Company generally provides a one-yearone-year warranty on instruments. Additionally, the Company provides a warranty on its consumables through the expiryexpiration date, which generally ranges from six to twelve months after the manufacture date. Thedate. At the time revenue is recognized, the Company establishes an accrual for estimated warranty expenses based on historical experience as well as anticipated product performance. The Company periodically reviews the adequacy of its warranty reserve and adjusts, if necessary, the warranty percentage and accrual based on actual experience and estimated costs to be incurred. Warranty expense is recorded as a component of cost of product revenue. Warranty expenses associated with extended maintenance contracts for systems are recorded as cost of service and other revenue as incurred. See note “6. Warranties” for further detailed discussion.
Revenue Recognition
The Company’s revenue is generated primarily from the sale of products and services. Product revenue primarily consists of sales of instrumentation and consumables used in genetic analysis. Service and other revenue primarily consists of revenue received for performing genotyping and sequencing services, extended warrantyinstrument service contract sales, and amounts earned under research agreements with government grants, which are recognized in the period during which the related costs are incurred.
The Company recognizes revenue when persuasive evidence of an arrangement exists, delivery has occurred or services have been rendered, the seller’s price to the buyer is fixed or determinable, and collectibility is reasonably assured. In instances where final acceptance of the product or system is required, revenue is deferred until all the acceptance criteria have been met. All revenue is recorded net of any discounts.
Revenue forfrom product sales is recognized generally upon transfer of title to the customer, provided that no significant obligations remain and collection of the receivable is reasonably assured. Revenue forfrom instrument service contracts is recognized as the services are rendered, typically evenly over the contract term. Revenue from genotyping and sequencing services is recognized when earned, which is generally at the time the genotyping or sequencing analysis data is made available to the customer or agreed upon milestones are reached.
In order to assess whether the price is fixed or determinable, the Company evaluates whether refund rights exist. If there are refund rights or payment terms based on future performance, the Company defers revenue recognition until the price becomes fixed or determinable. The Company assesses collectibility based on a number of factors, including past transaction history with the customer and the creditworthiness of the customer. If the Company determines that collection of a payment is not reasonably assured, revenue recognition is deferred until receipt of payment.
56
The Company regularly enters into contracts where revenue is derived from multiple deliverables including any mix of products or services. These products or services are generally delivered within a short time frame, approximately three to six months of, after the contract execution date. Revenue recognition for contracts with multiple deliverables is based on the individual units of accounting determined to exist in the contract. A delivered item is considered a separate unit of accounting when the delivered item has value to the customer on a stand-alone basis. Items are considered to have stand-alone value when they are sold separately by any vendor or when the customer could resell the item on a stand-alone basis.
60
price if VSOE does not exist. If neither VSOE nor third-party evidence exists, the Company uses its best estimate of the selling price for the deliverable.
In order to establish VSOE of selling price, the Company must regularly sell the product or service on a standalone basis with a substantial majority priced within a relatively narrow range. VSOE of selling price is usually the midpoint of that range. If there are not a sufficient number of standalone sales and VSOE of selling price cannot be determined, then the Company considers whether third party evidence can be used to establish selling price. Due to the lack of similar products and services sold by other companies within the industry, the Company has rarely established selling price using third-party evidence. If neither VSOE nor third party evidence of selling price exists, the Company determines its best estimate of selling price using average selling prices over a rolling12-month period coupled with an assessment of current market conditions. If the product or service has no history of sales or if the sales volume is not sufficient, the Company relies upon prices set by the Company’s pricing committee adjusted for applicable discounts. The Company recognizes revenue for delivered elements only when it determines there are no uncertainties regarding customer acceptance.
In certain markets, the Company sells products and provides services to customers through distributors that specialize in life science products. In most sales through distributors, the product is delivered directly to customers. In cases where the product is delivered to a distributor, revenue recognition is deferred until acceptance is received from the distributor, and/or the end-user, if required by the applicable sales contract. The terms of sales transactions through distributors are consistent with the terms of direct sales to customers. These transactions are accounted for in accordance with the Company’s revenue recognition policy described herein.
Shipping and Handling Expenses
Shipping and handling expenses are included in cost of product revenue.
Research and development expenses consist of costs incurred for internal and grant-sponsored research and development. Development
Research and development expenses include personnel expenses, contractor fees, license fees, facilities costs, and utilities. Expenditures relating to research and development are expensed in the period incurred.
Advertising Costs
The Company expenses advertising costs as incurred. Advertising costs were $6.9$7.3 million $4.2, $6.8 million, and $3.4$6.9 million for the years ended December 30, 2012, January 1, 2012, and January 2, 2011 January 3, 2010, and December 28, 2008,, respectively.
61
Leases are reviewed and classified as capital or operating at their inception. For leases that contain rent escalations, the Company records the total rent payableexpense on a straight-line basis over the term of the lease, which includes the construction build-out period but excludesand lease extension periods.periods, if appropriate. The difference between rent payments and straight-line rent expense is recorded as deferred rent in accrued liabilities and other long-term liabilities. Landlord allowances are also recorded in other long-term liabilities, which are amortized on a straight-linestraight-
57
line basis over the lease term as a reduction to rent expense. The Company capitalizes leasehold improvements and amortizes them over the shorter of the lease term or their expected useful lives.
In 2012, the Company completed the relocation of its headquarters to another facility in San Diego, California. Headquarter relocation expenses recorded in years ended December 30, 2012 and January 1, 2012 primarily consisted of accelerated depreciation expense, impairment of assets, additional rent expense during the transition period when both the new and former headquarter facilities are occupied, moving expenses, and cease-use losses. The Company recorded accelerated depreciation expense for leasehold improvements at its former headquarter facility based on the reassessed useful lives of less than a year. The Company recorded cease-use losses and the corresponding facility exit obligation upon vacating certain buildings of its former headquarters, calculated as the present value of the remaining lease obligation offset by estimated sublease rental receipts during the remaining lease period, adjusted for deferred items and estimated lease incentives. The key assumptions used in the calculation include the amount and timing of estimated sublease rental receipts, and the risk-adjusted discount rate.
Restructuring Charges
During the fourth quarter of the year ended January 1, 2012, the Company announced and executed a restructuring plan, to reduce the Company’s workforce and to consolidate certain facilities. The Company measured and accrued the liabilities associated with employee separation costs at fair value as of the date the plan was announced and terminations were communicated to employees, which primarily included severance pay and other separation costs such as outplacement services and benefits.
The fair value measurement of restructuring related liabilities requires certain assumptions and estimates to be made by the Company, such as the retention period of certain employees, the timing and amount of sublease income on properties to be vacated, and the operating costs to be paid until lease termination. It is the Company’s policy to use the best estimates based on facts and circumstances available at the time of measurement, review the assumptions and estimates periodically, and adjust the liabilities when necessary.
Income Taxes
The provision for income taxes is computed using the asset and liability method, under which deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the financial reporting and tax bases of assets and liabilities, and for the expected future tax benefit to be derived from tax loss and credit carryforwards. Deferred tax assets and liabilities are determined using the enacted tax rates in effect for the years in which those tax assets are expected to be realized. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in the provision for income taxes in the period that includes the enactment date.
Deferred tax assets are regularly assessed to determine the likelihood they will be recovered from future taxable income. A valuation allowance is established when the Company believes it is more likely than not the future realization of all or some of a deferred tax asset will not be achieved. In evaluating the ability to recover deferred tax assets within the jurisdiction which they arise the Company considers all available positive and negative evidence. Factors reviewed include the cumulative pre-tax book income for the past three years, scheduled reversals of deferred tax liabilities, history of earnings and reliable forecasting, projections of pre-tax book income over the foreseeable future, and the impact of any feasible and prudent tax planning strategies.
The Company recognizes excess tax benefits associated with share-based compensation to stockholders’ equity only when realized. When assessing whether excess tax benefits relating to share-based compensation have been realized, the Company follows thewith-and-without approach excluding any indirect effects of the excess tax deductions. Under this approach, excess tax benefits related to share-based compensation are not deemed to be realized until after the utilization of all other tax benefits available to the Company.
The Company recognizes the impact of a tax position in the financial statements only if that position is more likely than not of being sustained upon examination by taxing authorities, based on the technical merits of the position. Any interest and penalties related to uncertain tax positions will be reflected in income tax expense.
58
Functional Currency
62
income. Gains or (losses) resulting from remeasurement were $0.6 million, $(2.3) million, and $3.8 million forDuring the years ended December 30, 2012 and January 1, 2012, the Company recorded $2.2 million net gain and $2.0 million net loss from remeasurement, respectively. Gains and losses related to remeasurement were immaterial for the year ended January 2, 2011 January 3, 2010 and December 28, 2008, respectively..
Derivatives
The Company is exposed to foreign exchange rate risks in the normal course of business. To manage a portion of the accounting exposure resulting from changes in foreign currency exchange rates, the Company enters into foreign exchange contracts to hedge monetary assets and liabilities that are denominated in currencies other than the U.S. dollar. These foreign exchange contracts are carried at fair value and do not qualify for hedge accounting treatment and are not designated as hedging instruments. Changes in the value of the derivativederivatives are recognized in other (expense) income, net, in the consolidated statements of income forin the current period,respective periods, along with an offsetting remeasurement gain or loss on the underlying foreign currency denominated assets or liabilities.
As of December 30, 2012, the Company had foreign exchange forward contracts in place to hedge exposures in the euro, Japanese yen, and Australian dollar. As of December 30, 2012 and January 1, 2012, the total notional amount of outstanding forward contracts in place for foreign currency purchases was $51.2 million and $25.5 million, respectively. Non-designated foreign exchange forward contract related gain was $1.2 million for the year ended December 30, 2012 and immaterial for the years ended January 1, 2012 and January 2, 2011.
Share-Based Compensation
The Company uses the Black-Scholes-Merton option-pricing model to estimate the fair value of stock options granted and stock purchases under the Employee Stock Purchase Plan (ESPP). This model incorporates various assumptions including expected volatility, expected lifeterm of an award, expected dividends, and the risk-free interest rates. The Company determines the expected volatility by equally weighing the historical and implied volatility of the Company’s common stock. The historical volatility of the Company’s common stock over the most recent period is generally commensurate with the estimated expected lifeterm of the Company’s stock awards, adjusted for the impact of unusual fluctuations not reasonably expected to recur and other relevant factors. The implied volatility is calculated from the implied market volatility of exchange-traded call options on the Company’s common stock. The expected lifeterm of an award is based on historical forfeiture experience, exercise activity, and on the terms and conditions of the stock awards. The expected dividend yield is determined to be 0% given that the Company has never declared or paid cash dividends on its common stock and does not anticipate paying such cash dividends. The risk-free interest rate is based upon U.S. Treasury securities with remaining terms similar to the expected term of the share-based awards. The fair value of restricted stock units granted is based on the market price of ourthe Company’s common stock on the date of grant. The Company amortizesrecognizes the fair value of share-based compensation on a straight-line basis over the requisite service periods of the awards.
| Years Ended | ||||||
| January 2, | January 3, | December 28, | ||||
| 2011 | 2010 | 2008 | ||||
| Interest rate — stock options | 2.05 - 2.73% | 1.69 - 1.97% | 2.31 -3.52% | |||
| Interest rate — stock purchases | 0.17 - 0.48% | 0.28 - 2.90% | 1.88 -4.71% | |||
| Volatility — stock options | 46 - 48% | 55 - 58% | 51 - 65% | |||
| Volatility — stock purchases | 46 - 48% | 48 - 58% | 53 - 69% | |||
| Expected life — stock options | 6 years | 5 years | 5 - 6 years | |||
| Expected life — stock purchases | 6 - 12 months | 6 - 12 months | 6 - 12 months | |||
| Expected dividend yield | 0% | 0% | 0% | |||
| Weighted average fair value per share of options granted | $18.82 | $14.79 | $18.31 | |||
| Weighted average fair value per share of employee stock purchases | $11.10 | $9.24 | $11.45 | |||
63
| Years Ended | ||||||||||||
| January 2, | January 3, | December 28, | ||||||||||
| 2011 | 2010 | 2008 | ||||||||||
| Cost of product revenue | $ | 5,378 | $ | 4,776 | $ | 4,710 | ||||||
| Cost of service and other revenue | 470 | 514 | 400 | |||||||||
| Research and development | 25,428 | 19,960 | 14,086 | |||||||||
| Selling, general and administrative | 40,369 | 35,561 | 28,492 | |||||||||
| Share-based compensation expense before taxes | 71,645 | 60,811 | 47,688 | |||||||||
| Related income tax benefits | (25,231 | ) | (20,121 | ) | (15,844 | ) | ||||||
| Share-based compensation expense, net of taxes | $ | 46,414 | $ | 40,690 | $ | 31,844 | ||||||
Net Income per Share
Basic net income or loss per share is computed by dividing net income or loss by the weighted-averageweighted average number of common shares outstanding during the reporting period. Diluted net income per share is computed by dividing net income by the weighted average number of common shares outstanding during the reporting period increased to include dilutive potential common shares calculated using the treasury stock method. DilutiveDiluted net income per share reflects the potential common shares consist ofdilution from outstanding stock options, with combined exercise prices and unrecognized compensation expense that are less than the average market price of the Company’s common stock, restricted stock units, with unrecognized compensation expense,ESPP, warrants, shares subject to forfeiture, and convertible debtsenior notes. Under the treasury stock method, convertible senior notes will have a dilutive impact when the average market price of the Company’s common stock is above the applicable conversion price of $21.83 and warrants with exercise prices thatthe respective notes. In addition, the following amounts are less than the average market price of the Company’s common stock. Under the treasury stock method,assumed to be used to repurchase shares: the amount that must be paid to exercise stock options and warrants and purchase shares under the ESPP; the average amount of compensation expense for future services that the Company has not yet recognized for stock options, and restricted stock units, ESPP, and shares subject to forfeiture; and the amount of estimated tax benefits that will be recorded in additional paid-in capital when the expenses related to respective awards become deductible are assumed to be used to repurchase shares. In loss periods, basic net loss per share and diluted net loss per share are identical since the effectdeductible.
59
ILLUMINA, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)
The following table presents the calculation of weighted average shares used to calculate basic and diluted net income per share (in thousands):
| Years Ended | ||||||||||||
| January 2, | January 3, | December 28, | ||||||||||
| 2011 | 2010 | 2008 | ||||||||||
| Weighted average shares outstanding | 123,581 | 123,154 | 116,855 | |||||||||
| Plus: Effect of dilutive Convertible Senior Notes | 9,058 | 6,497 | 6,653 | |||||||||
| Plus: Effect of dilutive equity awards | 4,674 | 4,335 | 5,373 | |||||||||
| Plus: Effect of dilutive warrants sold in connection with the Convertible Senior Notes | 5,317 | 1,566 | 2,487 | |||||||||
| Plus: Effect of dilutive warrants assumed in the acquisition of Solexa | 803 | 1,544 | 2,239 | |||||||||
| Weighted-average shares used in calculating diluted net income per share | 143,433 | 137,096 | 133,607 | |||||||||
| Weighted average shares excluded from calculation due to anti-dilutive effect | 1,934 | 924 | 370 | |||||||||
| Years Ended | ||||||||
| December 30, 2012 | January 1, 2012 | January 2, 2011 | ||||||
| Weighted average shares outstanding | 122,999 | 123,399 | 123,581 | |||||
| Effect of dilutive potential common shares from: | ||||||||
| Convertible senior notes | 967 | 3,783 | 9,058 | |||||
| Equity awards | 3,906 | 4,703 | 4,674 | |||||
| Warrants sold in connection with convertible senior notes | 5,821 | 7,052 | 5,317 | |||||
| Warrants assumed in a prior acquisition | — | — | 803 | |||||
| Weighted average shares used in calculating diluted net income per share | 133,693 | 138,937 | 143,433 | |||||
| Potentially dilutive shares excluded from calculation due to anti-dilutive effect | 2,556 | 2,418 | 1,934 | |||||
Accumulated Other Comprehensive Income
Comprehensive income is comprised of net income and other comprehensive income. The Company has disclosed comprehensive income as a component of stockholders’ equity. AccumulativeAccumulated other comprehensive income on the consolidated balance sheets at December 30, 2012 and January 2, 2011 and January 3, 20101, 2012 includes accumulated foreign currency translation adjustments and unrealized gains and losses on the Company’savailable-for-sale securities. securities.
The components of accumulated other comprehensive income are as follows (in thousands):
| January 2, | January 3, | |||||||
| 2011 | 2010 | |||||||
| Foreign currency translation adjustments | $ | 1,338 | $ | 1,338 | ||||
Unrealized gain onavailable-for-sale securities, net of deferred tax | 427 | 1,492 | ||||||
| Total accumulated other comprehensive income | $ | 1,765 | $ | 2,830 | ||||
| December 30, 2012 | January 1, 2012 | ||||||
| Foreign currency translation adjustments | $ | 1,289 | $ | 1,289 | |||
| Unrealized gain on available-for-sale securities, net of deferred tax | 834 | 828 | |||||
| Total accumulated other comprehensive income | $ | 2,123 | $ | 2,117 | |||
| 2. | Balance Sheet Account Details |
Investments
The following is a summary of short-term investments (in thousands):
| January 2, 2011 | ||||||||||||||||
| Gross | Gross | |||||||||||||||
| Amortized | Unrealized | Unrealized | Estimated | |||||||||||||
| Cost | Gains | Losses | Fair Value | |||||||||||||
Available-for-sale securities: | ||||||||||||||||
| Debt securities in government sponsored entities | $ | 261,890 | $ | 106 | $ | (299 | ) | $ | 261,697 | |||||||
| Corporate debt securities | 329,823 | 1,170 | (235 | ) | 330,758 | |||||||||||
| U.S. treasury securities | 52,938 | 70 | (121 | ) | 52,887 | |||||||||||
Totalavailable-for-sale securities | $ | 644,651 | $ | 1,346 | $ | (655 | ) | $ | 645,342 | |||||||
| December 30, 2012 | January 1, 2012 | ||||||||||||||||||||||||||||||
Amortized Cost | Gross Unrealized Gains | Gross Unrealized Losses | Estimated Fair Value | Amortized Cost | Gross Unrealized Gains | Gross Unrealized Losses | Estimated Fair Value | ||||||||||||||||||||||||
| Available-for-sale securities: | |||||||||||||||||||||||||||||||
| Debt securities in government-sponsored entities | $ | 314,638 | $ | 251 | $ | (16 | ) | $ | 314,873 | $ | 393,759 | $ | 428 | $ | (148 | ) | $ | 394,039 | |||||||||||||
| Corporate debt securities | 471,989 | 1,059 | (187 | ) | 472,861 | 432,550 | 1,293 | (461 | ) | 433,382 | |||||||||||||||||||||
| U.S. treasury securities | 128,256 | 233 | — | 128,489 | 58,955 | 214 | — | 59,169 | |||||||||||||||||||||||
| Total available-for-sale securities | $ | 914,883 | $ | 1,543 | $ | (203 | ) | $ | 916,223 | $ | 885,264 | $ | 1,935 | $ | (609 | ) | $ | 886,590 | |||||||||||||
60
Available-For-Sale Securities
| January 3, 2010 | ||||||||||||||||
| Gross | Gross | |||||||||||||||
| Amortized | Unrealized | Unrealized | Estimated | |||||||||||||
| Cost | Gains | Losses | Fair Value | |||||||||||||
Available-for-sale securities: | ||||||||||||||||
| Debt securities in government sponsored entities | $ | 289,101 | $ | 702 | $ | (102 | ) | $ | 289,701 | |||||||
| Corporate debt securities | 190,949 | 2,039 | (166 | ) | 192,822 | |||||||||||
| U.S. treasury securities | 11,487 | 12 | (28 | ) | 11,471 | |||||||||||
Totalavailable-for-sale securities | 491,537 | 2,753 | (296 | ) | 493,994 | |||||||||||
| Trading securities: | ||||||||||||||||
| Auction rate securities | 54,900 | — | (6,129 | ) | 48,771 | |||||||||||
| Put option | — | 6,129 | — | 6,129 | ||||||||||||
| Total trading securities | 54,900 | 6,129 | (6,129 | ) | 54,900 | |||||||||||
| Total short-term investments | $ | 546,437 | $ | 8,882 | $ | (6,425 | ) | $ | 548,894 | |||||||
As of January 2, 2011December 30, 2012 the Company had 8359available-for-sale securities in a gross unrealized loss position, all of which had been in such position for less than twelve months. There were no unrealized losses due to credit issues for the periods presented. There were no impairments consideredother-than-temporary as it is more likely than not the Company will hold the securities until maturity or a recovery of the cost basis. The following table shows the fair values and the gross unrealized losses of the Company’s available-for- sale securities that were in an unrealized loss position as of December 30, 2012 and January 2, 2011 and January 3, 20101, 2012 aggregated by investment category (in thousands):
| January 2, 2011 | January 3, 2010 | |||||||||||||||
| Gross | Gross | |||||||||||||||
| Unrealized | Unrealized | |||||||||||||||
| Fair Value | Losses | Fair Value | Losses | |||||||||||||
| Debt securities in government sponsored entities | $ | 127,756 | $ | (299 | ) | $ | 73,783 | $ | (102 | ) | ||||||
| Corporate debt securities | 92,199 | (235 | ) | 26,488 | (166 | ) | ||||||||||
| U.S. treasury securities | 13,490 | (121 | ) | 4,471 | (28 | ) | ||||||||||
| Total | $ | 233,445 | $ | (655 | ) | $ | 104,742 | $ | (296 | ) | ||||||
| December 30, 2012 | January 1, 2012 | ||||||||||||||
| Fair Value | Gross Unrealized Losses | Fair Value | Gross Unrealized Losses | ||||||||||||
| Debt securities in government-sponsored entities | $ | 28,176 | $ | (16 | ) | $ | 133,904 | $ | (148 | ) | |||||
| Corporate debt securities | 130,224 | (187 | ) | 138,326 | (461 | ) | |||||||||
| Total | $ | 158,400 | $ | (203 | ) | $ | 272,230 | $ | (609 | ) | |||||
Realized gains and losses are determined based on the specific identification method and are reported in interest income in the consolidated statements of income. Gross realized gains on sales of available-for saleavailable-for-sale securities for the yearyears ended December 30, 2012, January 1, 2012, and January 2, 2011 were $1.7$1.6 million, $1.4 million, and gross realized losses were immaterial.$1.7 million, respectively. Gross realized gains and losses on sales ofavailable-for-sale securities were immaterial for each of the years ended December 30, 2012, January 3, 20101, 2012, and December 28, 2008.
66
January 2, 2011 were immaterial.
Contractual maturities ofavailable-for-sale debt securities as of January 2, 2011December 30, 2012 were as follows (in thousands):
| Estimated | ||||
| Fair Value | ||||
| Due within one year | $ | 230,421 | ||
| After one but within five years | 414,921 | |||
| Total | $ | 645,342 | ||
| Estimated Fair Value | |||
| Due within one year | $ | 328,991 | |
| After one but within five years | 587,232 | ||
| Total | $ | 916,223 | |
Cost-Method Investments
As of December 30, 2012 and January 3, 2010, the Company’s short-term investments included $54.9 million (at cost) of auction rate securities issued primarily by municipalities and universities. In November 2008, the Company signed an agreement granting the Company an option to sell all of its auction rate securities at par value to UBS during the period of June 30, 2010 through July 2, 2012. To account for the option, the Company recorded a separate freestanding asset (put option). On July 1, 2010, the Company exercised its option to sell all of its remaining auction rate securities at par. From January 3, 2010 through July 1, 2010 the increase in the fair value of the auction rate securities was equal to the decrease in the fair value of the put option. As such, no gain or loss was recorded as a result of the exercise of the put option and the sale of the auction rate securities.
2012Cost-Method Investments
During the fourth quarter of 2012, the Company sold its minority ownership interest in deCODE Genetics, Inc., an Icelandic company that focuses on the genetic studies of human disease, to Amgen Inc., a biotechnology medicines company based in the U.S. Gross proceeds received were $50.8 million, resulting in a gain of $48.6 million. Also during the fourth quarter of 2012, the Company received $6.0 million from an investee in principal payment of a loan that was previously impaired, and recorded the recovered funds in interest income in the consolidated statements of income.
As a result of its impairment analysis performed in the fourth quarter of 2012, the Company determined that a cost-method investment was other-than-temporarily impaired and recorded an impairment loss of $2.7 million. This determination was based upon operational performance trends coupled with uncertainty regarding the entity’s ability to obtain additional funding in a required timeframe for the entity to continue operations.
No impairment losses were recorded during the year ended January 1, 2012. In the year ended January 2, 2011, the Company determined that a $6.0 million cost-method investment and a related $6.8 million note receivable with interest receivable of $0.4 million were below carrying value and the impairment was other-than-temporary. As a result, the Company recorded an impairment charge of $13.2 million in cost-method investment gain (loss), net in the consolidated statements of income for the year ended January 2, 2011.
61
Accounts Receivable
Accounts receivable consist of the following (in thousands):
| January 2, | January 3, | |||||||
| 2011 | 2010 | |||||||
| Accounts receivable from product and service sales | $ | 165,117 | $ | 157,536 | ||||
| Other receivables | 2,167 | 1,613 | ||||||
| Total accounts receivable, gross | 167,284 | 159,149 | ||||||
| Allowance for doubtful accounts | (1,686 | ) | (1,398 | ) | ||||
| Total accounts receivable, net | $ | 165,598 | $ | 157,751 | ||||
67
| December 30, 2012 | January 1, 2012 | ||||||
| Accounts receivable from product and service sales | $ | 217,369 | $ | 175,226 | |||
| Other receivables | 1,886 | 2,657 | |||||
| Total accounts receivable, gross | 219,255 | 177,883 | |||||
| Allowance for doubtful accounts | (4,280 | ) | (3,997 | ) | |||
| Total accounts receivable, net | $ | 214,975 | $ | 173,886 | |||
Inventory
Inventory consists of the following (in thousands):
| December��30, 2012 | January 1, 2012 | ||||||
| Raw materials | $ | 61,665 | $ | 58,340 | |||
| Work in process | 75,675 | 53,412 | |||||
| Finished goods | 21,378 | 17,029 | |||||
| Total inventory | $ | 158,718 | $ | 128,781 | |||
Property and Equipment
Property and equipment, net consists of the following (in thousands):
| January 2, | January 3 | |||||||
| 2011 | 2010 | |||||||
| Raw materials | $ | 56,435 | $ | 39,839 | ||||
| Work in process | 73,759 | 52,059 | ||||||
| Finished goods | 24,290 | 11,475 | ||||||
| Total inventory, gross | 154,484 | 103,373 | ||||||
| Reserve for inventory | (12,273 | ) | (10,597 | ) | ||||
| Total inventory, net | $ | 142,211 | $ | 92,776 | ||||
| December 30, 2012 | January 1, 2012 | ||||||
| Leasehold improvements | $ | 87,734 | $ | 63,406 | |||
| Machinery and equipment | 158,112 | 143,816 | |||||
| Computer hardware and software | 58,313 | 54,826 | |||||
| Furniture and fixtures | 8,022 | 8,095 | |||||
| Construction in progress | 7,390 | 10,022 | |||||
| Total property and equipment, gross | 319,571 | 280,165 | |||||
| Accumulated depreciation | (153,404 | ) | (136,682 | ) | |||
| Total property and equipment, net | $ | 166,167 | $ | 143,483 | |||
| January 2, | January 3, | |||||||
| 2011 | 2010 | |||||||
| Leasehold improvements | $ | 55,681 | $ | 55,322 | ||||
| Manufacturing and laboratory equipment | 114,108 | 92,956 | ||||||
| Computer equipment and software | 41,500 | 37,071 | ||||||
| Furniture and fixtures | 6,732 | 5,993 | ||||||
| Leased equipment | 13,357 | — | ||||||
| Total property and equipment, gross | 231,378 | 191,342 | ||||||
| Accumulated depreciation | (101,504 | ) | (74,154 | ) | ||||
| Total property and equipment, net | $ | 129,874 | $ | 117,188 | ||||
Depreciation expense was $34.2$48.2 million $24.5, $55.6 million and $17.3$34.2 million for the years ended December 30, 2012, January 1, 2012, and January 2, 2011, respectively. Capital expenditures included accrued expenditures of $1.6 million, $5.9 million, and $1.8 million in the years ended December 30, 2012, January 3, 2010,1, 2012, and December 28, 2008,January 2, 2011, respectively. These amounts have been excluded from the Consolidated Statements of Cash Flows for the respective periods.
62
Accrued Liabilities
Accrued liabilities consist of the following (in thousands):
| January 2, | January 3, | |||||||
| 2011 | 2010 | |||||||
| Accrued compensation expenses | $ | 49,368 | $ | 32,487 | ||||
| Deferred revenue, current portion | 45,863 | 27,445 | ||||||
| Reserve for product warranties | 16,761 | 10,215 | ||||||
| Customer deposits | 14,900 | 6,121 | ||||||
| Accrued taxes payable | 13,277 | 12,109 | ||||||
| Acquisition related contingent consideration liability | 3,738 | — | ||||||
| Accrued royalties | 2,781 | 2,552 | ||||||
| Other accrued expenses | 9,476 | 7,324 | ||||||
| Total accrued liabilities | $ | 156,164 | $ | 98,253 | ||||
| December 30, 2012 | January 1, 2012 | ||||||
| Accrued compensation expenses | $ | 59,864 | $ | 52,035 | |||
| Deferred revenue, current portion | 55,817 | 52,573 | |||||
| Accrued taxes payable | 23,021 | 19,339 | |||||
| Customer deposits | 13,765 | 17,958 | |||||
| Reserve for product warranties | 10,136 | 11,966 | |||||
| Acquisition related contingent consideration liability, current portion | 9,490 | 2,335 | |||||
| Unsettled short-term investment purchase | 9,154 | — | |||||
| Facility exit obligation, current portion | 8,063 | 4,408 | |||||
| Accrued royalties | 2,836 | 5,682 | |||||
| Other accrued expenses | 9,731 | 10,819 | |||||
| Total accrued liabilities | $ | 201,877 | $ | 177,115 | |||
| 3. | Restructuring Activities |
In late 2011, the Company implemented a cost reduction initiative that included workforce reductions and the consolidation of certain facilities. In total, the Company notified approximately 200 employees of their involuntary termination.
A summary of the pre-tax charges and estimated total costs associated with the initiative is as follows (in thousands):
| Employee Separation costs | Facilities Exit Costs | Other Costs | Total | ||||||||||||
| Amount recorded in accrued liabilities as of January 1, 2012 | $ | 3,496 | $ | — | $ | 30 | $ | 3,526 | |||||||
| Additional expenses | 2,780 | 221 | 521 | 3,522 | |||||||||||
| Cash payments | (6,276 | ) | (221 | ) | (551 | ) | (7,048 | ) | |||||||
| Amount recorded in accrued liabilities as of December 30, 2012 | $ | — | $ | — | $ | — | $ | — | |||||||
| Cumulative expense recorded since inception in restructuring expense | $ | 10,463 | $ | 221 | $ | 974 | $ | 11,658 | |||||||
| Estimated total restructuring costs to be incurred | $ | 10,463 | $ | 221 | $ | 974 | $ | 11,658 | |||||||
| 4. | Acquisitions |
BlueGnome
On September 19, 2012, the Company announced the acquisition of BlueGnome Ltd. (BlueGnome), a provider of cytogenetics and in vitro fertilization screening products. Total consideration for the acquisition was $95.5 million, which included $88.0 million in initial cash payments and $7.5 million in fair value of contingent cash consideration of up to $20.0 million based on the achievement of certain revenue based milestones by December 28, 2014.
The Company estimated the fair value of contingent cash consideration using a probability weighted discounted cash flow approach, a Level 3 measurement based on unobservable inputs that are supported by little or no market activity and reflect the Company’s own assumptions in measuring fair value. The Company used a discount rate of 30% in the assessment of the acquisition date fair value for the contingent cash consideration. Future changes in significant inputs such as the discount rate and estimated probabilities of milestone achievements could have a significant effect on the fair value of the contingent consideration.
63
The Company allocated approximately $2.3$11.2 million of the total consideration to tangible assets, net of liabilities, and approximately $28.0$48.9 million to identified intangible assets, that will be amortized overincluding additional developed technologies of $25.0 million, customer relationships of $16.8 million, and a trade name of $7.1 million with average useful lifelives of 10 years.seven, five, and ten years, respectively. The Company also recorded a $10.7$12.1 million deferred tax liability to reflect the tax impact of thecertain identified intangible assets, that willthe amortization expenses for which are not generate tax deductible amortization expense and an $8.7 million deferred tax asset which primarily relates to acquired net operating loss carryforwards.deductible. The Company recorded the excess consideration of approximately $58.4$47.5 million as goodwill,goodwill.
Prior Acquisitions
On January 10, 2011, the Company acquired Epicentre Technologies Corporation (Epicentre), a provider of nucleic acid sample preparation reagents and specialty enzymes used in sequencing and microarray applications. Total consideration for the acquisition was $71.4 million, which included $59.4 million in net cash payments, $4.6 million in the fair value of contingent consideration settled in stock that is subject to forfeiture if certain non-revenue based milestones are not deductible for income tax purposes.met, and $7.4 million in the fair value of contingent cash consideration of up to $15.0 million based on the achievement of certain revenue based milestones by January 10, 2013.
The Company estimated the fair value of contingent cash consideration using a probability weighted discounted cash flow approach, a Level 3 measurement based on unobservable inputs that are supported by little or no market activity and reflects the Company’s own assumptions in measuring fair value. The Company used a discount rate of 21% in the assessment of the acquisition date fair value for the contingent cash consideration.
The Company allocated $0.9 million of the total consideration to tangible assets, net of liabilities, and $26.9 million to identified intangible assets, including additional developed technologies of $23.3 million, a trade name of $2.5 million, and customer relationships of $1.1 million, with weighted average useful lives of approximately nine, ten, and three years, respectively. The Company recorded the excess consideration of $43.6 million as goodwill.
On July 28, 2010, the Company completed an acquisition of another privately-held, development stage entity. Total consideration for the acquisition was $22.0 million.$22.0 million. As a result of this transaction, the companyCompany recorded an in-process research and development (IPR&D)IPR&D asset of $21.4$21.4 million in other assets (long-term).intangible assets. In determining the fair value of the IPR&D, various factors were considered, such as future revenue contributions, additional research and development costs to be incurred, and contributory asset charges. The fair value of the IPR&D was calculated using an income approach, and the rate used to discount net future cash flows to their present values was based on a risk-adjusted rate of return of approximately 28%. Significant factors considered in the calculation of the rate of return include the weighted average cost of capital, the weighted average return on assets, the internal rate of return, as well as the risks inherent in the development process for development-stage entities of similar sizes.
64
ILLUMINA, INC.
Prior to the acquisition, the Company paid $25.8had an equity interest in Helixis with a cost basis of $2.0 million that was accounted for under the cost-method of accounting. The Company recognized a gain of $2.9 million, which was included in other (expense) income, net, in its consolidated statement of income as a result of revaluing the Company’s equity interest in Helixis on the acquisition date.
In addition, the Company agreed to pay the former shareholders of another development stage company acquired in 2008 a certain amount of contingent cash including transaction costs.consideration based on the achievement of certain product-related and employment-related milestones. In accordance with the applicable accounting guidance effective at thatthe time, the Company recorded a charge of $24.7 millionsuch consideration was accounted for purchased in-process research and development (IPR&D). As partas additional elements of the cost of acquisition, agreement, Illumina agreed to payresulting in additional IPR&D charges in the former shareholdersyears ended January 1, 2012 and January 2, 2011 when the contingencies were resolved beyond a reasonable doubt and the considerations were issued or became issuable.
Summary of Contingent Compensation Expenses and IPR&D Charges
Contingent compensation expenses and IPR&D charges as a result of acquisitions consist of the entity up to an additional $35.0 million in contingent cash consideration based on the achievement of certain milestones. As contingent consideration payments are made,
69
| Years Ended | ||||||||||||
| January 2, | January 3, | December 28, | ||||||||||
| 2011 | 2010 | 2008 | ||||||||||
| IPR&D(1) | $ | 1,325 | $ | 11,325 | $ | 24,660 | ||||||
| Compensation expense(2) | 3,675 | 3,675 | 1,531 | |||||||||
| Years Ended | |||||||||||
| December 30, 2012 | January 1, 2012 | January 2, 2011 | |||||||||
| Contingent compensation expense, included in research and development expense | $ | 3,419 | $ | 4,799 | $ | 3,675 | |||||
| Contingent compensation expense, included in selling, general and administrative expense | 5,732 | 1,258 | — | ||||||||
| Total contingent compensation expense | $ | 9,151 | $ | 6,057 | $ | 3,675 | |||||
| IPR&D, included in acquisition related expense (gain), net | $ | — | $ | 5,425 | $ | 1,325 | |||||
| Intangible Assets |
The Company’s intangible assets, excluding goodwill, are comprised primarily of licensed technology from the Affymetrix settlement entered into on January 9, 2008,include acquired core technologyand licensed technologies, license agreements, trade name, and customer relationships from the acquisition of Solexa, and acquired core technology from the acquisition of Helixis. As a result of the Affymetrix settlement, the Company agreed, without admitting liability, to make a one-time payment to Affymetrix, of which $36.0 million was recorded as licensed technology and classified as an intangible asset. The effective life of the licensed technology extends through 2015, the final expiry date of all patents considered in valuingrelationships. Amortization for the intangible asset. Amortization related to the Affymetrix licensed technologyassets that have finite useful lives is generally recorded on a straight-line basis.
The following is a summary of the Company’s amortizableidentifiable intangible assets as of the respective balance sheet dates (in thousands):
| January 2, 2011 | January 3, 2010 | |||||||||||||||||||||||||||||||
| Weighted | Gross | Weighted | Gross | |||||||||||||||||||||||||||||
| Average | Carrying | Accumulated | Intangibles, | Average | Carrying | Accumulated | Intangibles, | |||||||||||||||||||||||||
| Useful Life | Amount | Amortization | Net | Useful Life | Amount | Amortization | Net | |||||||||||||||||||||||||
| Licensed technology | 8.0 | $ | 36,000 | $ | (15,849 | ) | $ | 20,151 | 8.0 | $ | 36,000 | $ | (11,820 | ) | $ | 24,180 | ||||||||||||||||
| Core technology | 10.0 | 51,500 | (10,604 | ) | 40,896 | 10.0 | 23,500 | (6,854 | ) | 16,646 | ||||||||||||||||||||||
| Customer relationships | 3.0 | 900 | (900 | ) | — | 3.0 | 900 | (875 | ) | 25 | ||||||||||||||||||||||
| License agreements | 8.9 | 10,654 | (1,677 | ) | 8,977 | 7.2 | 4,456 | (1,519 | ) | 2,937 | ||||||||||||||||||||||
| Total intangible assets, net | $ | 99,054 | $ | (29,030 | ) | $ | 70,024 | $ | 64,856 | $ | (21,068 | ) | $ | 43,788 | ||||||||||||||||||
| December 30, 2012 | January 1, 2012 | ||||||||||||||||||||||||||
Weighted Average Useful Life (years) | Gross Carrying Amount | Accumulated Amortization | Intangibles, Net | Weighted Average Useful Life (years) | Gross Carrying Amount | Accumulated Amortization | Intangibles, Net | ||||||||||||||||||||
| Intangible assets with finite useful lives: | |||||||||||||||||||||||||||
| Licensed technologies | 6.6 | $ | 46,904 | $ | (25,271 | ) | $ | 21,633 | 8.0 | $ | 36,000 | $ | (20,000 | ) | $ | 16,000 | |||||||||||
| Core technologies | 8.8 | 99,800 | (27,427 | ) | 72,373 | 9.7 | 74,800 | (18,544 | ) | 56,256 | |||||||||||||||||
| Customer relationships | 5.0 | 18,780 | (2,214 | ) | 16,566 | 3.0 | 1,980 | (1,253 | ) | 727 | |||||||||||||||||
| License agreements | 7.8 | 14,829 | (4,133 | ) | 10,696 | 8.9 | 12,404 | (2,605 | ) | 9,799 | |||||||||||||||||
| Trade name | 10.0 | 9,600 | (672 | ) | 8,928 | 10.0 | 2,500 | (245 | ) | 2,255 | |||||||||||||||||
| Indefinitely-lived Intangible Asset: | |||||||||||||||||||||||||||
| In-process research & development | — | — | — | 21,438 | — | 21,438 | |||||||||||||||||||||
| Total intangible assets, net | $ | 189,913 | $ | (59,717 | ) | $ | 130,196 | $ | 149,122 | $ | (42,647 | ) | $ | 106,475 | |||||||||||||
Additions to intangible assets in the current year are primarily due to the BlueGnome acquisition and technology license agreements entered into during the year. As discussed in note “1. Organization and Summary of Significant Accounting Policies,” IPR&D was impaired during the year ended December 30, 2012. Amortization expense associated with the intangible assets was $7.8$17.1 million $6.7 million, and $10.4 million for the yearsyear ended January 2, 2011, January 3, 2010, and December 28, 2008, respectively.30, 2012, $15.5 million of which related to acquired intangible assets.
70
65
Amortization expense associated with intangible assets for the years ended January 1, 2012 and January 2, 2011 were $13.6 million and $7.8 million, respectively.
The estimated annual amortization of intangible assets for the next five years is shown in the following table (in thousands). Actual amortization expense to be reported in future periods could differ from these estimates as a result of acquisitions, divestitures, asset impairments, andamong other factors.
| 2011 | $ | 10,071 | ||
| 2012 | 10,285 | |||
| 2013 | 10,270 | |||
| 2014 | 10,251 | |||
| 2015 | 10,251 | |||
| Thereafter | 18,896 | |||
| Total | $ | 70,024 | ||
| 2013 | $ | 24,644 | |
| 2014 | 23,860 | ||
| 2015 | 23,414 | ||
| 2016 | 18,715 | ||
| 2017 | 14,612 | ||
| Thereafter | 24,951 | ||
| Total | $ | 130,196 | |
| December 30, 2012 | January 1, 2012 | ||||||||||||||||||||||||||||||
| Level 1 | Level 2 | Level 3 | Total | Level 1 | Level 2 | Level 3 | Total | ||||||||||||||||||||||||
| Assets: | |||||||||||||||||||||||||||||||
| Money market funds (cash equivalent) | $ | 252,126 | $ | — | $ | — | $ | 252,126 | $ | 166,898 | $ | — | $ | — | $ | 166,898 | |||||||||||||||
| Debt securities in government-sponsored entities | — | 314,873 | — | 314,873 | — | 394,039 | — | 394,039 | |||||||||||||||||||||||
| Corporate debt securities | — | 472,861 | — | 472,861 | — | 433,382 | — | 433,382 | |||||||||||||||||||||||
| U.S. Treasury securities | 128,489 | — | — | 128,489 | 59,169 | — | — | 59,169 | |||||||||||||||||||||||
| Deferred compensation plan assets | — | 13,626 | — | 13,626 | — | 10,800 | — | 10,800 | |||||||||||||||||||||||
| Total assets measured at fair value | $ | 380,615 | $ | 801,360 | $ | — | $ | 1,181,975 | $ | 226,067 | $ | 838,221 | $ | — | $ | 1,064,288 | |||||||||||||||
| Liabilities: | |||||||||||||||||||||||||||||||
| Acquisition related contingent consideration liabilities | $ | — | $ | — | $ | 12,519 | $ | 12,519 | $ | — | $ | — | $ | 6,638 | $ | 6,638 | |||||||||||||||
| Deferred compensation liability | — | 12,071 | — | 12,071 | — | 8,970 | — | 8,970 | |||||||||||||||||||||||
| Total liabilities measured at fair value | $ | — | $ | 12,071 | $ | 12,519 | $ | 24,590 | $ | — | $ | 8,970 | $ | 6,638 | $ | 15,608 | |||||||||||||||
The Company holds available-for-sale securities that consist of highly liquid, investment grade debt securities. The Company determines the fourth quarterfair value of 2010,its debt security holdings based on pricing from a service provider. The service provider values the securities based on “consensus pricing,” using market prices from a variety of industry-standard independent data providers. Such market prices may be quoted prices in active markets for identical assets or liabilities (Level 1 inputs) or pricing determined using inputs that are observable either directly or indirectly (Level 2 inputs), such as quoted prices for similar assets or liabilities, yield curve, volatility factors, credit spreads, default rates, loss severity, current market and contractual prices for the underlying instruments or debt, broker and dealer quotes, as well as other relevant economic measures. The Company’s deferred compensation plan assets consist primarily of mutual funds. See note “14. Employee Benefit Plans” for additional information about our deferred compensation plan. The Company determined thatperforms certain procedures to corroborate the fair value of its holdings, including comparing prices obtained from service providers to prices obtained from other reliable sources.
The Company reassesses the fair value of contingent consideration to be settled in cash related to acquisitions on a $6.0 million cost-method investmentquarterly basis using the income approach. This is a Level 3 measurement. Significant assumptions used in the measurement include probabilities of achieving the remaining milestones and the discount rates, which depend on the milestone risk profiles. Due to changes in the estimated payments and a related $6.8 million note receivable with interest receivableshorter discounting period, the fair value of $0.4 million were below carrying value and the impairment wasother-than-temporary. This determination was based upon continued shortfalls from revenue plans coupled with events in the fourth quartercontingent consideration
66
ILLUMINA, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)
liabilities changed, resulting in a required timeframe for the entity to continue operations. As a result, the Company$2.0 million expense recorded an impairment charge of $13.2 million in other (expense) income,acquisition related expense (gain), net in the consolidated statements of income forduring the year ended January 2, 2011.December 30, 2012.
71
Changes in the Company’s reserve for product warrantiesestimated fair value of contingent consideration liabilities from January 1, 20083, 2010 through January 2, 2011December 30, 2012 are as follows (in thousands):
Contingent Consideration Liability (Level 3 Measurement) | |||
| Balance as of January 3, 2010 | $ | — | |
| Acquisition of Helixis | 14,114 | ||
| Gain recorded in acquisition related expense (gain), net | (10,376 | ) | |
| Balance as of January 2, 2011 | $ | 3,738 | |
| Acquisition of Epicentre | 7,400 | ||
| Gain recorded in acquisition related expense (gain), net | (4,500 | ) | |
| Balance as of January 1, 2012 | $ | 6,638 | |
| Acquisition of BlueGnome | 7,500 | ||
| Expense recorded in acquisition related expense (gain), net | 1,975 | ||
| Cash payments | (3,594 | ) | |
| Balance as of December 30, 2012 | $ | 12,519 | |
| 7. | Convertible Senior Notes |
In 2011, the Company issued $400.0$920.0 million aggregate principal amount of 0.625%0.25% convertible senior notes due 2014.2016 (2016 Notes) in an offering conducted in accordance with Rule 144A under the Securities Act of 1933, as amended. The net proceeds from2016 Notes were issued at 98.25% of par value. Debt issuance costs of approximately $0.4 million were primarily comprised of legal, accounting, and other professional fees, the offering, after deductingmajority of which were recorded in other noncurrent assets and are being amortized to interest expense over the initial purchasers’ discount and offering expenses, were approximately $390.3 million. The Company pays 0.625% interest per annum on the principal amountfive-year term of the notes, payable semi-annually in arrears in cash on February 15 and August 15 of each year. 2016 Notes.
The notes mature on February 15, 2014.
As noted in the indenture for the 2016 Notes, it is the Company’s intent and policy to settle conversions through combination settlement, which essentially involves repayment of an amount of cash equal to the “principal portion” and delivery of the second condition above were satisfied during each of the calendar quarters of 2010 and the first, second and third quarters of 2009. Accordingly, the notes were and continue to be convertible during the period from, and including, April 1, 2009 through, and including, December 31, 2009 and again during the period April 1, 2010 through, and including, March 31, 2011. Additionally, these same requirements were satisfied during the third quarter of 2008, and, as a result, the notes were convertible during the period from, and including, October 1, 2008 through, and including, December 31, 2008. On December 29, 2008, a noteholder converted notes“share amount” in an aggregate principal amount of $10.0 million. On February 4, 2009, the settlement date, we paid the noteholder the conversion value of the notes in cash, up to the principal amount of the notes. The excess of the conversion value over the principal amount, totaling $2.9 million, was paidportion in shares of common stock. This equity dilutionIn general, for each $1,000 in principal, the “principal portion” of cash upon settlement is defined as the lesser of $1,000, and the conversion value during the 20-day observation period as described in the indenture for the 2016 Notes. The conversion value is the sum of the notes was offset bydaily conversion value which is the reacquisitionproduct of the shares undereffective conversion rate divided by 20 days and the daily volume weighted average price (“VWAP”) of the Company’s common stock. The “share amount” is the cumulative “daily share amount” during the observation period, which is calculated by dividing the daily VWAP into the difference between the daily conversion value (i.e., conversion rate x daily VWAP) and $1,000.
67
The Company pays 0.25% interest per annum on the principal amount of the 2016 Notes semiannually in arrears in cash on March 15 and September 15 of each year. The Company paid $2.3 million in interest payments during the year ended December 30, 2012. The 2016 Notes mature on March 15, 2016. If a designated event, as defined in the indenture for the 2016 Notes, such as an acquisition, merger, or liquidation, occurs prior to the maturity date, subject to certain limitations, holders of the 2016 Notes may require the Company to repurchase all or a portion of their 2016 Notes for cash at a repurchase price equal to 100% of the principal amount of the 2016 Notes to be repurchased, plus any accrued and unpaid interest to, but excluding, the repurchase date.
The Company accounts separately for the liability and equity components of the 2016 Notes in accordance with authoritative guidance for convertible debt instruments that may be settled in cash upon conversion. The guidance requires the carrying amount of the liability component to be estimated by measuring the fair value of a similar liability that does not have an associated conversion feature. Because the Company has no outstanding non-convertible public debt, the Company determined that senior, unsecured corporate bonds traded on the market represent a similar liability to the convertible notesenior notes without the conversion option. Based on market data available for publicly traded, senior, unsecured corporate bonds issued by companies in the same industry and with similar maturity, the Company estimated the implied interest rate of its 2016 Notes to be 4.5%, assuming no conversion option. Assumptions used in the estimate represent what market participants would use in pricing the liability component, including market interest rates, credit standing, and yield curves, all of which are defined as Level 2 observable inputs. The estimated implied interest rate was applied to the 2016 Notes, which resulted in a fair value of the liability component of $748.5 million upon issuance, calculated as the present value of implied future payments based on the $920.0 million aggregate principal amount. The $155.4 million difference between the cash proceeds of $903.9 million and the estimated fair value of the liability component was recorded in additional paid-in capital as the 2016 Notes are not considered currently redeemable at the balance sheet date.
If the 2016 Notes were converted as of December 30, 2012, the if-converted value would not exceed the principal amount. As a policy election under applicable guidance related to the calculation of diluted net income per share, the Company elected the combination settlement method as its stated settlement policy and applied the treasury stock method. The 2016 Notes had an anti-dilutive effect for the years ended December 30, 2012 and January 1, 2012.
0.625% Convertible Senior Notes due 2014
In 2007, the Company issued $400.0 million principal amount of 0.625% convertible senior notes due 2014 (2014 Notes). The Company pays 0.625% interest per annum on the principal amount of the 2014 Notes, payable semi-annually in arrears in cash on February 15 and August 15 of each year. The 2014 Notes mature on February 15, 2014. The effective interest rate of the liability component was estimated to be 8.3%.
The Company entered into hedge transactions entered into in connectionconcurrently with the offeringissuance of the notes.
72
counterparties warrants exercisable, on a cashless basis, for up to 18,322,320approximately 18,322,000 shares of the Company’s common stock at a strike price of $31.435$31.435 per share, subject to adjustment. The proceeds from these warrants partially offset the cost to the Company of the convertible note hedge transaction that was not covered by the proceeds from the sale of the warrants was approximately $46.6 milliontransactions.
The 2014 Notes became convertible into cash and was reflected as a reduction of additional paid-in capital. The hedge transaction is expected to reduce the potential equity dilution upon conversion of the notes to the extent the Company exercises the hedge to purchase shares from the hedge counterparties to deliver to converting noteholders. However, the warrants could have a dilutive effect on the Company’s earnings per share to the extent that the price of the Company’s common stock exceeds the strike pricein various prior periods and became convertible again from April 1, 2012 through, and including, December 30, 2012. There were no conversions of the warrants.
68
As a result of the conversions during the year ended January 1, 2012, the Company recorded a gainlosses on extinguishment of $0.8 million in the first quarter of 2009,debt calculated as the difference between the carrying amountestimated fair value of the converteddebt and the carrying value of the notes and their estimated fair value as of the settlement date.dates. To measure the fair value of the converted notes as of the settlement date,dates, the Company calculated anapplicable interest rate of 11.3%rates were estimated using Level 2 Observable Inputs. This rate wasobservable inputs and applied to the converted notes and coupon interest rate using the same present value technique usedmethodology as in the issuance date valuation. If the 2014 Notes were converted as of December 30, 2012, the if-converted value would exceed the principal amount by $60.0 million.
The remaining period over whichfollowing table summarizes information about the equity and liability components of the 2014 and 2016 Notes (dollars in thousands). The fair values of the respective notes outstanding were measured based on quoted market prices.
| December 30, 2012 | January 1, 2012 | |||||||||||||||
| 2016 Notes | 2014 Notes | 2016 Notes | 2014 Notes | |||||||||||||
| Principal amount of convertible notes outstanding | $ | 920,000 | $ | 40,125 | $ | 920,000 | $ | 40,125 | ||||||||
| Unamortized discount of liability component | (114,594 | ) | (3,158 | ) | (147,034 | ) | (5,722 | ) | ||||||||
| Net carrying amount of liability component | 805,406 | 36,967 | 772,966 | 34,403 | ||||||||||||
| Less: current portion | — | (36,967 | ) | — | — | |||||||||||
| Long-term debt | $ | 805,406 | $ | — | $ | 772,966 | $ | 34,403 | ||||||||
| Conversion option subject to cash settlement | $ | — | $ | 3,158 | $ | — | $ | 5,722 | ||||||||
| Carrying value of equity component, net of issuance costs | $ | 155,366 | $ | 111,470 | $ | 155,366 | $ | 114,035 | ||||||||
| Fair value of outstanding notes | $ | 892,446 | $ | 101,470 | $ | 725,632 | $ | 60,122 | ||||||||
| Remaining amortization period of discount on the liability component | 3.2 years | 1.1 years | 4.2 years | 2.1 years | ||||||||||||
Contractual coupon interest expense and accretion of discount on the liability component will be amortized is 3.12 years.recorded for the convertible senior notes were as follows (in thousands):
| Years Ended | ||||||||||||
| December 30, 2012 | January 1, 2012 | January 2, 2011 | ||||||||||
| Contractual coupon interest expense | $ | 2,472 | $ | 2,285 | $ | 2,390 | ||||||
| Accretion of discount on the liability component | $ | 35,004 | $ | 32,173 | $ | 21,407 | ||||||
| 8. | Commitments |
Operating Leases
The Company leases office and manufacturing facilities under various noncancellable operating lease agreements. Facility leases generally provide for periodic rent increases, and many contain escalation clauses and renewal options. Certain leases require the Company to pay property taxes and routine maintenance. The Company is headquartered in San Diego, California and leases facilities in San Diego, California; Hayward, California; Carlsbad, California; Branford, Connecticut;Fairfax, Virginia; Madison, Wisconsin; the United Kingdom; the Netherlands; Japan; Singapore; Australia; Brazil; Canada; and China.
69
Annual future minimum payments under these operating leases as of January 2, 2011December 30, 2012 were as follows (in thousands):
| 2011 | $ | 13,965 | ||
| 2012 | 15,237 | |||
| 2013 | 22,500 | |||
| 2014 | 20,926 | |||
| 2015 | 20,059 | |||
| Thereafter | 406,574 | |||
| Total | $ | 499,261 | ||
| 2013 | $ | 27,676 | |
| 2014 | 23,970 | ||
| 2015 | 23,197 | ||
| 2016 | 23,416 | ||
| 2017 | 23,860 | ||
| Thereafter | 393,088 | ||
| Total | $ | 515,207 | |
Rent expense, net of amortization of the deferred gain on sale of property, was $14.7expenses were $21.4 million $13.6, $17.4 million, and $10.7$14.7 million for the years ended December 30, 2012, January 1, 2012, and January 2, 2011, respectively.
The Company recorded facility exit obligations upon vacating its former headquarters during the years ended December 30, 2012 and January 1, 2012. Changes in the facility exit obligation from January 1, 2012 through December 30, 2012 are as follows (in thousands):
| Balance as of January 1, 2012: | $ | 25,049 | |
| Additional facility exit obligation recorded | 24,878 | ||
| Accretion of interest expense | 2,129 | ||
| Cash payments | (6,704 | ) | |
| Balance as of December 30, 2012 | $ | 45,352 | |
Warranties
Changes in the Company’s reserve for product warranties from January 3, 2010 and December 28, 2008, respectively.
| Balance as of January 3, 2010 | $ | 10,215 | |
| Additions charged to cost of revenue | 25,146 | ||
| Repairs and replacements | (18,600 | ) | |
| Balance as of January 2, 2011 | 16,761 | ||
| Additions charged to cost of revenue | 17,913 | ||
| Repairs and replacements | (22,708 | ) | |
| Balance as of January 1, 2012 | 11,966 | ||
| Additions charged to cost of revenue | 17,279 | ||
| Repairs and replacements | (19,109 | ) | |
| Balance as of December 30, 2012 | $ | 10,136 | |
70
ILLUMINA, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)
| 9. |
| Years Ended | |||||||||||
| December 30, 2012 | January 1, 2012 | January 2, 2011 | |||||||||
| Cost of product revenue | $ | 7,575 | $ | 6,951 | $ | 5,378 | |||||
| Cost of service and other revenue | 461 | 695 | 470 | ||||||||
| Research and development | 30,879 | 32,105 | 25,428 | ||||||||
| Selling, general and administrative | 55,409 | 52,341 | 40,369 | ||||||||
| Share-based compensation expense before taxes | 94,324 | 92,092 | 71,645 | ||||||||
| Related income tax benefits | (30,759 | ) | (32,168 | ) | (25,231 | ) | |||||
| Share-based compensation expense, net of taxes | $ | 63,565 | $ | 59,924 | $ | 46,414 | |||||
The assumptions used for the Company announced atwo-for-one stock split inspecified reporting periods and the formresulting estimates of a 100% stock dividend with a record date of September 10, 2008 and a distribution date of September 22, 2008. Share andweighted-average fair value per share amounts have been restatedof options granted and for stock purchased under the ESPP during those periods are as follows:
| Years Ended | |||||||||||
| December 30, 2012 | January 1, 2012 | January 2, 2011 | |||||||||
| Stock options granted: | |||||||||||
| Risk-free interest rate | 0.56 - 0.93% | 0.85 - 2.23% | 2.05 - 2.73% | ||||||||
| Expected volatility | 41 - 48% | 41 - 53% | 46 - 48% | ||||||||
| Expected term | 4.0 - 6.6 years | 4.7 - 5.5 years | 6.0 years | ||||||||
| Expected dividends | — | — | — | ||||||||
| Weighted average fair value per share | $ | 15.47 | $ | 27.47 | $ | 18.82 | |||||
| Stock purchased under the ESPP: | |||||||||||
| Risk-free interest rate | 0.09 - 0.17% | 0.16 - 0.30% | 0.17 - 0.48% | ||||||||
| Expected volatility | 33 - 64% | 43 - 48% | 46 - 48% | ||||||||
| Expected term | 0.5 - 1.0 year | 0.5 - 1.0 year | 0.5 - 1.0 year | ||||||||
| Expected dividends | — | — | — | ||||||||
| Weighted average fair value per share | $ | 16.45 | $ | 20.08 | $ | 11.10 | |||||
As of December 30, 2012, approximately $177.8 million of total unrecognized compensation cost related to reflect the stock split for all periods presented.options, restricted stock units, and ESPP shares issued to date is expected to be recognized over a weighted-average period of approximately 2.3 years.
| 10. | Stockholders’ Equity |
Stock Options
Stock options granted at the time of hire primarily vest over a four or five-yearfive-year period, with 20% or 25% of options vesting on the first anniversary of the grant date and the remaining options vesting monthly over the remaining vesting period. Stock options granted subsequent to hiring primarily vest monthly over a four or five-yearfive-year period.Each grant of options has a
71
maximum term of ten years, measured from the applicable grant date, subject to earlier termination if the optionee’s service with us ceases. Vesting in all cases is subject to the individual’s continued service to us through the vesting date. The Company satisfies option exercises through the issuance of new shares.
74
The Company’s stock option activity under all stock option plans from January 1, 20083, 2010 through January 2, 2011December 30, 2012 is as follows:
| Weighted | ||||||||||||
| Average | ||||||||||||
| Weighted- | Grant-Date | |||||||||||
| Average | Fair Value | |||||||||||
| Options | Exercise Price | per Share | ||||||||||
| Outstanding at January 1, 2008 | 20,847,868 | $ | 12.13 | $ | 8.13 | |||||||
| Granted | 3,091,108 | 34.23 | 18.01 | |||||||||
| Exercised | (4,571,855 | ) | 8.52 | 6.02 | ||||||||
| Cancelled | (1,232,917 | ) | 19.93 | 11.18 | ||||||||
| Outstanding at December 28, 2008 | 18,134,204 | 16.26 | 10.08 | |||||||||
| Granted | 1,560,024 | 28.86 | 14.74 | |||||||||
| Exercised | (2,965,606 | ) | 10.56 | 7.21 | ||||||||
| Cancelled | (639,184 | ) | 14.88 | 9.82 | ||||||||
| Outstanding at January 3, 2010 | 16,089,438 | 18.59 | 11.07 | |||||||||
| Granted | 2,045,489 | 39.11 | 18.82 | |||||||||
| Exercised | (5,541,276 | ) | 16.65 | 10.08 | ||||||||
| Cancelled | (711,350 | ) | 21.76 | 11.78 | ||||||||
| Outstanding at January 2, 2011 | 11,882,301 | $ | 22.83 | $ | 12.82 | |||||||
Options (in thousands) | Weighted- Average Exercise Price | |||||
| Outstanding at January 3, 2010 | 16,089 | $ | 18.59 | |||
| Granted | 2,045 | 39.11 | ||||
| Exercised | (5,541 | ) | 16.65 | |||
| Cancelled | (711 | ) | 21.76 | |||
| Outstanding at January 2, 2011 | 11,882 | 22.83 | ||||
| Granted | 1,399 | 64.98 | ||||
| Exercised | (2,784 | ) | 17.98 | |||
| Cancelled | (119 | ) | 33.49 | |||
| Outstanding at January 1, 2012 | 10,378 | 29.69 | ||||
| Granted | 251 | 40.79 | ||||
| Exercised | (2,071 | ) | 20.34 | |||
| Cancelled | (207 | ) | 39.18 | |||
| Outstanding at December 30, 2012 | 8,351 | $ | 32.10 | |||
At January 2, 2011,December 30, 2012, outstanding options to purchase 6,950,184approximately 6,725,000 shares were exercisable with a weighted average per share exercise price of $17.70.$28.49. The weighted average remaining life in years of options outstanding and exercisable is 6.515.5 years and 5.675.0 years, respectively, as of January 2, 2011.December 30, 2012.
The aggregate intrinsic value of options outstanding and options exercisable as of January 2, 2011December 30, 2012 was $207.0 million and January 3, 2010 was $481.4$185.9 million and $317.2 million,, respectively. Aggregate intrinsic value represents the product of the number of options outstanding multiplied by the difference between the Company’s closing stock price per share on the last trading day of the fiscal period, which was $63.34$54.75 as of December 31, 2010,28, 2012, and the exercise price multiplied by the number of options outstanding.price. Total intrinsic value of options exercised was $156.9$60.6 million $73.4, $136.5 million, and $136.6$156.9 million for the years ended December 30, 2012, January 1, 2012, and January 2, 2011, respectively. Total fair value of options vested was $31.9 million, $49.5 million, and $47.3 million for the years ended December 30, 2012, January 1, 2012, and January 2, 2011, respectively.
Restricted Stock
The Company issues restricted stock units (RSUs) and restricted stock awards (RSAs). The Company grants RSUs pursuant to its 2005 Stock and Incentive Plan. RSUs are share awards that, upon vesting, will deliver to the holder shares of the Company’s common stock. For grants to new hires prior to July 2011 and for grants to existing employees, RSUs generally vest 15% on the first anniversary of the grant date, 20% on the second anniversary of the grant date, 30% on the third anniversary of the grant date, and 35% on the fourth anniversary of the grant date. For grants to new hires subsequent to July 2011, RSUs generally vest over a four-year period with equal vesting on anniversaries of the grant date. The Company satisfies RSU vesting through the issuance of new shares. The Company also issues RSAs that are released based on service related vesting conditions. RSAs may be issued from the Company’s treasury stock or granted pursuant to the Company’s 2005 Stock and Incentive Plan.
72
A summary of the Company’s restricted stock activity and related information from January 3, 2010 through December 30, 2012 is as follows:
Restricted Stock (in thousands) | Weighted Average Grant-Date Fair Value per Share | |||||
| Outstanding at January 3, 2010 | 2,509 | $ | 32.45 | |||
| Awarded | 1,353 | 50.74 | ||||
| Vested | (510 | ) | 32.10 | |||
| Cancelled | (243 | ) | 33.36 | |||
| Outstanding at January 2, 2011 | 3,109 | 40.39 | ||||
| Awarded | 1,780 | 45.10 | ||||
| Vested | (827 | ) | 36.47 | |||
| Cancelled | (356 | ) | 42.15 | |||
| Outstanding at January 1, 2012 | 3,706 | 43.36 | ||||
| Awarded | 1,952 | 48.42 | ||||
| Vested | (1,139 | ) | 40.33 | |||
| Cancelled | (394 | ) | 45.05 | |||
| Outstanding at December 30, 2012 | 4,125 | $ | 46.43 | |||
Based on the closing price per share of the Company’s common stock of $54.75 and $30.48 on December 28, 2008,2012 and December 30, 2011, respectively, the total pre-tax intrinsic value of all outstanding restricted stock as of December 30, 2012 and January 1, 2012 was $225.8 million and $112.9 million, respectively. Total fair value of restricted stock vested was $45.9 million, $30.2 million, and $16.4 million for the years ended December 30, 2012, January 1, 2012, and January 2, 2011, respectively.
Performance Stock Units
In March 2012, the Company’s Compensation Committee of the Company’s Board of Directors approved changes to the Company’s long-term equity incentive program for executive officers and approved the issuance of certain performance stock units at the end of a three-year performance period. The number of shares issuable will range from 50% and 150% of the shares approved in the award based on the Company’s performance relative to specified earnings per share targets at the end of the three-year performance period. A total of 587,000 shares were outstanding as of December 30, 2012 with a weighted-average grant-date fair value of $49.64, which represents the fair market value of one share of the Company’s common stock on the grant date.
Employee Stock Purchase Plan
The price at which stock is purchased under the ESPP is equal to 85% of the fair market value of the common stock on the first or last day of the offering period, whichever is lower. The initial offering period commenced in July 2000. In addition, beginning with fiscal 2001, the
The ESPP provides for annual increases of shares available for issuance by the lesser of 3% of the number of outstanding shares of the Company’s common stock on the last day of the immediately preceding fiscal year, 3,000,000 shares, or such lesser amount as determined by the Company’s board of directors. Shares totaling 372,544, 359,713,approximately 328,000, 328,000, and 276,198373,000 were issued under the ESPP during fiscal 2010, 2009,the years ended December 30, 2012, January 1, 2012, and 2008,January 2, 2011, respectively. As of December 30, 2012 and January 2, 2011 and January 3, 2010,1, 2012, there were 16,061,905approximately 15,406,000 shares and 13,434,49915,734,000 shares available for issuance under the ESPP, respectively.
73
Warrants
During the first anniversary of the grant date, 20% on the second anniversary of the grant date, 30% on the third anniversary of the grant date, and 35% on the fourth anniversary of the grant date. The Company satisfies RSU vesting through the issuance of new shares.
| Weighted Average | ||||||||
| Restricted | Grant-Date Fair | |||||||
| Stock Units(1) | Value per Share | |||||||
| Outstanding at January 1, 2008 | 394,500 | $ | 25.68 | |||||
| Awarded | 1,287,504 | 34.53 | ||||||
| Vested | (55,638 | ) | 25.67 | |||||
| Cancelled | (47,090 | ) | 32.85 | |||||
| Outstanding at December 28, 2008 | 1,579,276 | 32.68 | ||||||
| Awarded | 1,292,473 | 32.25 | ||||||
| Vested | (246,055 | ) | 32.33 | |||||
| Cancelled | (116,986 | ) | 33.19 | |||||
| Outstanding at January 3, 2010 | 2,508,708 | 32.45 | ||||||
| Awarded | 1,353,583 | 50.74 | ||||||
| Vested | (510,113 | ) | 32.10 | |||||
| Cancelled | (242,946 | ) | 33.36 | |||||
| Outstanding at January 2, 2011 | 3,109,232 | $ | 40.39 | |||||
On April 18, 2012, the Company’s Board of all warrants outstanding asDirectors authorized a $250 million stock repurchase program to be effected via a combination of January 2,Rule 10b5-1 and discretionary share repurchase programs. During the year ended December 30, 2012, the Company repurchased approximately 1,860,000 shares for $82.5 million.
In August 2011, is as follows:
| Number of Shares | Exercise Price | Expiration Date | ||||||
| 505,442 | $ | 10.91 | 1/19/2011 | |||||
| 18,322,320(1) | $ | 31.44 | 2/15/2014 | |||||
| 18,827,762 | ||||||||
76
Concurrently with the program.
In July 2010, the Company’s board of directors authorized a $200$200 million stock repurchase program, with $100$100 million allocated to repurchasing Company common stock under a 10b5-1 plan over a 12twelve month period and $100$100 million allocated to repurchasing Company common stock at management’s discretion during open trading windows. In fiscal 2010,During the year ended January 1, 2012, the Company repurchased 0.8 millionapproximately 2,438,000 shares for $44.0$156.0 million under the program. The authorized in July 2010.repurchase amount had been utilized completely as of January 1, 2012.
Stockholder Rights Plan
In connection with the unsolicited tender offer by Roche (refer to note “12. Unsolicited Tender Offer”), on January 25, 2012, the Company’s Board of Directors declared a dividend of one preferred share purchase right (Right) for each outstanding share of the Company’s common stock. Each Right entitles the registered holder to purchase from the Company one one-thousandth of a share of the Company’s Series A Junior Participating Preferred Stock, par value $0.01 per share (Preferred Shares), at a price of $275.00 per one thousandth of a Preferred Share, subject to adjustment. The Rights will not be exercisable until such time, if ever, that the Board of Directors determines to eliminate its deferral of the date on which separate Rights certificates are issued and the Rights trade separately from the Company’s common stock (Distribution Date). If a person or group (triggering party) acquires 15% or more of the Company’s outstanding common stock, each Right will entitle holders other than the triggering party to purchase, at the exercise price of the Right, a number of shares of common stock having a market value of two times the exercise price of the Right. If the Company is acquired in a merger or other business combination transaction after a person acquires 15% or more of the Company’s common stock, each Right will entitle holders other than the triggering party to purchase, at the Right’s then-current exercise price, a number of common shares of the acquiring company that at the time of such transaction have a market value of two times the exercise price of the Right. The Board of Directors will be entitled to redeem the Rights at a price of $0.001 per Right at any time before the Distribution Date. The Board of Directors will also be entitled to exchange the Rights at an exchange ratio per Right of one share of common stock after any person acquires beneficial ownership of 15% or more of the Company’s outstanding common stock, and prior to the acquisition of 50% or more of the Company’s outstanding common stock. The Rights will expire on January 26, 2017.
On May 3, 2001, the board of directors of the Company declared a dividend of one preferred share purchase right (a Right)(Right) for each outstanding share of common stock of the Company. The dividend was payable on May 14, 2001 to the stockholders of record on that date. Each Right entitles the registered holder to purchase from the Company one unit consisting of one-thousandthone thousandth of a share of its Series A Junior Participating Preferred Stock at a price of $100$100 per unit. The Rights will be exercisable if a person or group hereafter acquires beneficial ownership of 15% or more of the outstanding common stock of the Company or announces an offer for 15% or more of the outstanding common stock. If a person or group acquires 15% or
74
more of the outstanding common stock of the Company, each Right will entitle its holder to purchase, at the exercise price of the Right, a number of shares of common stock having a market value of two times the exercise price of the Right. If the Company is acquired in a merger or other business combination transaction after a person acquires 15% or more of the Company’s common stock, each Right will entitle its holder to purchase, at the Right’s then-current exercise price, a number of common shares of the acquiring company which at the time of such transaction have a market value of two times the exercise price of the Right. The board of directors will be entitled to redeem the Rights at a price of $0.01$0.01 per Right at any time before any such person acquires beneficial ownership of 15% or more of the outstanding common stock. The Rights expireexpired on May 14, 2011 unless such date is extended or the Rights are earlier redeemed or exchanged by the Company.2011.
| Legal Proceedings |
On November 24, 2010, Syntrix Biosystems, Inc. filed suit against the Company in the United States District Court for the Western District of Washington at Tacoma (Case No. C10-5870-BHS) alleging that the Company willfully infringed U.S. Patent No. 6,951,682 by selling its BeadChip array products, and that the Company misappropriated Syntrix’s trade secrets. Fact and expert discovery is complete in the case. In November and December 2012, the Company filed motions for summary judgment that the patent is not infringed and is invalid, and that Syntrix’s trade secrets claims are barred by various statutes of limitation. Syntrix filed a motion for summary judgment that the patent is valid. On January 30, 2013, the court granted the Company’s motion for summary judgment on Syntrix’s trade secret claims, and dismissed those claims from the case. The court denied Syntrix’s motion for summary judgment on validity, and denied the Company’s motion for summary judgment for non-infringement and invalidity. A trial is scheduled to begin on February 26, 2013.
The Company has thoroughly investigated Syntrix’s claims and believes the claims are without merit. While the Company believes there is no legal basis for its alleged liability, the Company cannot estimate the possible loss or range of possible loss as there are significant legal and factual issues to be resolved. For example, each party has filed motions seeking to exclude portions of the other party’s expert testimony and to preclude the other party from introducing certain other evidence at trial. In addition to post-trial briefing, the parties would likely engage in appellate motion practice, the result of which is also unpredictable and could significantly affect the outcome of the case.
| 12. | Unsolicited Tender Offer |
On January 27, 2012, CKH Acquisition Corporation and Roche Holding Ltd. (together, “Roche”) commenced an unsolicited tender offer (Offer) to purchase all outstanding shares of the Company’s common stock for $44.50 per share. As more fully described in the Company’s Solicitation/Recommendation on Schedule 14D-9 filed with the SEC on February 7, 2012 in response to the Offer, the Company’s Board of Directors unanimously recommended that the Company’s stockholders reject the Offer and not tender their shares to Roche for purchase.
On March 28, 2012, Roche revised the Offer to purchase all outstanding shares of the Company’s common stock for $51.00 per share. As more fully described in the Amendment No. 11 to Solicitation/Recommendation on Schedule 14D-9 filed
75
with the SEC on April 2, 2012 in response to the revised Offer, the Company’s Board of Directors unanimously recommended that the Company’s stockholders reject the Roche offer and not tender their shares to Roche for purchase. The Offer expired, without being extended, on April 20, 2012.
During the year ended December 30, 2012, the Company recorded $23.1 million in expenses in relation to the Offer, such expenses consisting primarily of legal, advisory, proxy solicitation, and other professional services fees.
| Income Taxes |
The income (loss) before income taxes summarized by region is as follows (in thousands):
| Years Ended | ||||||||||||
| January 2, | January 3, | December 28, | ||||||||||
| 2011 | 2010 | 2008 | ||||||||||
| United States | $ | 109,068 | $ | 65,081 | $ | 46,205 | ||||||
| Foreign | 76,311 | 49,044 | 26,482 | |||||||||
| Total income before income taxes | $ | 185,379 | $ | 114,125 | $ | 72,687 | ||||||
| Years Ended | |||||||||||
| December 30, 2012 | January 1, 2012 | January 2, 2011 | |||||||||
| United States | $ | 102,296 | $ | (7,100 | ) | $ | 109,068 | ||||
| Foreign | 120,312 | 140,145 | 76,311 | ||||||||
| Total income before income taxes | $ | 222,608 | $ | 133,045 | $ | 185,379 | |||||
The provision for income taxes consists of the following (in thousands):
| Years Ended | ||||||||||||
| January 2, | January 3, | December 28, | ||||||||||
| 2011 | 2010 | 2008 | ||||||||||
| Current: | ||||||||||||
| Federal | $ | 39,476 | $ | 43,565 | $ | 13,868 | ||||||
| State | 8,607 | 2,511 | 2,134 | |||||||||
| Foreign | 6,330 | 6,204 | 5,042 | |||||||||
| Total current provision | 54,413 | 52,280 | 21,044 | |||||||||
| Deferred: | ||||||||||||
| Federal | 6,557 | (14,607 | ) | 11,700 | ||||||||
| State | (6,808 | ) | 5,184 | 901 | ||||||||
| Foreign | 6,326 | (1,013 | ) | (374 | ) | |||||||
| Total deferred provision (benefit) | 6,075 | (10,436 | ) | 12,227 | ||||||||
| Total tax provision | $ | 60,488 | $ | 41,844 | $ | 33,271 | ||||||
| Years Ended | |||||||||||
| December 30, 2012 | January 1, 2012 | January 2, 2011 | |||||||||
| Current: | |||||||||||
| Federal | $ | 57,285 | $ | 43,161 | $ | 39,476 | |||||
| State | 10,121 | 3,958 | 8,607 | ||||||||
| Foreign | 31,504 | 24,154 | 6,330 | ||||||||
| Total current provision | 98,910 | 71,273 | 54,413 | ||||||||
| Deferred: | |||||||||||
| Federal | (7,724 | ) | (22,738 | ) | 6,557 | ||||||
| State | (7,708 | ) | (8,050 | ) | (6,808 | ) | |||||
| Foreign | (12,124 | ) | 5,932 | 6,326 | |||||||
| Total deferred (benefit) provision | (27,556 | ) | (24,856 | ) | 6,075 | ||||||
| Total tax provision | $ | 71,354 | $ | 46,417 | $ | 60,488 | |||||
The provision for income taxes reconciles to the amount computed by applying the federal statutory rate to income before taxes as follows (in thousands):
| Years Ended | ||||||||||||
| January 2, | January 3, | December 28, | ||||||||||
| 2011 | 2010 | 2008 | ||||||||||
| Tax at federal statutory rate | $ | 64,881 | $ | 39,944 | $ | 25,440 | ||||||
| State, net of federal benefit | 6,231 | 4,275 | 3,461 | |||||||||
| Research and other credits | (5,859 | ) | (4,050 | ) | (4,060 | ) | ||||||
| Acquired in-process research & development | 517 | 4,386 | 9,508 | |||||||||
| Change in valuation allowance | (9,497 | ) | (1,967 | ) | (6,892 | ) | ||||||
| Permanent differences | 1,397 | 2,093 | 1,449 | |||||||||
| Change in fair value of contingent consideration | (3,632 | ) | — | — | ||||||||
| Impact of foreign operations | 7,597 | (5,400 | ) | 4,124 | ||||||||
| Other | (1,147 | ) | 2,563 | 241 | ||||||||
| Total tax provision | $ | 60,488 | $ | 41,844 | $ | 33,271 | ||||||
78
76
| Years Ended | |||||||||||
| December 30, 2012 | January 1, 2012 | January 2, 2011 | |||||||||
| Tax at federal statutory rate | $ | 77,913 | $ | 46,566 | $ | 64,881 | |||||
| State, net of federal benefit | 4,056 | (49 | ) | 6,231 | |||||||
| Research and other credits | (2,766 | ) | (6,774 | ) | (5,859 | ) | |||||
| Acquired in-process research & development | 137 | 1,989 | 517 | ||||||||
| Change in valuation allowance | (37 | ) | (688 | ) | (9,497 | ) | |||||
| Permanent differences | 2,380 | 1,668 | 1,397 | ||||||||
| Change in fair value of contingent consideration | — | (1,311 | ) | (3,632 | ) | ||||||
| Impact of foreign operations | (10,644 | ) | 5,579 | 7,597 | |||||||
| Other | 315 | (563 | ) | (1,147 | ) | ||||||
| Total tax provision | $ | 71,354 | $ | 46,417 | $ | 60,488 | |||||
Significant components of the Company’s deferred tax assets and liabilities are as follows (in thousands):
| January 2, | January 3, | |||||||
| 2011 | 2010 | |||||||
| Deferred tax assets: | ||||||||
| Net operating losses | $ | 11,898 | $ | 15,869 | ||||
| Tax credits | 18,329 | 18,681 | ||||||
| Other accruals and reserves | 22,134 | 17,813 | ||||||
| Stock compensation | 23,829 | 25,442 | ||||||
| Impairment of cost-method investment | 5,058 | — | ||||||
| Other amortization | 4,893 | 4,216 | ||||||
| Other | 4,643 | 14,980 | ||||||
| Total deferred tax assets | 90,784 | 97,001 | ||||||
| Valuation allowance on deferred tax assets | (4,986 | ) | (14,852 | ) | ||||
| Net deferred tax assets | 85,798 | 82,149 | ||||||
| Deferred tax liabilities: | ||||||||
| Purchased intangible amortization | (22,605 | ) | (5,043 | ) | ||||
| Accrued litigation settlements | (3,276 | ) | (3,810 | ) | ||||
| Convertible debt | (3,191 | ) | (3,901 | ) | ||||
| Other | (3,861 | ) | (2,810 | ) | ||||
| Total deferred tax liabilities | (32,933 | ) | (15,564 | ) | ||||
| Net deferred tax assets | $ | 52,865 | $ | 66,585 | ||||
| December 30, 2012 | January 1, 2012 | ||||||
| Deferred tax assets: | |||||||
| Net operating losses | $ | 2,564 | $ | 4,981 | |||
| Tax credits | 16,447 | 16,647 | |||||
| Other accruals and reserves | 47,306 | 22,411 | |||||
| Stock compensation | 39,175 | 33,811 | |||||
| Inventory adjustments | 8,977 | 16,469 | |||||
| Impairment of cost-method investment | 1,406 | 4,972 | |||||
| Other amortization | 5,195 | 4,521 | |||||
| Other | 13,469 | 8,861 | |||||
| Total gross deferred tax assets | 134,539 | 112,673 | |||||
| Valuation allowance on deferred tax assets | (1,756 | ) | (1,799 | ) | |||
| Total deferred tax assets | 132,783 | 110,874 | |||||
| Deferred tax liabilities: | |||||||
| Purchased intangible amortization | (20,116 | ) | (19,760 | ) | |||
| Convertible debt | (38,910 | ) | (49,404 | ) | |||
| Property and equipment | (10,867 | ) | (4,369 | ) | |||
| Other | (6,682 | ) | (7,953 | ) | |||
| Total deferred tax liabilities | (76,575 | ) | (81,486 | ) | |||
| Net deferred tax assets | $ | 56,208 | $ | 29,388 | |||
A valuation allowance is established when it is more likely than not the future realization of all or some of the deferred tax assets will not be achieved. The evaluation of the need for a valuation allowance is performed on ajurisdiction-by-jurisdiction basis, and includes a review of all available positive and negative evidence. During 2010, the valuation allowance decreased by $9.9 million primarily due to increased profitability of certain foreign subsidiaries related to the corporate restructuring implemented during the fourth quarter. Based on the available evidence as of January 2, 2011,December 30, 2012, the Company was not able to conclude it is more likely than not certain U.S. and foreign deferred tax assets will be realized. Therefore, the Company recorded a valuation allowance of $1.9$1.8 million and $3.1 million against certain U.S. and foreign net deferred tax assets, respectively.assets.
As of January 2, 2011,December 30, 2012, the Company had net operating loss carryforwards for federal and state tax purposes of $37.5$16.8 million and $161.7$117.8 million, respectively, which will begin to expire in 2020 and 2017, respectively, unless utilized prior.2015, respectively. In addition, the Company also had U.S. federal and state research and development tax credit carryforwards of $13.7$39.7 million and $28.7 million, respectively,, which will begin to expire in 2027 and 2019 respectively, unless utilized prior..
77
Pursuant to Section 382 and 383 of the Internal Revenue Code, utilization of the Company’s net operating loss and credits may be subject to annual limitations in the event of any significant future changes in its ownership structure. These annual limitations may result in the expiration of net operating losses and credits prior to utilization. The deferred tax assets as of January 2, 2011December 30, 2012 are net of any previous limitations due to Section 382 and 383.
The Company recognizes excess tax benefits associated with share-based compensation to stockholders’ equity only when realized. When assessing whether excess tax benefits relating to share-based compensation
79
have been realized, the Company follows thewith-and-without approach excluding any indirect effects of the excess tax deductions. Under this approach, excess tax benefits related to share-based compensation are not deemed to be realized until after the utilization of all other tax benefits available to the Company. During 2010,the year ended December 30, 2012, the Company realized $42.4$17.0 million of such excess tax benefits, and accordingly recorded a corresponding credit to additional paid in capital. As of January 2, 2011,December 30, 2012, the Company has $16.7$9.8 million of unrealized excess tax benefits associated with share-based compensation. These tax benefits will be accounted for as a credit to additional paid-in capital, if and when realized, rather than a reduction of the provision for income taxes.
The Company’s manufacturing operations in Singapore operate under various tax holidays and incentives that begin to expire in 2018. For the year ended January 2, 2011,December 30, 2012, these tax holidays and incentives resulted in an approximate $2.3$10.2 million decrease to the provision for income taxes and an increase to net income per diluted share of $0.02.$0.08.
subject to local laws, customs, and tax consequences.
The following table summarizes the gross amount of the Company’s uncertain tax positions (in thousands):
| January 2, | January 3, | December 28, | ||||||||||
| 2011 | 2010 | 2008 | ||||||||||
| Balance at beginning of year | $ | 11,760 | $ | 9,402 | $ | 7,000 | ||||||
| Increases related to prior year tax positions | 5,066 | — | — | |||||||||
| Increases related to current year tax positions | 5,903 | 2,358 | 2,402 | |||||||||
| Balance at end of year | $ | 22,729 | $ | 11,760 | $ | 9,402 | ||||||
| December 30, 2012 | January 1, 2012 | January 2, 2011 | |||||||||
| Balance at beginning of year | $ | 28,396 | $ | 22,729 | $ | 11,760 | |||||
| Increases related to prior year tax positions | 2,573 | 875 | 5,066 | ||||||||
| Decreases related to prior year tax positions | (69 | ) | (382 | ) | — | ||||||
| Increases related to current year tax positions | 6,685 | 5,174 | 5,903 | ||||||||
| Balance at end of year | $ | 37,585 | $ | 28,396 | $ | 22,729 | |||||
Included in the balance of January 2, 2011, $18.3 million of the Company’s uncertain tax positions as of December 30, 2012, and January 1, 2012 are $29.9 million and $23.4 million, respectively, of net unrecognized tax benefits that, if recognized, would reduce the Company’s annual effective income tax rate if recognized.in future periods.
The Company does not expect its uncertain tax positions to change significantly over the next 12 months.months. Any interest and penalties related to uncertain tax positions will beare reflected in the provision for income tax expense. Astaxes. The Company recognized expenses of January 2, 2011, minimal interest was accrued$0.8 million and $1.1 million related to potential interest and penalties on uncertain tax positions during the Company’syears ended December 30, 2012 and January 1, 2012, respectively. A minimal amount was recognized in 2010 for potential interest and penalties on uncertain tax positions. The Company recorded a liability for potential interest and penalties of $2.1 million and $1.2 million as of December 30, 2012 and January 1, 2012, respectively. Tax years 19951997 to 20102012 remain subject to future examination by the major tax jurisdictions in which the Company is subject to tax.
| Employee Benefit Plans |
Retirement Plan
The Company has a 401(k) savings plan covering substantially all of its employees.employees in the United States. Company contributions to the plan are discretionary. During the years ended December 30, 2012, January 1, 2012, and January 2, 2011 January 3, 2010, and December 28, 2008,, the Company made matching contributions of $4.2$5.5 million $3.3, $5.3 million, and $2.6$4.2 million, respectively.
78
Deferred Compensation Plan
The Company adopted the Illumina, Inc. Deferred Compensation Plan (the Plan) that became effective January 1, 2008. Eligible participants, which include the Company’s senior level employees and members of the board of directors, can contribute up to 80% of their base salary and 100% of all other forms of compensation into the Plan, including bonus, equity awards, commission, and director fees. The Company has agreed to credit the participants’ contributions with earnings that reflect the performance of certain
80
independent investment funds. On a discretionary basis, the Company may also make employer contributions to participant accounts in any amount determined by the Company. The vesting schedules of employer contributions are at the sole discretion of the Compensation Committee. However, all employer contributions shall become 100% vested upon the occurrence of the participant’s disability, death or retirement or a change in control of the Company. The benefits under this plan are unsecured. Participants are generally eligible to receive payment of their vested benefit at the end of their elected deferral period or after termination of their employment with the Company for any reason or at a later date to comply with the restrictions of Section 409A. As of January 2, 2011, December 30, 2012, no employer contributions were made to the Plan.
In January 2008, the Company also established a rabbi trust for the benefit of the participants under the Plan. In accordance with authoritative guidance related to consolidation of variable interest entities and accounting for deferred compensation arrangements where amounts earned are held in a rabbi trust and invested, the Company has included the assets of the rabbi trust in its consolidated balance sheet since the trust’s inception. As of December 30, 2012 and January 2, 2011 and January 3, 2010,1, 2012, the assets of the trust were $6.1$13.6 million and $4.0$10.8 million, respectively, and liabilities of the Company were $5.3$12.1 million and $4.0$9.0 million, respectively. The assets and liabilities are classified as other assets and accrued liabilities, respectively, on the Company’s consolidated balance sheets. Changes in the values of the assets held by the rabbi trust are recorded in other (expense) income, net in the consolidated statement of income.income, and changes in the values of the deferred compensation liabilities are recorded in cost of sales or operating expenses.
| Segment Information, Geographic Data, and Significant Customers |
The Company is organized in two business segments, the operating segments: Life Sciences Business Unit and Diagnostics Business Unit. TheDiagnostics. Life Sciences Business Unitoperating segment includes all products and services that are primarily related to the research market, namely the product lines based on the Company’s sequencing, BeadArray, VeraCode, and real-time PCR technologies. The Diagnostics Business Unitoperating segment focuses on the emerging opportunity in molecular diagnostics. During all periods presented, the CompanyDiagnostics operating segment had limited activity related to the Diagnostics Business Unit.activity. Accordingly, the Company’s operating results for both units were reported on an aggregate basis as one reportable segment during these periods.segment. The Company will begin reporting in two segments once revenues, operating profit or loss, or assets of the Diagnostics Business Unit exceed operating segment exceeds 10% of the consolidated amounts.
The Company had revenue in the following regions for the years ended December 30, 2012, January 1, 2012, and January 2, 2011 January 3, 2010, and December 28, 2008 (in thousands):
| Years Ended | ||||||||||||
| January 2, | January 3, | December 28, | ||||||||||
| 2011 | 2010 | 2008 | ||||||||||
| United States | $ | 498,981 | $ | 347,195 | $ | 280,064 | ||||||
| United Kingdom | 60,521 | 55,854 | 67,973 | |||||||||
| Other European countries | 163,062 | 140,931 | 127,397 | |||||||||
| Asia-Pacific | 143,441 | 96,396 | 72,740 | |||||||||
| Other markets | 36,736 | 25,948 | 25,051 | |||||||||
| Total | $ | 902,741 | $ | 666,324 | $ | 573,225 | ||||||
| Years Ended | |||||||||||
| December 30, 2012 | January 1, 2012 | January 2, 2011 | |||||||||
| United States | $ | 568,443 | $ | 528,723 | $ | 498,981 | |||||
| United Kingdom | 81,678 | 67,578 | 60,521 | ||||||||
| Other European countries | 209,726 | 210,393 | 163,062 | ||||||||
| Asia-Pacific | 232,498 | 197,005 | 143,441 | ||||||||
| Other markets | 56,171 | 51,836 | 36,736 | ||||||||
| Total | $ | 1,148,516 | $ | 1,055,535 | $ | 902,741 | |||||
Net revenues are attributable to geographic areas based on the region of destination.
The majority of our product sales consist of consumables and instruments. For the years ended December 30, 2012, January 1, 2012, and January 2, 2011 January 3, 2010, and December 28, 2008,, consumable sales represented 56%64%, 59%56%, and 58%56%, respectively, of total revenues and instrument sales comprised 36%27%, 34%35%, and 32%36%, respectively, of total revenues. The Company’s customers include leading genomic research centers, academic institutions, government laboratories, and clinical research organizations, as well as pharmaceutical, biotechnology, agrigenomics, and consumer genomics companies, and in vitro fertilization clinics. The
81
79
Net long-lived assets exclude goodwill and other intangible assets since they are not allocated on a geographic basis. The Company had net long-lived assets consisting of property and equipment in the following regions as of December 30, 2012 and January 2, 2011 and January 3, 20101, 2012 (in thousands):
| January 2, | January 3, | |||||||
| 2011 | 2010 | |||||||
| United States | $ | 75,206 | $ | 75,095 | ||||
| United Kingdom | 26,578 | 27,862 | ||||||
| Other European countries | 1,709 | 864 | ||||||
| Singapore | 14,739 | 12,599 | ||||||
| Other Asia-Pacific countries | 11,642 | 768 | ||||||
| Total | $ | 129,874 | $ | 117,188 | ||||
| December 30, 2012 | January 1, 2012 | ||||||
| United States | $ | 126,749 | $ | 94,624 | |||
| United Kingdom | 21,740 | 22,642 | |||||
| Singapore | 12,504 | 14,673 | |||||
| Other countries | 5,174 | 11,544 | |||||
| Total | $ | 166,167 | $ | 143,483 | |||
| Quarterly Financial Information (unaudited) |
The following financial information reflects all normal recurring adjustments, except as noted below, which are, in the opinion of management, necessary for a fair statement of the results and cash flows of interim periods. All quarters for fiscal years 20102012 and 20092011 ended December 30, 2012 and January 2, 2011 and January 3, 2010, respectively1, 2012 were 13 weeks except for the fourth quarter of fiscal year 2009, which was 14 weeks. Summarized quarterly data for fiscal years 20102012 and 20092011 are as follows (in thousands except per share data):
| First Quarter | Second Quarter | Third Quarter | Fourth Quarter | |||||||||||||
| 2010: | ||||||||||||||||
| Total revenue | $ | 192,131 | $ | 212,003 | $ | 237,309 | $ | 261,298 | ||||||||
| Gross profit | 132,178 | 146,091 | 157,145 | 166,126 | ||||||||||||
| Net income | 21,208 | 29,796 | 35,447 | 38,440 | ||||||||||||
| Net income per share, basic | 0.18 | 0.24 | 0.28 | 0.31 | ||||||||||||
| Net income per share, diluted | 0.16 | 0.21 | 0.24 | 0.25 | ||||||||||||
| 2009: | ||||||||||||||||
| Total revenue | $ | 165,757 | $ | 161,643 | $ | 158,360 | $ | 180,564 | ||||||||
| Gross profit | 110,065 | 111,158 | 107,126 | 125,526 | ||||||||||||
| Net income | 18,811 | 24,688 | 17,077 | 11,705 | ||||||||||||
| Net income per share, basic | 0.15 | 0.20 | 0.14 | 0.10 | ||||||||||||
| Net income per share, diluted | 0.14 | 0.18 | 0.12 | 0.09 | ||||||||||||
| First Quarter | Second Quarter | Third Quarter | Fourth Quarter | ||||||||||||
| 2012: | |||||||||||||||
| Total revenue | $ | 272,770 | $ | 280,607 | $ | 285,874 | $ | 309,265 | |||||||
| Gross profit | 181,011 | 192,997 | 195,873 | 203,647 | |||||||||||
| Net income | 26,202 | 23,401 | 29,748 | 71,903 | |||||||||||
| Net income per share, basic | 0.21 | 0.19 | 0.24 | 0.58 | |||||||||||
| Net income per share, diluted | 0.20 | 0.18 | 0.22 | 0.53 | |||||||||||
| 2011: | |||||||||||||||
| Total revenue | $ | 282,515 | $ | 287,450 | $ | 235,499 | $ | 250,071 | |||||||
| Gross profit | 188,041 | 193,356 | 157,115 | 170,586 | |||||||||||
| Net income | 24,137 | 30,620 | 20,151 | 11,720 | |||||||||||
| Net income per share, basic | 0.19 | 0.25 | 0.17 | 0.10 | |||||||||||
| Net income per share, diluted | 0.16 | 0.22 | 0.15 | 0.09 | |||||||||||
| Subsequent |
On January 10, 2011,6, 2013, the Company acquired Epicentre Biotechnologies,entered into a definitive agreement to acquire Verinata Health, Inc. (Verinata), a leading provider of nucleic acid sample preparation reagents and specialty enzymes used in sequencing and microarray applications. Total consideration exchangednon-invasive tests for the acquisition includes $60early identification of fetal chromosomal abnormalities, for consideration of $350 million in cash $15 million in stock that is subject to forfeiture if certain non-revenue based milestones are not met, and up to $15$100 million in contingent considerationmilestone payments based onthrough 2015. In connection with the achievement of certain revenue-based milestones by January 10, 2013. Due to the limited time since theintended acquisition, date, the Company has not completed the initial purchase accountingalso agreed to provide bridge financing to Verinata for this acquisition, including the assessment of fair values of consideration exchanged, assets acquired, and liabilities assumed.
82
ITEM 9. Changes In and Disagreements with its hedging counterparties to repurchase the same amountAccountants on Accounting and Financial Disclosure.
None.
80
Table of shares as exchanged in the conversions. The majority of the notified conversions have not been executed as theContentstwenty-day
observation period has not concluded as of February 28, 2011.
83
| Controls and Procedures. |
We design our internal controls to provide reasonable assurance that (1) our transactions are properly authorized; (2) our assets are safeguarded against unauthorized or improper use; and (3) our transactions are properly recorded and reported in conformity with U.S. generally accepted accounting principles. We also maintain internal controls and procedures to ensure that we comply with applicable laws and our established financial policies.
During the fourth quarter of 2012, there were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and evaluating our disclosure controls and procedures, our management recognized15d-15(f) of the Exchange Act) that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desiredmaterially affected or are reasonably likely to materially affect internal control objectives, and our management have concluded that the disclosure controls and procedures are effective at the reasonable assurance level. Because of inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues, if any, within a company have been detected.over financial reporting.
An evaluation was also performed under the supervision and with the participation of our management, including our chief executive officer and chief financial officer, of any change in our internal control over financial reporting that occurred during the fourth quarter of 20102012 and that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. The evaluation did not identify any such change.
MANAGEMENT’S REPORT ON INTERNAL CONTROL OVER FINANCIAL REPORTING
Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Exchange ActRules 13a-15(f). Because of its inherent limitations, internal control over financial reporting may not prevent or detect all misstatements. Therefore, even those systems determined to be effective can provide only reasonable assurance with respect to financial statement preparation and presentation.
We conducted an evaluation of the effectiveness of our internal control over financial reporting based on the framework in Internal Control — Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on our evaluation under the framework in Internal Control — Integrated Framework, our management concluded that our internal control over financial reporting was effective as of January 2, 2011.December 30, 2012. The effectiveness of our internal control over financial reporting as of January 2, 2011December 30, 2012 has been audited by Ernst & Young LLP, an independent registered public accounting firm, as stated in their report which is included herein.
84
81
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
The Board of Directors and Stockholders of
Illumina, Inc.
We have audited Illumina, Inc.’s internal control over financial reporting as of January 2, 2011,December 30, 2012, based on criteria established in Internal Control — Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (the COSO criteria). Illumina, Inc.’s management is responsible for maintaining effective internal control over financial reporting, and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Management’s Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the company’s internal control over financial reporting based on our audit.
We conducted our audit in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.
A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the company’s assets that could have a material effect on the financial statements.
Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.
In our opinion, Illumina, Inc. maintained, in all material respects, effective internal control over financial reporting as of January 2, 2011,December 30, 2012, based on the COSO criteria.
We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), the accompanying consolidated balance sheets of Illumina, Inc. as of December 30, 2012 and January 2, 2011 and January 3, 2010,1, 2012, and the related consolidated statements of income, comprehensive income, stockholders’ equity, and cash flows for each of the three fiscal years in the period ended January 2, 2011December 30, 2012 of Illumina, Inc. and our report dated February 28, 201115, 2013 expressed an unqualified opinion thereon.
/s/ EErnstRNST & YoungYOUNG LLP
San Diego, California
February 28, 201115, 2013
85
82
| Other Information. |
None.
PART III
| Directors, Executive Officers, and Corporate Governance. |
(a) Identification of Directors. Information concerning our directors is incorporated by reference from the section entitled “Proposal One: Election of Directors,” “Information About Directors,” “Director Compensation”Compensation,” and “Board of Directors and Corporate Governance” to be contained in our definitive Proxy Statement with respect to our 20112013 Annual Meeting of Stockholders to be filed with the SEC no later than April 9, 2011.29, 2013.
(b) Identification of Executive Officers. Information concerning our executive officers is incorporated by reference from the section entitled “Executive Officers” to be contained in our definitive Proxy Statement with respect to our 20112013 Annual Meeting of Stockholders to be filed with the SEC no later than April 9, 2011.29, 2013.
(c) Compliance with Section 16(a) of the Exchange Act. Information concerning compliance with Section 16(a) of the Securities Exchange Act of 1934 is incorporated by reference from the section entitled “Section 16(a) Beneficial Ownership Reporting Compliance” to be contained in our definitive Proxy Statement with respect to our 20112013 Annual Meeting of Stockholders to be filed with the SEC no later than April 9, 2011.29, 2013.
(d) Information concerning the audit committee financial expert as defined by the SEC rules adopted pursuant to the Sarbanes-Oxley Act of 2002 is incorporated by reference from the section entitled “Board of Directors and Corporate Governance” to be contained in our definitive Proxy Statement with respect to our 20112013 Annual Meeting of Stockholders to be filed with the SEC no later than April 9, 2010.29, 2013.
Code of Ethics
We have adopted a code of ethics for our directors, officers, and employees, which is available on our website at www.illumina.com in the Corporate Governance portal of the Investor Relations section under “Company.” A copy of the Code of Ethics is available in print free of charge to any stockholder who requests a copy. Interested parties may address a written request for a printed copy of the Code of Ethics to: Corporate Secretary, Illumina, Inc., 9885 Towne Centre Dr.,5200 Illumina Way, San Diego, California 92121.92122. We intend to satisfy the disclosure requirement regarding any amendment to, or a waiver from, a provision of the Code of Ethics for our principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions, by posting such information on our website. The information on, or that can be accessed from, our website is not incorporated by reference into this report.
| Executive Compensation. |
Information concerning executive compensation is incorporated by reference from the sections entitled “Compensation Discussion and Analysis,” “Director Compensation”Compensation,” and “Executive Compensation” to be contained in our definitive Proxy Statement with respect to our 20112013 Annual Meeting of Stockholders to be filed with the SEC no later than April 9, 2011.29, 2013.
| Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters. |
Information concerning the security ownership of certain beneficial owners and management and information covering securities authorized for issuance under equity compensation plans is incorporated by reference from the sections entitled “Stock Ownership of Principal Stockholders and Management,” “Executive Compensation”Compensation,” and “Equity Compensation Plan Information” to be contained in our definitive
86
Proxy Statement with respect to our 20112013 Annual Meeting of Stockholders to be filed with the SEC no later than April 9, 2011.29, 2013.
| Certain Relationships and Related Transactions, and Director Independence. |
Information concerning certain relationships and related transactions, and director independence is incorporated by reference from the sections entitled “Proposal One: Election of Directors,” “Information About Directors,” “Director Compensation,” “Executive Compensation”Compensation,” and “Certain Relationships and Related Party Transactions” to be contained in our definitive Proxy Statement with respect to our 20112013 Annual Meeting of Stockholders to be filed with the SEC no later than April 9, 2011.29, 2013.
83
| Principal Accountant Fees and Services. |
Information concerning principal accountant fees and services is incorporated by reference from the sections entitled “Proposal Two: Ratification of Appointment of Independent Registered Public Accountants”Accounting Firm” and “Independent Registered Public Accountants” to be contained in our definitive Proxy Statement with respect to our 20112013 Annual Meeting of Stockholders to be filed with the SEC no later than April 9, 2011.29, 2013.
PART IV
| Exhibits, Financial Statement Schedules. |
1. Financial Statements: See “Index to Consolidated Financial Statements” in Part II, Item 8 of thisForm 10-K.
2. Financial Statement Schedule: See “Schedule II — Valuation and Qualifying Accounts and Reserves” in this section of thisForm 10-K.
3. Exhibits: The exhibits listed in the accompanying index to exhibits are filed or incorporated by reference as part of thisForm 10-K.
87
SCHEDULE II — VALUATION AND QUALIFYING ACCOUNTS AND RESERVES
| Balance at | Additions Charged | |||||||||||||||
| Beginning of | to Expense/ | Balance at End of | ||||||||||||||
| Period | Revenue(1) | Deductions(2) | Period | |||||||||||||
| (In thousands) | ||||||||||||||||
| Year ended January 2, 2011 | ||||||||||||||||
| Allowance for doubtful accounts | $ | 1,398 | 341 | (53 | ) | $ | 1,686 | |||||||||
| Reserve for inventory | 10,597 | 9,559 | (7,883 | ) | 12,273 | |||||||||||
| Year ended January 3, 2010 | ||||||||||||||||
| Allowance for doubtful accounts | $ | 1,138 | 828 | (568 | ) | $ | 1,398 | |||||||||
| Reserve for inventory | 6,431 | 8,403 | (4,237 | ) | 10,597 | |||||||||||
| Year ended December 28, 2008 | ||||||||||||||||
| Allowance for doubtful accounts | $ | 540 | 893 | (295 | ) | $ | 1,138 | |||||||||
| Reserve for inventory | 2,089 | 7,154 | (2,812 | ) | 6,431 | |||||||||||
Balance at Beginning of Period | Additions Charged to Expense/ Revenue(1) | Deductions(2) | Balance at End of Period | ||||||||||
| (In thousands) | |||||||||||||
| Year ended December 30, 2012 | |||||||||||||
| Allowance for doubtful accounts | $ | 3,997 | 2,191 | (1,908 | ) | $ | 4,280 | ||||||
| Year ended January 1, 2012 | |||||||||||||
| Allowance for doubtful accounts | $ | 1,686 | 4,201 | (1,890 | ) | $ | 3,997 | ||||||
| Year ended January 2, 2011 | |||||||||||||
| Allowance for doubtful accounts | $ | 1,398 | 341 | (53 | ) | $ | 1,686 | ||||||
| (1) | Additions to the allowance for doubtful accounts |
| (2) | Deductions for allowance for doubtful accounts |
88
85
| INDEX TO EXHIBITS | |||||||||||||
| Incorporated by Reference | |||||||||||||
| Exhibit | Filing | Filed | |||||||||||
| Number | Exhibit Description | Form | File Number | Exhibit | Date | Herewith | |||||||
| 2.1 | Agreement and Plan of Merger by and among Illumina, Inc., TP Corporation, Verinata Health, Inc. and Shareholder Representative Services LLC (as the Stockholder Representative), dated as of January 6, 2013 | X | |||||||||||
| 3.1 | Amended and Restated Certificate of Incorporation | 8-K | 000-30361 | 3.1 | 9/23/2008 | ||||||||
| 3.2 | Amended and Restated Bylaws | 8-K | 000-30361 | 3.2 | 4/27/2010 | ||||||||
| 3.3 | Certificate of Designations of Series A Junior Participating Preferred Stock, as filed with the Secretary of State of the State of Delaware on January 26, 2012 | 8-K | 000-30361 | 3.1 | 1/26/2012 | ||||||||
| 4.1 | Specimen Common Stock Certificate | S-1/A | 333-33922 | 4.1 | 7/3/2000 | ||||||||
| 4.2 | Rights Agreement, dated as of January 26, 2012, between Illumina, Inc. and Computershare Trust Company, N.A., as Rights Agent | 8-K | 000-30361 | 4.1 | 1/26/2012 | ||||||||
| 4.3 | Indenture related to the 0.625% Convertible Senior Notes due 2014, dated as of February 16, 2007, between Illumina and The Bank of New York, as trustee | 8-K | 000-30361 | 4.1 | 2/16/2007 | ||||||||
| 4.4 | Indenture related to the 0.25% Convertible Senior Notes due 2016, dated as of March 18, 2011, between Illumina and The Bank of New York Mellon Trust Company, N.A., as trustee | 10-Q | 000-30361 | 4.1 | 5/4/2011 | ||||||||
| +10.1 | Form of Indemnification Agreement between Illumina and each of its directors and executive officers | 10-Q | 000-30361 | 10.55 | 7/25/2008 | ||||||||
| +10.2 | Amended and Restated Change in Control Severance Agreement between Illumina and Jay T Flatley, dated October 22, 2008 | 10-K | 000-30361 | 10.33 | 2/26/2009 | ||||||||
| +10.3 | Form of Change in Control Severance Agreement between Illumina and each of its executive officers | 10-K | 000-30361 | 10.34 | 2/26/2009 | ||||||||
| +10.4 | 2000 Employee Stock Purchase Plan, as amended and restated through February 2, 2012 | 10-K | 000-30361 | 10.4 | 2/24/2012 | ||||||||
| +10.5 | 2005 Stock and Incentive Plan, as amended and restated through April 22, 2010 | S-8 | 333-168393 | 4.5 | 7/29/2010 | ||||||||
| +10.6 | Form of Restricted Stock Unit Agreement for Non-Employee Directors under 2005 Stock and Incentive Plan | 10-K | 000-30361 | 10.6 | 2/24/2012 | ||||||||
| +10.7 | Form of Stock Option Agreement for Non-Employee Directors under 2005 Stock and Incentive Plan | 10-K | 000-30361 | 10.7 | 2/24/2012 | ||||||||
| +10.8 | Form of Restricted Stock Unit Agreement for Employees under 2005 Stock and Incentive Plan | 10-K | 000-30361 | 10.8 | 2/24/2012 | ||||||||
86
| INDEX TO EXHIBITS — (Continued) | |||||||||||||
| +10.9 | Form of Stock Option Agreement for Employees under 2005 Stock and Incentive Plan | 10-K | 000-30361 | 10.9 | 2/24/2012 | ||||||||
| +10.10 | New Hire Stock and Incentive Plan, as amended and restated through October 28, 2009 | 10-K | 000-30361 | 10.7 | 2/26/2010 | ||||||||
| 10.11 | License Agreement, effective as of May 6, 1998, between Tufts University and Illumina | 10-Q | 000-30361 | 10.5 | 5/3/2007 | ||||||||
| +10.12 | The Solexa Unapproved Company Share Option Plan | 8-K | 000-30361 | 99.3 | 11/26/2007 | ||||||||
| +10.13 | The Solexa Share Option Plan for Consultants | 8-K | 000-30361 | 99.4 | 11/26/2007 | ||||||||
| +10.14 | Solexa Limited Enterprise Management Incentive Plan | 8-K | 000-30361 | 99.5 | 11/26/2007 | ||||||||
| +10.15 | Amended and Restated Solexa 2005 Equity Incentive Plan | 10-K | 000-30361 | 10.25 | 2/26/2009 | ||||||||
| +10.16 | Amended and Restated Solexa 1992 Stock Option Plan | 10-K | 000-30361 | 10.26 | 2/26/2009 | ||||||||
| 10.17 | License Agreement, dated June 24, 2002, between Dade Behring Marburg GmbH and Illumina (with certain confidential portions omitted) | S-3/A | 333-111496 | 10.23 | 3/2/2004 | ||||||||
| 10.18 | Non-exclusive License Agreement, dated January 24, 2002, between Amersham Biosciences Corp. and Illumina (with certain confidential portions omitted) | S-3/A | 333-111496 | 10.24 | 3/2/2004 | ||||||||
| 10.19 | Amended and Restated Lease between BMR-9885 Towne Centre Drive LLC and Illumina for the 9885 Towne Centre Drive property, dated January 26, 2007 | 10-Q | 000-30361 | 10.41 | 5/3/2007 | ||||||||
| 10.20 | Settlement and Cross License Agreement dated August 18, 2004 between Applera Corporation and Illumina (with certain confidential portions omitted) | 10-Q | 000-30361 | 10.27 | 11/12/2004 | ||||||||
| 10.21 | Collaboration Agreement, dated December 17, 2004, between Invitrogen Corporation and Illumina (with certain confidential portions omitted) | 10-K | 000-30361 | 10.28 | 3/8/2005 | ||||||||
| 10.22 | Joint Development and Licensing Agreement, dated May 15, 2006, between deCODE genetics, ehf. and Illumina (with certain confidential portions omitted) | 10-Q | 000-30361 | 10.32 | 8/2/2006 | ||||||||
| 10.23 | Lease between BMR-9885 Towne Centre Drive LLC and Illumina for the 9865 Towne Centre Drive property, dated January 26, 2007 | 10-Q | 000-30361 | 10.42 | 5/3/2007 | ||||||||
| 10.24 | Settlement and Release Agreement between Affymetrix, Inc. and Illumina, dated January 9, 2008 | 10-K | 000-30361 | 10.44 | 2/26/2008 | ||||||||
| 10.25 | Confirmation of Convertible Bond Hedge Transaction, dated February 12, 2007, by and between Illumina and Goldman, Sachs & Co. | 8-K | 000-30361 | 10.1 | 2/16/2007 | ||||||||
| 10.26 | Confirmation of Convertible Bond Hedge Transaction, dated February 12, 2007, by and between Illumina and Deutsche Bank AG London | 8-K | 000-30361 | 10.2 | 2/16/2007 | ||||||||
87
| INDEX TO EXHIBITS — (Continued) | |||||||||||||
| 10.27 | Confirmation Issuer Warrant Transaction, dated February 12, 2007, by and between Illumina and Goldman, Sachs & Co. | 8-K | 000-30361 | 10.3 | 2/16/2007 | ||||||||
| 10.28 | Confirmation Issuer Warrant Transaction, dated February 12, 2007, by and between Illumina and Deutsche Bank AG London | 8-K | 000-30361 | 10.4 | 2/16/2007 | ||||||||
| 10.29 | Amendment to the Confirmation of Issuer Warrant Transaction, dated February 13, 2007, by and between Illumina and Goldman, Sachs & Co. | 8-K | 000-30361 | 10.5 | 2/16/2007 | ||||||||
| 10.30 | Amendment to the Confirmation of Issuer Warrant Transaction, dated February 13, 2007, by and between Illumina and Deutsche Bank AG London | 8-K | 000-30361 | 10.6 | 2/16/2007 | ||||||||
| 10.31 | Amended and Restated Lease Agreement, dated March 27, 2012, between ARE-SD Region No. 32, LLC and Illumina | 10-Q | 000-30361 | 10.1 | 5/3/2012 | ||||||||
| +10.32 | Deferred Compensation Plan, effective December 1, 2007 | 14D-9 | 005-60457 | 99(e)(6) | 2/7/2012 | ||||||||
| 21.1 | Subsidiaries of Illumina | X | |||||||||||
| 23.1 | Consent of Independent Registered Public Accounting Firm | X | |||||||||||
| 24.1 | Power of Attorney (included on the signature page) | X | |||||||||||
| 31.1 | Certification of Jay T. Flatley pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 | X | |||||||||||
| 31.2 | Certification of Marc A. Stapley pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 | X | |||||||||||
| 32.1 | Certification of Jay T. Flatley pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 | X | |||||||||||
| 32.2 | Certification of Marc A. Stapley pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 | X | |||||||||||
| 101.INS | XBRL Instance Document | X | |||||||||||
| 101.SCH | XBRL Taxonomy Extension Schema | X | |||||||||||
| 101.CAL | XBRL Taxonomy Extension Calculation Linkbase | X | |||||||||||
| 101.LAB | XBRL Taxonomy Extension Label Linkbase | X | |||||||||||
| 101.PRE | XBRL Taxonomy Extension Presentation Linkbase | X | |||||||||||
| 101.DEF | XBRL Taxonomy Extension Definition Linkbase | X | |||||||||||
| Incorporated by Reference | ||||||||||||||||
| Exhibit | Filing | Filed | ||||||||||||||
| Number | Exhibit Description | Form | File Number | Exhibit | Date | Herewith | ||||||||||
| 3 | .1 | Amended and Restated Certificate of Incorporation | 8-K | 000-30361 | 3 | .1 | 09/23/08 | |||||||||
| 3 | .2 | Amended and Restated Bylaws | 8-K | 000-30361 | 3 | .2 | 04/27/10 | |||||||||
| 3 | .3 | Certificate of Designation for Series A Junior Participating Preferred Stock (included as Exhibit A to exhibit 4.3) | 8-A | 000-30361 | 4 | .3 | 05/14/01 | |||||||||
| 4 | .1 | Specimen Common Stock Certificate | S-1/A | 333-33922 | 4 | .1 | 07/03/00 | |||||||||
| 4 | .2 | Rights Agreement, dated as of May 3, 2001, between Illumina and Equiserve Trust Company, N.A. | 8-A | 000-30361 | 4 | .3 | 05/14/01 | |||||||||
| 4 | .3 | Indenture related to the 0.625% Convertible Senior Notes due 2014, dated as of February 16, 2007, between Illumina and The Bank of New York, as trustee | 8-K | 000-30361 | 4 | .1 | 02/16/07 | |||||||||
| +10 | .1 | Form of Indemnification Agreement between Illumina and each of its directors and officers | S-1/A | 333-33922 | 10 | .1 | 07/03/00 | |||||||||
| +10 | .2 | 1998 Incentive Stock Plan | S-1/A | 333-33922 | 10 | .2 | 07/03/00 | |||||||||
| +10 | .3 | 2000 Employee Stock Purchase Plan, as amended and restated through October 28, 2009 | 10-K | 000-30361 | 10 | .3 | 02/26/10 | |||||||||
| +10 | .4 | 2000 Stock Plan, as amended and restated through March 21, 2002 | 10-Q | 000-30361 | 10 | .22 | 05/13/02 | |||||||||
| +10 | .5 | 2005 Stock and Incentive Plan, as amended and restated through October 28, 2009 | 10-K | 000-30361 | 10 | .5 | 02/26/10 | |||||||||
| +10 | .6 | Form of Restricted Stock Unit Agreement for Non-Employee Directors under 2005 Stock and Incentive Plan | 10-K | 000-30361 | 10 | .35 | 02/26/09 | |||||||||
| +10 | .7 | New Hire Stock and Incentive Plan, as amended and restated through October 28, 2009 | 10-K | 000-30361 | 10 | .7 | 02/26/10 | |||||||||
| 10 | .8 | License Agreement, effective as of May 6, 1998, between Tufts University and Illumina | 10-Q | 000-30361 | 10 | .5 | 05/03/07 | |||||||||
| +10 | .9 | The Solexa Unapproved Company Share Option Plan | 8-K | 000-30361 | 99 | .3 | 11/26/07 | |||||||||
| +10 | .10 | The Solexa Share Option Plan for Consultants | 8-K | 000-30361 | 99 | .4 | 11/26/07 | |||||||||
| +10 | .11 | Solexa Limited Enterprise Management Incentive Plan | 8-K | 000-30361 | 99 | .5 | 11/26/07 | |||||||||
| +10 | .12 | Amended and Restated Solexa 2005 Equity Incentive Plan | 10-K | 000-30361 | 10 | .25 | 02/26/09 | |||||||||
| +10 | .13 | Amended and Restated Solexa 1992 Stock Option Plan | 10-K | 000-30361 | 10 | .26 | 02/26/09 | |||||||||
| 10 | .14 | License Agreement, dated June 24, 2002, between Dade Behring Marburg GmbH and Illumina (with certain confidential portions omitted) | S-3/A | 333-111496 | 10 | .23 | 03/02/04 | |||||||||
| 10 | .15 | Non-exclusive License Agreement, dated January 24, 2002, between Amersham Biosciences Corp. and Illumina (with certain confidential portions omitted) | S-3/A | 333-111496 | 10 | .24 | 03/02/04 | |||||||||
89
| Incorporated by Reference | ||||||||||||||||
| Exhibit | Filing | Filed | ||||||||||||||
| Number | Exhibit Description | Form | File Number | Exhibit | Date | Herewith | ||||||||||
| 10 | .16 | Amended and Restated Lease between BMR-9885 Towne Centre Drive LLC and Illumina for the 9885 Towne Centre Drive property, dated January 26, 2007 | 10-Q | 000-30361 | 10 | .41 | 05/03/07 | |||||||||
| 10 | .17 | Settlement and Cross License Agreement dated August 18, 2004 between Applera Corporation and Illumina (with certain confidential portions omitted) | 10-Q | 000-30361 | 10 | .27 | 11/12/04 | |||||||||
| 10 | .18 | Collaboration Agreement, dated December 17, 2004, between Invitrogen Corporation and Illumina (with certain confidential portions omitted) | 10-K | 000-30361 | 10 | .28 | 03/08/05 | |||||||||
| +10 | .19 | Offer letter for Christian O. Henry dated April 26, 2005 | 10-Q | 000-30361 | 10 | .33 | 08/08/05 | |||||||||
| 10 | .20 | Joint Development and Licensing Agreement, dated May 15, 2006, between deCODE genetics, ehf. and Illumina (with certain confidential portions omitted) | 10-Q | 000-30361 | 10 | .32 | 08/02/06 | |||||||||
| +10 | .21 | Amended and Restated Change in Control Severance Agreement between Illumina and Jay T Flatley, dated October 22, 2008 | 10-K | 000-30361 | 10 | .33 | 02/26/09 | |||||||||
| +10 | .22 | Form of Amended and Restated Change in Control Severance Agreement between Illumina and its executive officers | 10-K | 000-30361 | 10 | .34 | 02/26/09 | |||||||||
| +10 | .23 | Form of Restricted Stock Unit Agreement for Non-Employee Directors under Illumina’s 2005 Stock and Incentive Plan | 10-K | 000-30361 | 10 | .35 | 02/26/09 | |||||||||
| 10 | .24 | Lease between BMR-9885 Towne Centre Drive LLC and Illumina for the 9865 Towne Centre Drive property, dated January 26, 2007 | 10-Q | 000-30361 | 10 | .42 | 05/03/07 | |||||||||
| 10 | .25 | Settlement and Release Agreement between Affymetrix, Inc. and Illumina, dated January 9, 2008 | 10-K | 000-30361 | 10 | .44 | 02/26/08 | |||||||||
| 10 | .26 | Confirmation of Convertible Bond Hedge Transaction, dated February 12, 2007, by and between Illumina and Goldman, Sachs & Co. | 8-K | 000-30361 | 10 | .1 | 02/16/07 | |||||||||
| 10 | .27 | Confirmation of Convertible Bond Hedge Transaction, dated February 12, 2007, by and between Illumina and Deutsche Bank AG London | 8-K | 000-30361 | 10 | .2 | 02/16/07 | |||||||||
| 10 | .28 | Confirmation Issuer Warrant Transaction, dated February 12, 2007, by and between Illumina and Goldman, Sachs & Co. | 8-K | 000-30361 | 10 | .3 | 02/16/07 | |||||||||
| 10 | .29 | Confirmation Issuer Warrant Transaction, dated February 12, 2007, by and between Illumina and Deutsche Bank AG London | 8-K | 000-30361 | 10 | .4 | 02/16/07 | |||||||||
| 10 | .30 | Amendment to the Confirmation of Issuer Warrant Transaction, dated February 13, 2007, by and between Illumina and Goldman, Sachs & Co. | 8-K | 000-30361 | 10 | .5 | 02/16/07 | |||||||||
90
| Incorporated by Reference | ||||||||||||||||
| Exhibit | Filing | Filed | ||||||||||||||
| Number | Exhibit Description | Form | File Number | Exhibit | Date | Herewith | ||||||||||
| 10 | .31 | Amendment to the Confirmation of Issuer Warrant Transaction, dated February 13, 2007, by and between Illumina and Deutsche Bank AG London | 8-K | 000-30361 | 10 | .6 | 02/16/07 | |||||||||
| +10 | .32 | Indemnification Agreement between Illumina and Gregory F. Heath | 10-Q | 000-30361 | 10 | .55 | 07/25/08 | |||||||||
| +10 | .33 | Indemnification Agreement between Illumina and Joel McComb | 10-Q | 000-30361 | 10 | .56 | 07/25/08 | |||||||||
| +10 | .34 | Severance and Release Agreement between Illumina and Joel McComb | 10-K | 000-30361 | 10 | .34 | 02/26/10 | |||||||||
| 10 | .35 | Lease Agreement, dated December 30, 2010, between ARE-SD Region No. 32, LLC and Illumina | X | |||||||||||||
| 21 | .1 | Subsidiaries of Illumina | X | |||||||||||||
| 23 | .1 | Consent of Independent Registered Public Accounting Firm | X | |||||||||||||
| 24 | .1 | Power of Attorney (included on the signature page) | X | |||||||||||||
| 31 | .1 | Certification of Jay T. Flatley pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 | X | |||||||||||||
| 31 | .2 | Certification of Christian O. Henry pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 | X | |||||||||||||
| 32 | .1 | Certification of Jay T. Flatley pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 | X | |||||||||||||
| 32 | .2 | Certification of Christian O. Henry pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 | X | |||||||||||||
| + | Management contract or corporate plan or arrangement |
Supplemental Information
No Annual Report to stockholders or proxy materials has been sent to stockholders as of the date of this report. The Annual Report to stockholders and proxy material will be furnished to our stockholders subsequent to the filing of this Annual Report onForm 10-K and we will furnish such material to the SEC at that time.
91
88
89
SIGNATURES
Pursuant to the requirements of the Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized, on February 28, 2011.15, 2013.
ILLUMINA, INC. | ||
| By | /s/ JAY T. FLATLEY | |
Jay T. Flatley President and Chief Executive Officer | ||
90
February 15, 2013
POWER OF ATTORNEY
KNOW ALL PERSONS BY THESE PRESENT, that each person whose signature appears below constitutes and appoints Jay T. Flatley and Christian O. Henry,Marc A. Stapley, and each or any one of them, his or her true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him and in his or her name, place and stead, in any and all capacities, to sign any and all amendments to this Annual Report onForm 10-K, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their, his, or hisher substitutes or substitute, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Exchange Act of 1934, this Annual Report onForm 10-K has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
/s/ JAY T. FLATLEY | President, Chief Executive Officer and Director (Principal Executive Officer) | February 15, 2013 | ||||
| Jay T. Flatley | ||||||
/s/ M | ||||||
| Senior Vice President and Chief Financial Officer (Principal Financial | February | |||||
92
| Stapley | ||||||
/s/ M | Vice President and Chief Accounting Officer (Principal Accounting Officer) | February | ||||
| Michel Bouchard | ||||||
/s/ WILLIAM H. RASTETTER | February | |||||
| William H. Rastetter | ||||||
/s/ A. B | Director | February | ||||
| A. Blaine Bowman | ||||||
/s/ D | Director | February | ||||
| Daniel M. Bradbury | ||||||
/s/ KARIN EASTHAM | Director | February 15, 2013 | ||||
| Karin Eastham | ||||||
/s/ ROBERT S. EPSTEIN | Director | February 15, 2013 | ||||
| Robert S. Epstein | ||||||
/s/ PAUL GRINT | Director | February 15, 2013 | ||||
| Paul Grint | ||||||
| Director | ||||||
| Gerald Möller | ||||||
/s/ DAVID R. WALT | Director | February 15, 2013 | ||||
| David R. Walt | ||||||
/s/ ROY WHITFIELD | Director | February 15, 2013 | ||||
| Roy Whitfield |
93
91